var title_f10_44_10944="Tilt test in syncope";
var content_f10_44_10944=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67278&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67278&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Determinants of tilt table positivity in syncope",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 600px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The results of the tilt table test are dependent upon the clinical characteristics of the patient being studied. Of importance are age (greater or less than 50), presence of structural heart disease (SHD) or noncardiovascular abnormality that might result in sudden diminished consciousness (SDC), or a single syncopal episode or single or multiple episodes of presyncope without loss of consciousness (&lt;2 syncope). As an example, the tilt test was negative in all patients under age 50 who had SHD or SDC and less than two syncopal episodes (top row).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Fitzpatrick, AP, Lee, RJ, Epstein, LM, et al, Heart 1996; 76:406.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_44_10944=[""].join("\n");
var outline_f10_44_10944=null;
var title_f10_44_10945="Vessel occlusion sickle cell";
var content_f10_44_10945=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F80615&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F80615&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Proposed mechanisms of vascular occlusion in sickle cell disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 391px; height: 362px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A (on left) illustrates adhesion of sickle cells to the vascular endothelium in post-capillary venules and venules. Panel B (on right) illustrates the subsequent trapping of dense red cells (in blue) in the partially obstructed post-capillary venules, followed by retrograde obstruction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_44_10945=[""].join("\n");
var outline_f10_44_10945=null;
var title_f10_44_10946="Propylhexedrine: Drug information";
var content_f10_44_10946=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Propylhexedrine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F215014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Benzedrex&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F215023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Adrenergic Agonist Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F215015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Decongestant:",
"     </b>",
"     Nasal: Two inhalations in each nostril, not more frequently than every 2 hours",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F215019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children 6-12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F215016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F215006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Inhaler, nasal: 0.4-0.5 mg/inhalation (1s) [total content 250 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F214996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F215008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For nasal inhalation only.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F215007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical nasal decongestant",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F215021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Nasal: Burning, stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Sneezing, nasal discharge increased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F215010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to propylhexedrine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F214999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Not for OTC use in children &lt;6 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nasal: For nasal use only. Do not exceed recommended dosage; do not use for more than 3 days.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6222606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Alpha1-Agonists may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha1-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10234 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-4B2100FB5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_44_10946=[""].join("\n");
var outline_f10_44_10946=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215014\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215023\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215015\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215019\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215016\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215006\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214996\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215008\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215007\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215021\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215010\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214999\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299952\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6222606\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10234\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10234|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_44_10947="Shenton line";
var content_f10_44_10947=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F82640&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F82640&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Shenton line",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 447px; height: 596px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shenton line as seen in an AP diagram of the hips. Shenton line is drawn from the medial border of the femoral neck to the superior border of the obturator foramen. In the normal right hip, it is a continuous contour, whereas in the hip with DDH (the left hip), it is disrupted.",
"    <div class=\"footnotes\">",
"     DDH: developmental dysplasia of the hip.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_44_10947=[""].join("\n");
var outline_f10_44_10947=null;
var title_f10_44_10948="Perirectal fistula EUS";
var content_f10_44_10948=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F82082&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F82082&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Perirectal fistula",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 319px; height: 319px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Radial scanning endoscopic ultrasound image showing the relationship between a fistula and the external anal sphincter (EAS) and vagina. Air within the fistula makes it visible on the endoscopic ultrasound image.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David A Schwartz, MD and Maurits J Wiersema, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_44_10948=[""].join("\n");
var outline_f10_44_10948=null;
var title_f10_44_10949="Adefovir: Drug information";
var content_f10_44_10949=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Adefovir: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/27/30133?source=see_link\">",
"    see \"Adefovir: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/34/10789?source=see_link\">",
"    see \"Adefovir: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F130623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Hepsera&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F4663221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Hepsera&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F130640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiretroviral Agent, Reverse Transcriptase Inhibitor (Nucleotide)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F130625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Hepatitis B (chronic):",
"     </b>",
"     Oral: 10 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Treatment duration (AASLD practice guidelines):",
"     </i>",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatitis Be antigen (HBeAg) positive chronic hepatitis: Treat &ge;1 year until HBeAg seroconversion and undetectable serum HBV DNA; continue therapy for &ge;6 months after HBeAg seroconversion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     HBeAg negative chronic hepatitis: Treat &gt;1 year until hepatitis B surface antigen (HBsAg) clearance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients not achieving a &lt;2 log decrease in serum HBV DNA after at least 6 months of therapy should either receive additional treatment or be switched to an alternative therapy (Lok, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F5657903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/34/10789?source=see_link\">",
"      see \"Adefovir: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Hepatitis B (chronic):",
"     </b>",
"     Children &ge;12 years: Oral: 10 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F130626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F130627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adult recommendations only (no dosage adjustment recommendations available for patients &lt;18 years with renal impairment):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;50 mL/minute: No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-49 mL/minute: 10 mg every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-19 mL/minute: 10 mg every 72 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: 10 mg every 7 days (following dialysis)",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F130628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment required.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F130602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as dipivoxil:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepsera&reg;: 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F130587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F130604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F130603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of chronic hepatitis B with evidence of active viral replication (based on persistent elevation of ALT/AST or histologic evidence), including patients with lamivudine-resistant hepatitis B",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F130638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (24% to 25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (15%), diarrhea (up to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Hepatitis exacerbation (up to 25% within 12 weeks of adefovir discontinuation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (up to 25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Hematuria (grade &ge;3: 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash, pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypophosphatemia (&lt;2 mg/dL: 1% and 3% in pre-/post-liver transplant patients, respectively)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Flatulence (up to 8%), dyspepsia (5% to 9%), nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (up to 10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Serum creatinine increased (&ge;0.5 mg/dL: 2% to 3% in compensated liver disease; incidence may be higher in patients with decompensated cirrhosis or in liver transplant recipients), renal failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     In liver transplant patients with baseline renal dysfunction, frequency of increased serum creatinine has been observed to be as high as 32% to 51% at 48 and 96 weeks post-transplantation, respectively; considering the concomitant use of other potentially nephrotoxic medications, baseline renal insufficiency, and predisposing comorbidities, the role of adefovir in these changes could not be established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (6% to 8%), rhinitis (up to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Fanconi syndrome, hepatitis, myopathy, nephrotoxicity, osteomalacia, pancreatitis, proximal renal tubulopathy",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F130607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to adefovir or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F130591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lactic acidosis/hepatomegaly:",
"     <b>",
"      [U.S Boxed Warning]: Fatal cases of  lactic acidosis and severe hepatomegaly with steatosis have been reported with the use of nucleoside analogues alone or in combination with other antiretrovirals;",
"     </b>",
"     use with caution in patients with risk factors for liver disease (risk may be increased with female gender, obesity, pregnancy or prolonged exposure) and suspend treatment in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or hepatotoxicity (transaminase elevation may/may not accompany hepatomegaly and steatosis).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Chronic hepatitis B:",
"     <b>",
"      [U.S. Boxed Warning]: Severe, acute exacerbation of hepatitis B may occur upon discontinuation.",
"     </b>",
"     Exacerbations may occur in up to 25% of patients and usually within 12 weeks and may be self-limited or resolve upon resuming treatment; risk may be increased with advanced liver disease or cirrhosis. Monitor liver function several months after stopping treatment; reinitiation of antihepatitis B therapy may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; HIV:",
"     <b>",
"      [U.S. Boxed Warning]:",
"     </b>",
"     <b>",
"      May cause the development of HIV resistance in chronic hepatitis B patients with unrecognized or untreated HIV infection.",
"     </b>",
"     Determine HIV status prior to initiating treatment with adefovir.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment:",
"     <b>",
"      [U.S. Boxed Warning]: Use with caution in patients with renal dysfunction or in patients at risk of renal toxicity (including concurrent nephrotoxic agents or NSAIDs).",
"     </b>",
"     Chronic administration may result in nephrotoxicity. Dosage adjustment is required in adult patients with renal dysfunction or in patients who develop renal dysfunction during therapy; no data available for use in children &ge;12 years or adolescents with renal impairment. Calculation of creatinine clearance in all patients is recommended prior to initiating therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tenofovir: Do not use concurrently with tenofovir (Viread&reg;) or any product containing tenofovir (eg, Truvada&reg;, Atripla&reg;, Complera&reg;).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children &lt;12 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Not recommended as first line therapy of chronic HBV due to weak antiviral activity and high rate of resistance after first year. May be more appropriate as second-line agent in treatment-na&iuml;ve patients. Combination therapy with lamivudine in nucleoside-na&iuml;ve patients has not been shown to provide synergistic antiviral effects. However, in patients with lamivudine-resistant HBV, switching to adefovir monotherapy was associated with a higher risk of adefovir resistance compared to adding adefovir to lamivudine therapy (Lok, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F130596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ganciclovir-Valganciclovir: May enhance the adverse/toxic effect of Reverse Transcriptase Inhibitors (Nucleoside). Hematologic toxicity is of specific concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ribavirin: May enhance the hepatotoxic effect of Reverse Transcriptase Inhibitors (Nucleoside). Lactic acidosis may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tenofovir: Adefovir may diminish the therapeutic effect of Tenofovir. Specifically, adefovir-associated mutations in Hepatitis B viral reverse transcriptase may decrease viral susceptibility to tenofovir. Adefovir may increase the serum concentration of Tenofovir. Tenofovir may increase the serum concentration of Adefovir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F130620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Should be avoided in hepatitis B infection due to potential hepatic toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Does not have a significant effect on adefovir absorption.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F130598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F130610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. There are no adequate and well-controlled studies in pregnant women. Use in pregnancy only when clearly needed. Pregnant women exposed to adefovir should be registered with the pregnancy registry (800-258-4263).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F130632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F130611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F130609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Hepsera Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (30): $1263.16",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F130600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     HIV status (prior to initiation of therapy); serum creatinine (prior to initiation and during therapy; every 3 months in patients with medical conditions which predispose to renal insufficiency and in all patients treated for &gt;1 year; more frequent monitoring required if pre-existing real insufficiency detected [Lok, 2009]); LFTs for several months following discontinuation of adefovir; HBV DNA (every 3-6 months during therapy); HBeAg and anti-HBe",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F130612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Adepact (KP);",
"     </li>",
"     <li>",
"      Adepam (KP);",
"     </li>",
"     <li>",
"      Adeptin (KP);",
"     </li>",
"     <li>",
"      Adesera (IN);",
"     </li>",
"     <li>",
"      Adesil (KP);",
"     </li>",
"     <li>",
"      Adevir (KP);",
"     </li>",
"     <li>",
"      Afoliva (KP);",
"     </li>",
"     <li>",
"      Everhepa (KP);",
"     </li>",
"     <li>",
"      Hepcure (KP);",
"     </li>",
"     <li>",
"      Hepovir (PK);",
"     </li>",
"     <li>",
"      Hepsera (AR, AT, AU, BE, BG, BR, CH, CL, CN, CO, CR, CZ, DE, DK, DO, EE, ES, FI, FR, GB, GR, GT, HK, HN, ID, IE, IL, IT, KP, MT, MY, NI, NL, NO, NZ, PA, PE, PH, PK, PL, PT, RU, SE, SG, SK, SV, TH, TR, TW, VE);",
"     </li>",
"     <li>",
"      Hepssel (KP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F130590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acyclic nucleotide reverse transcriptase inhibitor (adenosine analog) which interferes with HBV viral RNA-dependent DNA polymerase resulting in inhibition of viral replication.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F130606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 0.35-0.39 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &le;4%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Prodrug; rapidly converted to adefovir (active metabolite) in intestine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 59%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 7.5 hours; prolonged in renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 1.75 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (45% as active metabolite within 24 hours)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al, &ldquo;Adefovir Dipivoxil for the Treatment of  Hepatitis B e Antigen-Negative Chronic Hepatitis B,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 348(9):800-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/44/10949/abstract-text/12606734/pubmed\" id=\"12606734\" target=\"_blank\">",
"        12606734",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lok AS and McMahon BJ, &ldquo;Chronic Hepatitis B: Update 2009,&rdquo;",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2009, 50(3):661-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/44/10949/abstract-text/19714720/pubmed\" id=\"19714720\" target=\"_blank\">",
"        19714720",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marcellin P, Chang T-T, Lim SG, et al, &ldquo;Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen-Positive Chronic Hepatitis B,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 348(9):808-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/44/10949/abstract-text/12606735/pubmed\" id=\"12606735\" target=\"_blank\">",
"        12606735",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8690 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-201.248.109.99-7E3FD85ED5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_44_10949=[""].join("\n");
var outline_f10_44_10949=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708606\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130623\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4663221\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130640\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130625\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5657903\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130626\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130627\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130628\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130602\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130587\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130604\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130603\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130638\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130607\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130591\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298688\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130596\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130620\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130598\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130610\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130632\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130611\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130609\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130600\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130612\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130590\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130606\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8690\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8690|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/27/30133?source=related_link\">",
"      Adefovir: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/34/10789?source=related_link\">",
"      Adefovir: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_44_10950="Principles of complex trait genetics";
var content_f10_44_10950=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Principles of complex trait genetics",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/44/10950/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/44/10950/contributors\">",
"     Juan C Celed&oacute;n, MD, DrPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/44/10950/contributors\">",
"     Gary M Hunninghake, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/44/10950/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/44/10950/contributors\">",
"     Benjamin A Raby, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/44/10950/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/44/10950/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/44/10950/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H3540509\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most human genetic traits can be classified as either monogenic or complex. Monogenic traits are strongly influenced by variation within a single gene and are recognized by their classic patterns of inheritance within families. While monogenic traits formed the basis for &ldquo;classic&rdquo; genetics, it has become clear that conditions whose inheritance strictly conforms to Mendelian principles are relatively rare. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35718?source=see_link\">",
"     \"Overview of Mendelian inheritance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43717?source=see_link\">",
"     \"Glossary of genetic terms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Complex traits are believed to result from variation within multiple genes and their interaction with behavioral and environmental factors. Complex traits do not follow readily predictable patterns of inheritance. &nbsp;",
"   </p>",
"   <p>",
"    This distinction between monogenic and complex traits, while useful, can be overly simplistic. Traits that appear to be monogenic can be influenced by variation in multiple genes (&ldquo;modifier genes&rdquo;) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10950/abstract/1\">",
"     1",
"    </a>",
"    ]; complex traits can be predominantly influenced by variation in a single gene [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10950/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the challenges related to the identification of complex trait susceptibility genes, the factors that contribute to phenotypic complexity, and current understanding of the genetic architecture of complex genetic traits. Genetic traits with monogenic inheritance, either with a Mendelian or a non-Mendelian pattern, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35718?source=see_link\">",
"     \"Overview of Mendelian inheritance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/46/43750?source=see_link\">",
"     \"Non-Mendelian inheritance patterns of monogenic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3540524\">",
"    <span class=\"h1\">",
"     SPECTRUM OF GENETIC VARIATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most monogenic diseases are caused by mutations that reduce the function or stability of a single protein by altering its three-dimensional structure. These mutations include point mutations (eg, changes in single nucleotides that alter the amino acid sequence), insertions, or deletions in the DNA sequence that encodes the protein; or changes in the non-coding DNA that interfere with gene splicing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/38/21097?source=see_link&amp;anchor=H1497147#H1497147\">",
"     \"Basic principles of genetic disease\", section on 'Nonsense mutation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In complex genetic traits, the spectrum of genetic mutation (ie, the types of mutations and the number of mutations involved in a single disease) is broad and more complicated, and it is often difficult to identify a single causal genetic change. These traits tend to be polygenic. Further, although coding mutations have been identified in complex diseases, most of the genetic variations mapped for complex genetic traits tend to be non-coding (located in non-genic, regulatory or intronic regions) and likely act by altering the control of gene expression (eg, interfering with a transcription factor binding site), the stability of the RNA or protein product, or posttranslational modification of the protein product, rather than altering the amino acid sequence directly. (See",
"    <a class=\"local\" href=\"#H3540531\">",
"     'Determinants of genetic effect'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The genetic variation in complex traits is also more difficult to analyze. Several factors contribute to difficulty in the recognition of functional regulatory variation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Regulatory variants reside in noncoding sequences of the genome. Functional sequence annotation of noncoding sequences is frequently less comprehensive than annotation for coding regions.",
"     </li>",
"     <li>",
"      Numerous genetic variants have been identified that are strongly associated with a complex disease, but are not near any known gene (eg, the 9p21 locus in coronary artery disease) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/44/10950/abstract/3\">",
"       3",
"      </a>",
"      ]. The mechanisms by which such variants affect complex traits are more difficult to uncover [",
"      <a class=\"abstract\" href=\"UTD.htm?10/44/10950/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Susceptibility loci for complex traits may influence the regulation of several genes within a genomic region [",
"      <a class=\"abstract\" href=\"UTD.htm?10/44/10950/abstract/5\">",
"       5",
"      </a>",
"      ]. This suggests that some regulatory regions of DNA, rather than affecting a single gene, could play a role in regulating the regional transcription patterns of multiple genes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3540531\">",
"    <span class=\"h2\">",
"     Determinants of genetic effect",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whereas Mendelian traits are characterized by a strong genotype-phenotype correlation, complex genetic traits typically exhibit weak correlations between genotype and phenotype. Data from genome-wide association studies (GWAS) of complex traits demonstrate that many disease susceptibility variants, by themselves, confer only a modestly increased risk (ie, relative risk ranging between 1.1 and 1.5). (See",
"    <a class=\"local\" href=\"#H3540594\">",
"     'Approaches to identifying genetic determinants of complex traits'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The relatively weak genotype-phenotype correlations for complex traits may be explained by the following hypotheses:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Regulatory variation",
"      </strong>",
"      &mdash; Changes in the non-coding (ie, regulatory) regions of genes may alter the quantity of a protein without changing its function. The effect on cellular phenotype may be more subtle than the effect of coding mutations that affect protein structure.",
"     </li>",
"     <li>",
"      <strong>",
"       Polygenic effects",
"      </strong>",
"      &mdash; Most complex genetic traits are likely the result of variation within multiple genes. Any individual genetic variant might only confer a relatively small effect; the cumulative effect of multiple genetic variants would result in a much larger overall effect on the trait.",
"     </li>",
"     <li>",
"      <strong>",
"       Gene-gene interactions",
"      </strong>",
"      &mdash; Some genetic variants may only have an effect that is contingent upon the presence of additional genetic variants at nearby or distant loci. Determining these interactions between genes presents an enormous mathematical challenge.",
"     </li>",
"     <li>",
"      <strong>",
"       Gene-environment interactions",
"      </strong>",
"      &mdash; Environmental exposures (broadly defined as all non-genetic exposures) are likely to have a strong influence on the manifestation of most complex traits. These can include behavioral exposures and exposures about which the individual is unaware. The effect of a particular environmental exposure on the expression of a genetic determinant has been demonstrated for some conditions (ie, the effect of an MMP12 variant on chronic obstructive pulmonary disease [COPD] risk is dependent on cigarette smoke exposure) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/44/10950/abstract/6\">",
"       6",
"      </a>",
"      ]. Determining how these gene-environment interactions are manifested also presents a substantial mathematical challenge.",
"     </li>",
"     <li>",
"      <strong>",
"       Rare (uncommon) susceptibility variants",
"      </strong>",
"      &mdash; Rare (uncommon) susceptibility variants are uncommon genetic changes that may play a minor role in a disease phenotype in the population as a whole, yet can have a large effect on the phenotype of single individual. These rare variants are difficult to incorporate into population-based genotype-phenotype correlations because of limited statistical power to detect their effect with usual sample size and challenges in developing models to examine their joint effects. (See",
"      <a class=\"local\" href=\"#H3540587\">",
"       'Common disease-rare variant hypothesis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Epigenetic mechanisms",
"      </strong>",
"      &mdash; Epigenetic mechanisms influence the expression of a gene without changing any DNA sequence. Such mechanisms may be heritable or post-natal and include DNA methylation and histone modification. Environmental or behavioral exposures may lead to human disease through epigenetics. For example, cigarette smoking can induce increased DNA methylation and thus reduced expression of genes acting as tumor suppressors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3540573\">",
"    <span class=\"h1\">",
"     COMMON VERSUS RARE ALLELES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The polygenic nature of complex traits is widely accepted, but controversy exists regarding the likely frequency of the most important susceptibility alleles for complex traits [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10950/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. The relative contribution of common variants (minor allele frequency [MAF] &ge;5 percent) or rare variants (MAF &le;1 percent) as critical determinants of complex traits is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H707825542\">",
"    <span class=\"h2\">",
"     Impact on disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The comparative impact of common or rare alleles likely depends on the complex trait of interest and whether &ldquo;impact&rdquo; is defined on the basis of population attributable risk (favoring common variants) or risk prediction (favoring rare variants with larger effects). Population attributable risk (PAR) refers to the proportion of subjects affected by a disease in a population that can be explained by exposure to a particular risk factor. Risk prediction relates to the likelihood that an individual with a particular risk factor will develop a disease. A classic example from epidemiology helps illustrate the differences between these two concepts:",
"   </p>",
"   <p>",
"    Lung cancer risk is increased in both people who smoke and in people who have an occupational history of asbestos exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10950/abstract/9\">",
"     9",
"    </a>",
"    ]. The risk for lung cancer in an individual who worked in an asbestos factory is significantly greater than the risk for lung cancer in the average smoker. However, cigarette smoking is considerably more common than having worked in an asbestos factory. Thus, although exposure to asbestos confers a greater risk for lung cancer (better risk prediction) than a history of smoking at an individual level, reducing exposure to cigarette smoking would have a much greater impact in reducing the number of lung cancer cases than eliminating asbestos. Viewed through this framework, it is clear that there is value to identifying common and rare determinants of complex genetic traits, as they both affect the development of human diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3540580\">",
"    <span class=\"h2\">",
"     Common disease-common variant hypothesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The common disease-common variant hypothesis posits that common genetic variants underlie susceptibility to most common traits (eg, cardiovascular disease, diabetes, or asthma) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10950/abstract/10\">",
"     10",
"    </a>",
"    ]. This hypothesis is rooted in population genetics theory, which states that the current human population is the result of a global expansion from a smaller founding population from sub-Saharan Africa. Thus, the current human population shares common genetic variants that were present in the founding population, and common complex traits are the result of inheriting these variants [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10950/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To a certain extent, the identification of nearly 1450 highly replicable genetic loci from genome-wide association studies (GWAS) supports the common disease-common variant hypothesis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10950/abstract/12\">",
"     12",
"    </a>",
"    ]. However, rare variants may partly explain findings for common variants in GWAS [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10950/abstract/13\">",
"     13",
"    </a>",
"    ] and explain some of the unexplained or &ldquo;missing&rdquo; heritability for most complex traits. (See",
"    <a class=\"local\" href=\"#H3540594\">",
"     'Approaches to identifying genetic determinants of complex traits'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/38/3689?source=see_link&amp;anchor=H7#H7\">",
"     \"Genetic association studies: Principles and applications\", section on 'Genome-wide association studies (GWAS)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3540587\">",
"    <span class=\"h2\">",
"     Common disease-rare variant hypothesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;To date, more than 1450 common susceptibility variants have been mapped. For a given complex trait (eg, asthma), however, the variants identified explain only a small fraction of the total heritability (proportion of phenotypic variation explained by genetics). Moreover, they appear to be of limited value in predicting disease risk. As an example, while up to 80 percent of the variability in height is felt to be due to genetic factors [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10950/abstract/14,15\">",
"     14,15",
"    </a>",
"    ], the combined effect of 20 genetic loci identified by GWAS explained less than 3 percent of the heritability of height [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10950/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since the loci identified by an initial GWAS likely represent the loci with the greatest contribution to the heritability, it has been argued that further study of common genetic variation in increasingly larger samples is unlikely to uncover a substantial portion of the &ldquo;missing heritability&rdquo; of complex traits [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10950/abstract/7\">",
"     7",
"    </a>",
"    ], which may be at least partly due to the effects of rare variants. Rare variants may be more valuable in predicting disease risk at an individual level than common variants [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10950/abstract/17-19\">",
"     17-19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2886789\">",
"    <span class=\"h2\">",
"     Other hypotheses",
"    </span>",
"    &nbsp;&mdash;&nbsp;As stated above, the causes of a significant proportion of the heritability of complex traits have yet to be identified. There are plausible explanations for this, including gene-by-gene or gene-by-environment interactions and epigenetic",
"    <strong>",
"    </strong>",
"    mechanisms. Most GWAS performed to date have analyzed data from the perspective of identifying those associations found most frequently, thereby detecting variants with the most significant p-values but not necessarily the strongest genetic effects. Similarly, virtually all published GWAS use a univariate modeling approach that tests for association one variant at a time, ignoring possible effects of two or more variants acting in combination.",
"   </p>",
"   <p>",
"    The inherent complexity of common diseases suggests that consideration of these issues will be fruitful. However, the required statistical methods needed for such analyses; the computational resources needed to search for complex gene-gene and gene-environment interactions; as well as resources to integrate epigenetic and genomics data at a genome-wide scale, are only now being developed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3540594\">",
"    <span class=\"h1\">",
"     APPROACHES TO IDENTIFYING GENETIC DETERMINANTS OF COMPLEX TRAITS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Linkage analysis, a statistical technique that successfully identified causal genes for over 2000 monogenic diseases, has had limited success for gene mapping of complex traits (eg, identification of maturity onset diabetes of the young [MODY] 1, 2, and 3 for diabetes) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10950/abstract/20\">",
"     20",
"    </a>",
"    ]. Identifying genetic determinants for complex traits has proven to be very challenging. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43717?source=see_link\">",
"     \"Glossary of genetic terms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Until the mid-1990s, the two main approaches to identify susceptibility variants for complex traits were positional cloning (genome-wide linkage analysis followed by fine mapping analyses of linkage and association) and candidate-gene association studies. The candidate gene approach (ie, making an educated guess about the role of a gene in a disease based on prior knowledge of the functions of that gene) has been occasionally successful (eg, identification of APOE4 for Alzheimer's disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10950/abstract/21\">",
"     21",
"    </a>",
"    ]. However, many findings have been inconsistently replicated and applications are limited to conditions with known biology.",
"   </p>",
"   <p>",
"    A genetic mapping technique, now called genome-wide association study (GWAS), involves the simultaneous testing of multiple genetic variants spread across the human genome for association with a particular disease or trait. Whereas candidate gene approaches require a priori knowledge about the functions of a gene, GWAS studies are a way to scan all the genes in the genome without bias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/38/3689?source=see_link\">",
"     \"Genetic association studies: Principles and applications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    GWAS became feasible upon compilation of high resolution linkage disequilibrium maps of common genetic variants (through the International HapMap Project) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10950/abstract/22\">",
"     22",
"    </a>",
"    ], and with the advent of high throughput genome-wide genotyping technologies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10950/abstract/23\">",
"     23",
"    </a>",
"    ]. To date, GWAS have identified over 1449 highly-replicable genetic loci for 237 human traits [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10950/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    GWAS have identified susceptibility loci with [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10950/abstract/24\">",
"     24",
"    </a>",
"    ] and without [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10950/abstract/25\">",
"     25",
"    </a>",
"    ] known function. In addition, loci identified by GWAS are providing surprising genetic links among seemingly unrelated complex traits (eg, a single nucleotide polymorphism [SNP] in the transcription factor 2 gene, also known as hepatocyte nuclear factor-1-beta [HF1B], is associated with both type 2 diabetes and prostate cancer) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10950/abstract/26\">",
"     26",
"    </a>",
"    ]. Although much work remains to be done with regard to functional characterization of well-replicated loci, GWAS have yielded novel insights into the pathogenesis of numerous complex traits. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/63/5112?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of genetic variation\", section on 'Nucleotide substitutions and single nucleotide polymorphisms (SNPs)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The hallmark of a significant finding of genetic association for a complex trait is the ability to reproduce an original finding of association in independent populations. Demonstration that a statistically-significant genotype-phenotype correlation can be found in an independent population is considered the most rigorous proof of genetic association and has become a standard in the field. In contrast, all singular findings of genetic association should be considered speculative. An important caveat to this rule is that certain susceptibility loci may only be relevant to certain ethnic groups. Thus, an observation about a genotype-phenotype association should first be tested in a cohort belonging to the same ethnic group as the initial analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10950/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3540615\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complex trait conditions are those that cannot be explained by alteration of a single gene (ie, monogenic). They are typically polygenic, with additional influences from gene-gene and gene-environment interactions. (See",
"      <a class=\"local\" href=\"#H3540509\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complex genetic traits involve a broader spectrum of mutations than typically seen with monogenic conditions. This spectrum of mutations includes variations in regulatory genes residing in noncoding DNA sequences. (See",
"      <a class=\"local\" href=\"#H3540524\">",
"       'Spectrum of genetic variation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The correlation between genotype and phenotype for complex genetic traits is weaker than for Mendelian traits. This weaker correlation is potentially influenced by polygenic effects, gene-gene and gene-environment interactions, epigenetic phenomena, and unidentified rare disease-susceptibility variants. (See",
"      <a class=\"local\" href=\"#H3540531\">",
"       'Determinants of genetic effect'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complex genetic traits may be associated with commonly occurring allelic variants that individually have a weak effect or with rare variants that have a stronger effect. Common variants have a greater impact on population attributable risk, while uncommon variants have a greater impact on risk prediction at the level of the individual. (See",
"      <a class=\"local\" href=\"#H3540573\">",
"       'Common versus rare alleles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Techniques to identify complex trait genes include linkage analyses, candidate gene testing, and genome-wide association studies (GWAS). GWAS have identified over 1450 highly-replicable genetic loci for complex human traits. Replication of findings in another cohort is an essential element to validate findings from an initial GWAS. (See",
"      <a class=\"local\" href=\"#H3540594\">",
"       'Approaches to identifying genetic determinants of complex traits'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10950/abstract/1\">",
"      Gu Y, Harley IT, Henderson LB, et al. Identification of IFRD1 as a modifier gene for cystic fibrosis lung disease. Nature 2009; 458:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10950/abstract/2\">",
"      Stefansson H, Rye DB, Hicks A, et al. A genetic risk factor for periodic limb movements in sleep. N Engl J Med 2007; 357:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10950/abstract/3\">",
"      Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10950/abstract/4\">",
"      Harismendy O, Notani D, Song X, et al. 9p21 DNA variants associated with coronary artery disease impair interferon-&gamma; signalling response. Nature 2011; 470:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10950/abstract/5\">",
"      Verlaan DJ, Berlivet S, Hunninghake GM, et al. Allele-specific chromatin remodeling in the ZPBP2/GSDMB/ORMDL3 locus associated with the risk of asthma and autoimmune disease. Am J Hum Genet 2009; 85:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10950/abstract/6\">",
"      Hunninghake GM, Cho MH, Tesfaigzi Y, et al. MMP12, lung function, and COPD in high-risk populations. N Engl J Med 2009; 361:2599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10950/abstract/7\">",
"      Goldstein DB. Common genetic variation and human traits. N Engl J Med 2009; 360:1696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10950/abstract/8\">",
"      Hirschhorn JN. Genomewide association studies--illuminating biologic pathways. N Engl J Med 2009; 360:1699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10950/abstract/9\">",
"      DOLL R. Mortality from lung cancer in asbestos workers. Br J Ind Med 1955; 12:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10950/abstract/10\">",
"      Reich DE, Lander ES. On the allelic spectrum of human disease. Trends Genet 2001; 17:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10950/abstract/11\">",
"      Cargill M, Daley GQ. Mining for SNPs: putting the common variants--common disease hypothesis to the test. Pharmacogenomics 2000; 1:27.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.genome.gov/multimedia/illustrations/GWAS_2011_2.pdf (Accessed on November 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10950/abstract/13\">",
"      Dickson SP, Wang K, Krantz I, et al. Rare variants create synthetic genome-wide associations. PLoS Biol 2010; 8:e1000294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10950/abstract/14\">",
"      Carmichael CM, McGue M. A cross-sectional examination of height, weight, and body mass index in adult twins. J Gerontol A Biol Sci Med Sci 1995; 50:B237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10950/abstract/15\">",
"      Silventoinen K, Sammalisto S, Perola M, et al. Heritability of adult body height: a comparative study of twin cohorts in eight countries. Twin Res 2003; 6:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10950/abstract/16\">",
"      Weedon MN, Lango H, Lindgren CM, et al. Genome-wide association analysis identifies 20 loci that influence adult height. Nat Genet 2008; 40:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10950/abstract/17\">",
"      Meigs JB, Shrader P, Sullivan LM, et al. Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med 2008; 359:2208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10950/abstract/18\">",
"      Paynter NP, Chasman DI, Buring JE, et al. Cardiovascular disease risk prediction with and without knowledge of genetic variation at chromosome 9p21.3. Ann Intern Med 2009; 150:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10950/abstract/19\">",
"      Kraft P, Hunter DJ. Genetic risk prediction--are we there yet? N Engl J Med 2009; 360:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10950/abstract/20\">",
"      Bell GI, Polonsky KS. Diabetes mellitus and genetically programmed defects in beta-cell function. Nature 2001; 414:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10950/abstract/21\">",
"      Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 1993; 90:1977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10950/abstract/22\">",
"      International HapMap Consortium. A haplotype map of the human genome. Nature 2005; 437:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10950/abstract/23\">",
"      Wang DG, Fan JB, Siao CJ, et al. Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome. Science 1998; 280:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10950/abstract/24\">",
"      Kathiresan S, Melander O, Anevski D, et al. Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med 2008; 358:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10950/abstract/25\">",
"      Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006; 314:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10950/abstract/26\">",
"      Gudmundsson J, Sulem P, Steinthorsdottir V, et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet 2007; 39:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10950/abstract/27\">",
"      Yasuda K, Miyake K, Horikawa Y, et al. Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nat Genet 2008; 40:1092.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14600 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-B3512DFB86-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_44_10950=[""].join("\n");
var outline_f10_44_10950=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3540615\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3540509\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3540524\">",
"      SPECTRUM OF GENETIC VARIATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3540531\">",
"      Determinants of genetic effect",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3540573\">",
"      COMMON VERSUS RARE ALLELES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H707825542\">",
"      Impact on disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3540580\">",
"      Common disease-common variant hypothesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3540587\">",
"      Common disease-rare variant hypothesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2886789\">",
"      Other hypotheses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3540594\">",
"      APPROACHES TO IDENTIFYING GENETIC DETERMINANTS OF COMPLEX TRAITS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3540615\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/38/21097?source=related_link\">",
"      Basic principles of genetic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/38/3689?source=related_link\">",
"      Genetic association studies: Principles and applications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43717?source=related_link\">",
"      Glossary of genetic terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/46/43750?source=related_link\">",
"      Non-Mendelian inheritance patterns of monogenic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35718?source=related_link\">",
"      Overview of Mendelian inheritance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/63/5112?source=related_link\">",
"      Overview of genetic variation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_44_10951="ALCL hallmark cells";
var content_f10_44_10951=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F85992&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F85992&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    ALK positive anaplastic large cell lymphoma, classical variant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The lymphoma cells are large and anaplastic. Hallmark cells with horseshoe-shaped nuclei and perinuclear hofs are present (arrows). Hematoxylin-eosin stain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Ioachim HL, Medeiros LJ. Ioachim&rsquo;s Lymph Node Pathology, 4th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_44_10951=[""].join("\n");
var outline_f10_44_10951=null;
var title_f10_44_10952="Echocardiographic evaluation of the thoracic and proximal abdominal aorta";
var content_f10_44_10952=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Echocardiographic evaluation of the thoracic and proximal abdominal aorta",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/44/10952/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/44/10952/contributors\">",
"     Nelson B Schiller, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/44/10952/contributors\">",
"     Xiushui Ren, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/44/10952/contributors\">",
"     Bryan Ristow, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/44/10952/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/44/10952/contributors\">",
"     Warren J Manning, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/44/10952/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/44/10952/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/44/10952/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiography enables qualitative and quantitative evaluation of the thoracic and proximal abdominal aorta [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10952/abstract/1\">",
"     1",
"    </a>",
"    ]. Transthoracic echocardiography (TTE) provides views of the proximal ascending aorta, aortic arch and portions of the descending aorta. However, transesophageal echocardiography (TEE) rather than TTE is indicated for comprehensive imaging of the aorta, especially in the emergency evaluation of aortic dissection or traumatic rupture of the aortic isthmus [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10952/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of aortic dissection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31878?source=see_link\">",
"     \"Transesophageal echocardiography in traumatic rupture of the aortic isthmus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Echocardiographic evaluation of the aorta for atherosclerotic plaque, sinus of Valsalva aneurysms, aortic dilatation, and dissection will be reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NORMAL AORTIC ROOT AND ASCENDING AORTA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The proximal ascending aorta attaches to the left ventricle at the annulus (hinge line of the aortic leaflets) and includes the aortic root (comprised of the three sinuses of Valsalva), the sinotubular junction, and the tubular ascending portion of the aorta. The aortic root is a direct continuation of the left ventricular outflow tract and is located right and posterior to the pulmonary infundibulum. The lower portion of the aortic root is connected to the muscular interventricular septum, the membranous septum, and to the mitral-aortic fibrous continuity (also known as the mitral-aortic intervalvular fibrosa).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Two-dimensional echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;TTE examination of the proximal ascending aorta is generally performed in the left parasternal long-axis view (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77446 \" href=\"UTD.htm?20/7/20592\">",
"     image 1",
"    </a>",
"    ). Many sonographers limit their interrogation of the aorta to the proximal sinuses of Valsalva, missing the opportunity to more fully visualize the aorta. Moving up an intercostal interspace or tilting the probe cranially enables imaging of the more superior ascending aorta.",
"   </p>",
"   <p>",
"    Right parasternal views, recorded with the patient in a right lateral decubitus position, may also be revealing [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10952/abstract/3\">",
"     3",
"    </a>",
"    ]. This method is especially useful when the aorta dilates to the right of the sternum.",
"   </p>",
"   <p>",
"    A cross sectional image of the aortic root is obtained in the parasternal short-axis view (",
"    <a class=\"graphic graphic_figure graphicRef67673 \" href=\"UTD.htm?12/49/13074\">",
"     figure 1",
"    </a>",
"    ). The suprasternal notch view visualizes the aortic arch.",
"   </p>",
"   <p>",
"    TEE provides more highly resolved images of the ascending aorta, aortic arch, and descending thoracic aorta than TTE, although a small portion of the distal ascending aorta and proximal arch cannot be seen due to interposition of the right mainstem bronchus and trachea.",
"   </p>",
"   <p>",
"    All imaged portions of the aorta should be evaluated for the presence of plaque, dilatation and dissection (including intramural hematoma). Views used for measurement should be those that show the maximum diameter of the aortic root [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10952/abstract/3\">",
"     3",
"    </a>",
"    ]. The aortic root at the level of the sinuses generally has the largest diameter (normal &le;3.7 cm), while the ascending aortic diameter at the sinotubular junction and above is slightly smaller (normal &lt;3.5 cm). Age and body surface area adjusted normal values for the aortic root have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10952/abstract/4\">",
"     4",
"    </a>",
"    ] and have been recommended for use as normative standards by the",
"    <a class=\"external\" href=\"file://www.asefiles.org/ChamberQuantification.pdf\">",
"     American Society of Echocardiography",
"    </a>",
"    (ASE) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10952/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Evaluation of coronary arteries",
"    </span>",
"    &nbsp;&mdash;&nbsp;The origins of the coronary artery are visible in both short- and long-axis views on adequate TTE or TEE images. The left main artery can often be followed to and beyond its bifurcation into the anterior descending artery and circumflex artery (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79123 graphicRef54573 \" href=\"UTD.htm?2/51/2868\">",
"     image 2A-B",
"    </a>",
"    ); the right coronary artery can usually be followed for up to 3 cm from its origin. While echocardiography is not a practical method to detect luminal obstruction, careful gain manipulation makes it possible to detect larger bright densities along the course of the vessel that probably represent proximal calcification.",
"   </p>",
"   <p>",
"    In adults, an anomalous origin of the coronary arteries is difficult to establish with an echocardiogram. The best clue to the presence of a single coronary artery, or one that ends in a coronary cameral fistula, is to observe the greatly enlarged coronary artery origin often associated with this abnormality. At times, these vessels dilate to the point that they may be confused with a sinus of Valsalva aneurysm. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/56/14218?source=see_link\">",
"     \"Congenital and pediatric coronary artery abnormalities\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most cameral fistulae that terminate in one of the ventricles can be detected and localized by observing the abnormal color flow signal that marks the entrance of the fistula into the chamber. There are several reports from Japan of success in identifying the proximal aneurysms of Kawasaki's disease by echocardiography. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30826?source=see_link\">",
"     \"Cardiovascular sequelae of Kawasaki disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     M-mode echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The motion of the aortic root on the M-mode echocardiogram is an indicator of global left ventricular systolic and diastolic function [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10952/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Since aortic root motion reflects the events of atrial filling and emptying, it also provides information about left atrial function (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58902 graphicRef56155 graphicRef79751 \" href=\"UTD.htm?30/55/31609\">",
"     image 3A-C",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    During systole, the aortic root normally moves anteriorly over 7 mm and returns almost completely to its starting point immediately after the conclusion of ejection. The atrial or presystolic contribution to aortic root motion is normally minimal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Abnormal aortic root motion on M-mode echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the systolic excursion of the aortic root is decreased, stroke volume is probably reduced, an effect that is independent of the left ventricular ejection fraction. As an example, if the left ventricle is hypovolemic but contracts normally, the aortic root motion will be decreased. Aortic root motion will also be decreased if the ejection fraction is severely reduced and the ventricle is increased in size (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53355 \" href=\"UTD.htm?29/56/30592\">",
"     image 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Augmented root motion with full opening of the aortic valve suggests a high cardiac output. High output states are quite easy to recognize and their appreciation is helpful in clinical management. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/47/9978?source=see_link\">",
"       \"High-output heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Normal or augmented systolic motion of the aortic root in the face of reduced aortic leaflet separation suggests atrial filling out of proportion to aortic flow and is typical of mitral insufficiency.",
"     </li>",
"     <li>",
"      If the initial diastolic posterior motion of the aortic root is slowed, and the late diastolic posterior motion of the aorta is exaggerated with atrial systole, reduced LV compliance is suspected.",
"     </li>",
"     <li>",
"      Aortic root motion tends to be flat in restrictive diastolic states, reflecting the reduced cardiac output generally associated with restrictive cardiomyopathy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     AORTIC PLAQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atherosclerotic plaque is visualized as a region of intimal thickening or protrusion. Plaque may be accompanied by focal calcifications, ulcerations,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    superimposed thrombi. The presence of thoracic aortic plaque, even when visualized in the descending aorta, has been associated with an increased risk of ischemic stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10952/abstract/8\">",
"     8",
"    </a>",
"    ]. Aortic plaque may be a marker of vascular disease and other risk factors for cerebrovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10952/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Care must be taken not to confuse anterior aortic wall thickening with the right coronary artery.",
"   </p>",
"   <p>",
"    Studies have found increased risk of stroke among patients with protruding aortic atheroma &ge; 4 or 5 mm thick. Our institution uses the following TEE grading scale for aortic intimal thickness: grade 0 = normal, grade 1 = mild intimal thickening, grade 2 = moderate intimal thickening less than 5 mm, grade 3 = protruding atheroma &ge; 5 mm thick, and grade 4 = mobile thrombi on atheroma.",
"   </p>",
"   <p>",
"    On TEE, the presence of large, mobile, or ulcerated plaques is associated with increased risk of stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10952/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. The management of aortic plaques is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10809?source=see_link\">",
"     \"Embolism from aortic plaque: Thromboembolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31994?source=see_link\">",
"     \"Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SINUS OF VALSALVA ANEURYSMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sinus of Valsalva aneurysms are occasionally seen on long- and short-axis views of the two-dimensional echocardiogram. The most common location is the right sinus of Valsalva, from which rupture may extend into the right ventricle or, less frequently, the right atrium or interventricular septum [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10952/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The next most likely location of the aneurysm is the noncoronary sinus, followed by the left sinus. Infrequently, the aneurysm ruptures into the left ventricle (mimicking aortic regurgitation) or into the left atrium. In a report of 86 patients undergoing sinus of Valsalva aneurysm repair, 44 percent had associated aortic regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10952/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Contrast echocardiography is helpful in delineating the aneurysm and shunt arising from rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10952/abstract/14\">",
"     14",
"    </a>",
"    ]. However, color flow Doppler imaging is the technique of choice for identifying a ruptured sinus of Valsalva aneurysm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     AORTIC DILATATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2003",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    practice guidelines for echocardiography recommend echocardiography for evaluation of suspected dilatation of the proximal aorta (",
"    <a class=\"graphic graphic_movie graphicRef79876 \" href=\"UTD.htm?31/57/32656\">",
"     movie 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10952/abstract/1\">",
"     1",
"    </a>",
"    ]. TTE is recommended as the first choice for this indication with TEE used only if the TTE examination is incomplete or additional information is needed.",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines also recommend echocardiography to evaluate aortic root dilation in Marfan syndrome or other connective tissue syndromes. In addition, the guidelines recommend TTE to examine first-degree relatives of patients with Marfan syndrome or other connective tissue disorders. The 2010",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines for the diagnosis and management of patients with thoracic aortic disease recommend echocardiogram should be performed at the time of diagnosis of Marfan syndrome, six months thereafter to determine the rate of enlargement, and annually if stability of the aortic diameter is documented and less than 4.5 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10952/abstract/15\">",
"     15",
"    </a>",
"    ]. The diagnosis and management of the Marfan syndrome are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=see_link\">",
"     \"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/51/5945?source=see_link\">",
"     \"Management of Marfan syndrome and related disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    practice guidelines for valvular disease recommend measuring the diameters of the aortic root and ascending aorta by TTE for patients with a bicuspid aortic [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10952/abstract/16\">",
"     16",
"    </a>",
"    ]. Magnetic resonance imaging (MRI) or computed tomography (CT) is recommended if the aortic root or ascending aorta cannot be adequately measured by echocardiography. Yearly echocardiography, MRI, or CT is recommended for patients with bicuspid aortic valves and dilatation of the aortic root or ascending aorta (diameter greater than 4.0 cm, with consideration of a lower threshold for patients of small stature). Issues related to bicuspid aortic valve disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6169?source=see_link\">",
"     \"Clinical manifestations and diagnosis of bicuspid aortic valve\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7078?source=see_link\">",
"     \"Treatment of bicuspid aortic valve stenosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25050?source=see_link\">",
"     \"Course and management of chronic aortic regurgitation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/25/27032?source=see_link\">",
"     \"Pregnancy in women with a bicuspid aortic valve\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Limited data are available to compare echocardiography and CT evaluation of thoracic aortic dilatation and thoracic aneurysm. &nbsp;In a small prospective study of 44 patients with known ascending aortic aneurysm, TTE and CT measurements of aortic diameters correlated well [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10952/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Causes of aortic root and ascending aortic dilatation and aneurysm formation include hypertension (the most common cause), atherosclerosis, aortic dissection, aortic stenosis (post-stenotic dilatation), bicuspid aortic valve (associated with aortic dilatation even without significant stenosis), aortic regurgitation, and the Marfan syndrome and other causes of annuloaortic ectasia. Less common etiologies of aortic dilatation include inflammatory causes, such as Takayasu arteritis and infectious causes, such as syphilis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22712?source=see_link\">",
"     \"Clinical features and diagnosis of thoracic aortic aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Various disease processes are associated with different patterns of aortic dilatation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypertension appears to have a minor impact on aortic root diameter at the level of the sinuses of Valsalva [",
"      <a class=\"abstract\" href=\"UTD.htm?10/44/10952/abstract/18-20\">",
"       18-20",
"      </a>",
"      ], but is associated with enlargement at the sinotubular junction and tubular ascending aorta [",
"      <a class=\"abstract\" href=\"UTD.htm?10/44/10952/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Congenital aortic stenosis is associated with more significant post-stenotic dilatation than degenerative aortic stenosis with similar valve areas (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef51528 \" href=\"UTD.htm?7/36/7746\">",
"       image 5",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/44/10952/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Symmetric dilatation of the three sinuses is most commonly seen in patients with Marfan syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?10/44/10952/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]. This dilation usually, but not always, terminates abruptly at the sinotubular junction and gives these roots a distinctive appearance unlike that of other causes of annuloaortic ectasia (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef52118 graphicRef50641 \" href=\"UTD.htm?38/13/39127\">",
"       image 6A-B",
"      </a>",
"      ). In addition to root dilatation, patients with Marfan syndrome frequently have aortic regurgitation because aortic annulus dilation causes cusp malcoaptation (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef52118 graphicRef50641 \" href=\"UTD.htm?38/13/39127\">",
"       image 6A-B",
"      </a>",
"      ). Issues related to echocardiography in Marfan syndrome are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=see_link\">",
"       \"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Aortic dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;TEE is an appropriate initial test to evaluate suspected aortic dissection (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69205 \" href=\"UTD.htm?41/48/42767\">",
"     image 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10952/abstract/2\">",
"     2",
"    </a>",
"    ]. Choice among TEE, MRI or CT for initial noninvasive imaging of aortic dissection is governed by clinical considerations and availability (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of aortic dissection\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    TEE imaging can help determine the potential for aortic valve-sparing operations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10952/abstract/24\">",
"     24",
"    </a>",
"    ]. However, TEE evaluation of branch vessel involvement may be incomplete and additional imaging with other techniques may be required [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10952/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TTE has limited utility for evaluation of the thoracic aorta for dissection. The primary problem with TTE in this setting is its inability to adequately visualize the distal ascending, transverse, and descending thoracic aorta in a substantial majority of patients. Although an undulating intimal flap may be seen in the proximal aorta in some patients (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75705 \" href=\"UTD.htm?2/57/2960\">",
"     image 8",
"    </a>",
"    ), TTE is less sensitive and specific for detection of aortic dissection than TEE, CT, and MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10952/abstract/25-27\">",
"     25-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a result, the role of TTE in suspected aortic dissection is primarily for diagnosis of cardiac complications of dissection, including aortic insufficiency, pericardial",
"    <span class=\"nowrap\">",
"     effusion/tamponade,",
"    </span>",
"    and regional left ventricular systolic function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DESCENDING THORACIC AORTA AND AORTIC ARCH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The descending thoracic aorta can be seen posterior to the long- and short-axis parasternal views on TTE (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef60999 graphicRef53998 graphicRef79701 graphicRef61910 \" href=\"UTD.htm?32/3/32825\">",
"     image 9A-D",
"    </a>",
"    ). In the parasternal long-axis view, the descending aorta can be seen in cross-section at the posterior atrioventricular groove, situated outside the pericardium. In the parasternal short-axis plane, an oblique longitudinal section of the descending aorta can be seen.",
"   </p>",
"   <p>",
"    Imaging can identify dilation or an aneurysm and may permit detection of dissection. The descending aorta is a useful landmark for distinguishing pleural and pericardial effusions, since the pericardium encloses the heart anterior to the descending aorta.",
"   </p>",
"   <p>",
"    On TTE, the aortic arch is visualized in the suprasternal notch view. This view is recommended as a routine component of TTE examination, particularly in cases with bicuspid aortic valve which is frequently associated with coarctation of the aorta. In the suprasternal notch view, color and spectral Doppler interrogation of the proximal descending aorta may detect accelerated flow characteristic of coarctation. If forward velocity in the descending aorta by continuous-wave Doppler exceeds 2",
"    <span class=\"nowrap\">",
"     m/sec,",
"    </span>",
"    aortic coarctation should be suspected. If the run-off at the site of coarctation is delayed, severe coarctation must be considered, and alternate imaging modalities such as MRI can be helpful in confirming diagnosis and grading severity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/53/23385?source=see_link&amp;anchor=H21#H21\">",
"     \"Clinical manifestations and diagnosis of coarctation of the aorta\", section on 'Echocardiography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Views of the descending thoracic aorta as it courses along the spine can be obtained in the apical views; posterior angulation often produces long-axis (in the two chamber view) and short-axis (in the four chamber view) images (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79701 graphicRef60999 \" href=\"UTD.htm?6/25/6548\">",
"     image 9C",
"    </a>",
"    ). Although the aorta is too deep in the far field to be well resolved, the size of the aorta can generally be measured. A normal caliber aorta is evidence against dissection at that location.",
"   </p>",
"   <p>",
"    When aortic dissection involves the thoracic aorta, especially if there is extravasation of blood around the aorta, the vessel can be imaged from the left paraspinal window. This strategy can be used to supply additional evidence about the state of the thoracic aorta. However, transesophageal echocardiography is the method of choice for detecting pathology of the thoracic aorta.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Abdominal aorta",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subcostal imaging of the proximal abdominal aorta is often included in the TTE examination [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10952/abstract/28\">",
"     28",
"    </a>",
"    ]. The structure can be found to the left of the spine running parallel, but to the left of and deep to, the inferior vena cava (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77731 graphicRef77191 \" href=\"UTD.htm?41/7/42103\">",
"     image 10A-B",
"    </a>",
"    ). Differentiation of the aorta from the vena cava can be made by appreciating the systolic pulsations of the aorta, which are usually easy to recognize.",
"   </p>",
"   <p>",
"    Using the subcostal approach, atheromatous irregularities and aneurysms of the proximal abdominal aorta are readily seen (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67861 graphicRef81130 graphicRef60665 \" href=\"UTD.htm?18/23/18807\">",
"     image 11A-C",
"    </a>",
"    ). Since the descending aorta is closer to the transducer in this view than in other TTE views, the yield for intimal flaps of aortic dissection is higher from this window. In addition, comparing the smoothness of the inner layer of the aorta to the vena cava gives some indication of the degree of atheromatous change that is present in the aorta and, by inference, in the remainder of the vascular tree. Atheromatous change is typically appreciated as obvious irregularities along the usually smooth interior of the vessel.",
"   </p>",
"   <p>",
"    Although TEE is the preferred technique for evaluating the aorta, it does not image the aorta very far below the diaphragm [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10952/abstract/29\">",
"     29",
"    </a>",
"    ]. Ideally, linear arrays should be used for more comprehensive evaluation of the abdominal aorta.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     OTHER GREAT VESSELS",
"    </span>",
"    &nbsp;&mdash;&nbsp;TTE is useful in evaluating the other great vessels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Pulmonary artery",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the parasternal long-axis view, imaging just superior to the left atrium usually demonstrates the right pulmonary artery as it crosses under the ascending aorta. Inspecting the bifurcation of the pulmonary artery in its long-axis (in the parasternal short-axis view) may reveal the relationship between the left pulmonary artery and the descending aorta (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64091 graphicRef63066 \" href=\"UTD.htm?27/13/27859\">",
"     image 12A-B",
"    </a>",
"    ). Color Doppler near the pulmonary artery bifurcation in this view can detect the retrograde continuous flow characteristic of a patent ductus arteriosus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Carotid arteries and subclavian vessels",
"    </span>",
"    &nbsp;&mdash;&nbsp;The innominate, left common carotid, and left subclavian vessel origins can be imaged by TTE from the suprasternal notch. From the neck, the carotid and vertebral arteries can be studied effectively by trained vascular sonographers using dedicated linear array transducers. Skill in performing this examination is helpful when evaluating a patient for dissection of the aorta because detection of extension of the dissection into the carotid arteries has important clinical implications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14304927\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transthoracic echocardiography (TTE) provides views of the proximal ascending aorta, aortic arch, and portions of the descending aorta. However, transesophageal echocardiography (TEE) is superior to TTE for comprehensive imaging of the aorta, especially in the emergency evaluation of aortic dissection or traumatic rupture of the aortic isthmus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=see_link\">",
"       \"Clinical manifestations and diagnosis of aortic dissection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31878?source=see_link\">",
"       \"Transesophageal echocardiography in traumatic rupture of the aortic isthmus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      TEE provides more highly resolved images of the ascending aorta, aortic arch, and descending thoracic aorta than TTE, although a small portion of the distal ascending aorta and proximal arch cannot be seen by TEE due to interposition of the right mainstem bronchus and trachea. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Two-dimensional echocardiography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presence of large, mobile, or ulcerated plaques in the thoracic aorta on TEE is associated with an increased risk of stroke. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Aortic plaque'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Echocardiography is the primary modality for identification of sinus of Valsalva aneurysms and any associated shunt arising from rupture. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Sinus of Valsalva aneurysms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Echocardiography enables identification of aortic dilatation and is indicated for monitoring of individuals at risk for progressive aortic dilatation, particularly those with Marfan syndrome or a bicuspid aortic valve. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Aortic dilatation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      TEE is an appropriate initial test to evaluate suspected aortic dissection. Choice among TEE, MRI, or CT for initial noninvasive imaging of aortic dissection is governed by clinical considerations and availability. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=see_link\">",
"       \"Clinical manifestations and diagnosis of aortic dissection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10952/abstract/1\">",
"      Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation 2003; 108:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10952/abstract/2\">",
"      Douglas PS, Khandheria B, Stainback RF, et al. ACCF/ASE/ACEP/ASNC/SCAI/SCCT/SCMR 2007 appropriateness criteria for transthoracic and transesophageal echocardiography: a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American Society of Echocardiography, American College of Emergency Physicians, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and the Society for Cardiovascular Magnetic Resonance endorsed by the American College of Chest Physicians and the Society of Critical Care Medicine. J Am Coll Cardiol 2007; 50:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10952/abstract/3\">",
"      Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10952/abstract/4\">",
"      Roman MJ, Devereux RB, Kramer-Fox R, O'Loughlin J. Two-dimensional echocardiographic aortic root dimensions in normal children and adults. Am J Cardiol 1989; 64:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10952/abstract/5\">",
"      Djalaly A, Schiller NB, Poehlmann HW, et al. Diastolic aortic root motion in left ventricular hypertrophy. Chest 1981; 79:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10952/abstract/6\">",
"      Strunk BL, Fitzgerald JW, Lipton M, et al. The posterior aortic wall echocardiogram. Its relationship to left atrial volume change. Circulation 1976; 54:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10952/abstract/7\">",
"      Pratt RC, Parisi AF, Harrington JJ, Sasahara AA. The influence of left ventricular stroke volume on aortic root motion: an echocardiographic study. Circulation 1976; 53:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10952/abstract/8\">",
"      Blackshear JL, Pearce LA, Hart RG, et al. Aortic plaque in atrial fibrillation: prevalence, predictors, and thromboembolic implications. Stroke 1999; 30:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10952/abstract/9\">",
"      Nam HS, Han SW, Lee JY, et al. Association of aortic plaque with intracranial atherosclerosis in patients with stroke. Neurology 2006; 67:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10952/abstract/10\">",
"      Meissner I, Khandheria BK, Sheps SG, et al. Atherosclerosis of the aorta: risk factor, risk marker, or innocent bystander? A prospective population-based transesophageal echocardiography study. J Am Coll Cardiol 2004; 44:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10952/abstract/11\">",
"      Ferrari E, Vidal R, Chevallier T, Baudouy M. Atherosclerosis of the thoracic aorta and aortic debris as a marker of poor prognosis: benefit of oral anticoagulants. J Am Coll Cardiol 1999; 33:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10952/abstract/12\">",
"      Milani RV, Lavie CJ, Gilliland YE, et al. Overview of transesophageal echocardiography for the chest physician. Chest 2003; 124:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10952/abstract/13\">",
"      Moustafa S, Mookadam F, Cooper L, et al. Sinus of Valsalva aneurysms--47 years of a single center experience and systematic overview of published reports. Am J Cardiol 2007; 99:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10952/abstract/14\">",
"      Terdjman M, Bourdarias JP, Farcot JC, et al. Aneurysms of sinus of Valsalva: two-dimensional echocardiographic diagnosis and recognition of rupture into the right heart cavities. J Am Coll Cardiol 1984; 3:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10952/abstract/15\">",
"      Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the diagnosis and management of patients with thoracic aortic disease. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology,American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons,and Society for Vascular Medicine. J Am Coll Cardiol 2010; 55:e27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10952/abstract/16\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10952/abstract/17\">",
"      Tamborini G, Galli CA, Maltagliati A, et al. Comparison of feasibility and accuracy of transthoracic echocardiography versus computed tomography in patients with known ascending aortic aneurysm. Am J Cardiol 2006; 98:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10952/abstract/18\">",
"      Kim M, Roman MJ, Cavallini MC, et al. Effect of hypertension on aortic root size and prevalence of aortic regurgitation. Hypertension 1996; 28:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10952/abstract/19\">",
"      Palmieri V, Bella JN, Arnett DK, et al. Aortic root dilatation at sinuses of valsalva and aortic regurgitation in hypertensive and normotensive subjects: The Hypertension Genetic Epidemiology Network Study . Hypertension 2001; 37:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10952/abstract/20\">",
"      Vasan RS, Larson MG, Levy D. Determinants of echocardiographic aortic root size. The Framingham Heart Study. Circulation 1995; 91:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10952/abstract/21\">",
"      Ben-Dor I, Sagie A, Weisenberg D, et al. Comparison of diameter of ascending aorta in patients with severe aortic stenosis secondary to congenital versus degenerative versus rheumatic etiologies. Am J Cardiol 2005; 96:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10952/abstract/22\">",
"      Eisenberg MJ, Rice SA, Paraschos A, et al. The clinical spectrum of patients with aneurysms of the ascending aorta. Am Heart J 1993; 125:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10952/abstract/23\">",
"      Dev V, Goswami KC, Shrivastava S, et al. Echocardiographic diagnosis of aneurysm of the sinus of Valsalva. Am Heart J 1993; 126:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10952/abstract/24\">",
"      David TE, Feindel CM, Webb GD, et al. Long-term results of aortic valve-sparing operations for aortic root aneurysm. J Thorac Cardiovasc Surg 2006; 132:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10952/abstract/25\">",
"      Nienaber CA, von Kodolitsch Y, Nicolas V, et al. The diagnosis of thoracic aortic dissection by noninvasive imaging procedures. N Engl J Med 1993; 328:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10952/abstract/26\">",
"      Roudaut RP, Billes MA, Gosse P, et al. Accuracy of M-mode and two-dimensional echocardiography in the diagnosis of aortic dissection: an experience with 128 cases. Clin Cardiol 1988; 11:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10952/abstract/27\">",
"      Khandheria BK, Tajik AJ, Taylor CL, et al. Aortic dissection: review of value and limitations of two-dimensional echocardiography in a six-year experience. J Am Soc Echocardiogr 1989; 2:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10952/abstract/28\">",
"      Eisenberg MJ, Geraci SJ, Schiller NB. Screening for abdominal aortic aneurysms during transthoracic echocardiography. Am Heart J 1995; 130:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10952/abstract/29\">",
"      Banning AP, Masani ND, Ikram S, et al. Transoesophageal echocardiography as the sole diagnostic investigation in patients with suspected thoracic aortic dissection. Br Heart J 1994; 72:461.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5293 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-199.231.185.123-EFBF5593C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_44_10952=[""].join("\n");
var outline_f10_44_10952=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14304927\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NORMAL AORTIC ROOT AND ASCENDING AORTA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Two-dimensional echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Evaluation of coronary arteries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      M-mode echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Abnormal aortic root motion on M-mode echocardiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      AORTIC PLAQUE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SINUS OF VALSALVA ANEURYSMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      AORTIC DILATATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DESCENDING THORACIC AORTA AND AORTIC ARCH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Abdominal aorta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      OTHER GREAT VESSELS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Pulmonary artery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Carotid arteries and subclavian vessels",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14304927\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/5293\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5293|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?20/7/20592\" title=\"diagnostic image 1\">",
"      2D TTE parasternal long axis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?6/50/6944\" title=\"diagnostic image 2A\">",
"      Short axis left main CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/42/29359\" title=\"diagnostic image 2B\">",
"      2D TTE Parasternal short axis coronary arteries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?43/4/44096\" title=\"diagnostic image 3A\">",
"      2D and M mode parasternal short axis echo normal aortic root",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?40/12/41152\" title=\"diagnostic image 3B\">",
"      M mode echo normal aorta and left atrium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/54/16228\" title=\"diagnostic image 3C\">",
"      2D TEE and M mode images parasternal short axis aortic valve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/56/30592\" title=\"diagnostic image 4\">",
"      M mode aorta cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?7/36/7746\" title=\"diagnostic image 5\">",
"      Long axis poststenotic dilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/2/28706\" title=\"diagnostic image 6A\">",
"      M mode echo aortic root Marfan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?32/38/33378\" title=\"diagnostic image 6B\">",
"      Aortic root enlargement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/48/42767\" title=\"diagnostic image 7\">",
"      TEE aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/57/2960\" title=\"diagnostic image 8\">",
"      Ascending aortic dissection on echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/22/36207\" title=\"diagnostic image 9A\">",
"      Thoracic aorta dilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/4/38977\" title=\"diagnostic image 9B\">",
"      2D TTE Parasternal views descending thoracic aorta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/50/1824\" title=\"diagnostic image 9C\">",
"      2D TTE 2-chamber descending thoracic aorta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/5/18512\" title=\"diagnostic image 9D\">",
"      2D TTE 4-chamber descending thoracic aorta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?14/3/14386\" title=\"diagnostic image 10A\">",
"      2D TTE Subcostal abdominal aorta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/40/8835\" title=\"diagnostic image 10B\">",
"      Echo image abdominal aorta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?6/54/7009\" title=\"diagnostic image 11A\">",
"      Abdominal aortic aneurysm long and short axis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?16/16/16655\" title=\"diagnostic image 11B\">",
"      Dissection of the abdominal aorta on longitudinal ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/59/30655\" title=\"diagnostic image 11C\">",
"      Dissection of the abdominal aorta on transverse ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/33/43551\" title=\"diagnostic image 12A\">",
"      2D TTE RV outflow tract view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?20/44/21199\" title=\"diagnostic image 12B\">",
"      Long axis pulmonary artery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5293|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/49/13074\" title=\"figure 1\">",
"      2D TTE parasternal short axis view aortic root",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5293|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?31/57/32656\" title=\"movie 1\">",
"      Aortic root aneurysm parasternal long axis echocardiogram",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30826?source=related_link\">",
"      Cardiovascular sequelae of Kawasaki disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22712?source=related_link\">",
"      Clinical features and diagnosis of thoracic aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=related_link\">",
"      Clinical manifestations and diagnosis of aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6169?source=related_link\">",
"      Clinical manifestations and diagnosis of bicuspid aortic valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/53/23385?source=related_link\">",
"      Clinical manifestations and diagnosis of coarctation of the aorta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/56/14218?source=related_link\">",
"      Congenital and pediatric coronary artery abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25050?source=related_link\">",
"      Course and management of chronic aortic regurgitation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10809?source=related_link\">",
"      Embolism from aortic plaque: Thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31994?source=related_link\">",
"      Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=related_link\">",
"      Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/47/9978?source=related_link\">",
"      High-output heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/51/5945?source=related_link\">",
"      Management of Marfan syndrome and related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/25/27032?source=related_link\">",
"      Pregnancy in women with a bicuspid aortic valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31878?source=related_link\">",
"      Transesophageal echocardiography in traumatic rupture of the aortic isthmus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7078?source=related_link\">",
"      Treatment of bicuspid aortic valve stenosis in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_44_10953="Guideline adherence and outcomes in coronary heart disease and heart failure";
var content_f10_44_10953=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Guideline adherence and outcomes in coronary heart disease and heart failure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/44/10953/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/44/10953/contributors\">",
"     Vijay S Ramanath, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/44/10953/contributors\">",
"     Kim A Eagle, MD, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/44/10953/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/44/10953/contributors\">",
"     Suzanne W Fletcher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/44/10953/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/44/10953/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/44/10953/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effective management of coronary heart disease (CHD) and heart failure (HF) is a challenge to clinicians as a consequence of their prevalence, the rapid evolution of therapies to improve outcomes, and patient, practitioner, and system obstacles to the delivery of care. As a result, clinicians often rely on professional societies for guidance in treating their patients with these illnesses.",
"   </p>",
"   <p>",
"    Organizations such as the American Heart Association (AHA), the American College of Cardiology (ACC), the European Society of Cardiology, the International Society for Heart and Lung Transplantation, and the Heart Failure Society of America have developed and disseminated guidelines to aid practitioners in the management of these complex medical conditions.",
"   </p>",
"   <p>",
"    The guideline committees summarize the evidence and expert opinion, and provide final, graded recommendations for patient evaluation and therapy. The guidelines address both acute inpatient and chronic outpatient care. Although some improvements in the use of these evidence-based therapies have occurred, compliance with all appropriate therapies remains suboptimal [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/1-14\">",
"     1-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will: review the evidence for the importance of guideline adherence in the management of myocardial infarction and HF; review how well these guidelines are adhered to; and provide evidence based strategies for improving their. The more general discussion of the assessment, use and value of clinical practice guidelines can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/35/20024?source=see_link\">",
"     \"Clinical practice guidelines\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CORONARY HEART DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence from randomized trials involving thousands of patients in the United States strongly supports the use of a number of interventions in most patients with CHD such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , statins, beta blockers, angiotensin converting enzyme (ACE) inhibitors,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    , and cardiac rehabilitation programs after MI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Efficacy of CHD guideline adherence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reductions in mortality have been demonstrated with consistent administration of recommended therapies in patients with CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/1-10,15-17\">",
"     1-10,15-17",
"    </a>",
"    ]. The magnitude of the effect of adherence to the multiple recommendations provided by guidelines was best illustrated in an observational study of almost 65,000 patients with a non-ST elevation acute coronary syndrome (ACS) from 2001 to 2003 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/1\">",
"     1",
"    </a>",
"    ]. Every 10 percent increase in composite adherence to nine",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guideline-recommended therapies was associated with a 10 percent reduction in in-hospital mortality (adjusted odds ratio 0.90, 95% CI 0.84-0.97). In-hospital mortality was significantly lower in the hospitals in the highest compared to lowest adherence quartile (4.2 versus 6.3 percent).",
"   </p>",
"   <p>",
"    Further support for the benefit of following guideline recommendations comes from a report from the CRUSADE registry [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/17\">",
"     17",
"    </a>",
"    ]. Patients with Medicaid, compared to those of similar age (less than 65) who were covered by a Health Maintenance Organization or private insurance, were less likely to receive guideline recommended medical and interventional therapies. They had a significantly higher in-hospital mortality rate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Predictors of guideline non-adherence",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the type of health insurance, as discussed above, other predictors of early discontinuation of guideline recommendations have been identified. In a report of over one thousand patients enrolled in a registry after an acute coronary syndrome, 28 percent of patients had discontinued one or more of the following guideline recommended therapies at three months:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    , angiotensin receptor blockers or statin therapy. Most discontinuation (68 percent) was patient initiated, while the rest was with the input of providers [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/18\">",
"     18",
"    </a>",
"    ]. Independent predictors of discontinuation were no pharmacy co-insurance, increasing number of medications, not using reminder tools, lower education and dialysis.",
"   </p>",
"   <p>",
"    While not specifically identified as a predictor,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    is not uncommonly discontinued prematurely in preparation for upcoming surgery in patients on dual antiplatelet therapy for either recent stent placement or after and acute coronary syndrome. The potential for an increased risk of coronary artery stent thrombosis with premature clopidogrel cessation needs to be considered by practitioners and their patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=see_link&amp;anchor=H11#H11\">",
"     \"Antiplatelet therapy after coronary artery stenting\", section on 'Early noncardiac surgery or gastrointestinal endoscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Assessment of CHD guideline adherence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The latest guidelines for the management of acute MI were published by the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    in 2007 for non-ST elevation acute coronary syndromes and in 2004 for ST elevation MI [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. The",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    published a focused update of the latter guideline in 2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Guideline adherence has been measured primarily through retrospective, observational studies using patient databases in both inpatient and outpatient settings [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/1,2,22-25\">",
"     1,2,22-25",
"    </a>",
"    ]. Many studies have used these patient databases to identify characteristics that are predictive of higher guideline adherence, and to assess whether hospitals' overall adherence is associated with improved in-hospital mortality rates [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/1,2,26\">",
"     1,2,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, meta-analyses of clinical trials have demonstrated the short- and long-term benefits of an early invasive approach as opposed to a conservative approach in most patients with a non-ST elevation ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=see_link\">",
"     \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Guidelines for CHD management in ambulatory settings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long term care of the patient occurs in the outpatient setting and organizations such as the Kaiser Permanente Care Management Institute have made recommendations for the primary care setting. These graded recommendations provide guidance for primary care clinicians on the use of antiplatelet agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ), beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor blockers (ARBs), and lipid management and dietary fat modification. Comorbidities such as mild-to-moderate reversible airway disease, severe chronic obstructive pulmonary disease (COPD), and heart failure are addressed [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/29\">",
"     29",
"    </a>",
"    ]. Similar recommendations are also available through the Veterans Health Administration, Department of Defense [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     HEART FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials have demonstrated the efficacy of beta blockers, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), mineralocorticoid receptor antagonists (in selected patients), and loop diuretics, in decreasing morbidity and mortality of HF patients. As a result, such therapies are recommended in major society guidelines from the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    and the European Society of Cardiology [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\", section on 'Pharmacologic therapy of HF'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Beta blockers in HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blockers are underutilized in patients with HF (53 percent in ADHERE [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/33\">",
"     33",
"    </a>",
"    ]) despite clear evidence of reduced mortality and morbidity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=see_link\">",
"     \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36282?source=see_link\">",
"     \"Rationale for and clinical trials of beta blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adherence to the recommendation for outpatient beta blocker use in patients with documented HF was directly evaluated in a randomized trial in which 169 patients were assigned to one of three groups: a control group that consisted of patients assigned to clinicians who were given an educational presentation on the use of beta blockers in HF; a second group that received computerized provider reminders supporting the use of beta blockers; and a third group in which a nurse facilitator initiated and titrated the beta blocker [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After 12 months, the proportion of patients who were initiated or uptitrated and maintained on beta blockers was 67 percent in the nurse facilitator group compared to 16 percent in the",
"    <span class=\"nowrap\">",
"     provider/patient",
"    </span>",
"    notification group, and 27 percent in the control group. Similar dramatic differences were noted in the proportion of patients who were treated with the target beta blocker dose (43 versus 2 and 10 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Efficacy of HF guideline adherence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prospective studies evaluating outcomes in relation to adherence in patients with HF are not available, in contrast to the above observations in patients with CHD. Nevertheless, retrospective observations provide support for lower rates of hospital admissions [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The MAHLER study evaluated hospitalization rates in the top, middle, and bottom tertiles for mean guideline adherence [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/35\">",
"     35",
"    </a>",
"    ]. There was a significant increase in hospitalization rates for heart failure (6.7, 9.7, and 14.7 percent) and for cardiovascular disease (11.2, 15.9, and 20.6 percent) in the bottom two tertiles.",
"   </p>",
"   <p>",
"    A related issue from guideline compliance is heart failure disease management programs that are aimed at patient compliance with clinician recommendations. This issue is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link&amp;anchor=H43#H43\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\", section on 'Heart failure disease management programs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Assessment of HF guideline adherence",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above for CHD, guideline adherence in HF management has largely been determined through retrospective, observational studies using both in-hospital and outpatient databases. These studies have consistently suggested suboptimal utilization of recommended drug therapies in both the inpatient and outpatient settings [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/12,33-35,37,38\">",
"     12,33-35,37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Acute Decompensated Heart Failure National Registry (ADHERE) evaluated guideline adherence in 81,142 patient admissions from July 2002 to December 2003 [",
"      <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/33\">",
"       33",
"      </a>",
"      ]. Among academic and non-academic hospitals providing care for HF patients, there was significant variability in conforming to quality-of-care indicators. The mean rate of conformity was 86 percent for assessment of left ventricular function, 72 percent for use of ACE inhibitors in patients with left ventricular systolic dysfunction, 24 percent for discharge instructions, and 43 percent for counseling for smoking cessation. The rate of conformity was higher in academic hospitals.",
"     </li>",
"     <li>",
"      The MAHLER study evaluated the medical management of HF (NYHA class II to class IV) in 1410 patients in 150 randomly selected",
"      <span class=\"nowrap\">",
"       cardiologists/cardiology",
"      </span>",
"      departments from six countries in Europe [",
"      <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/35\">",
"       35",
"      </a>",
"      ]. An ACE inhibitor or ARB was prescribed in 87 percent of patients, a beta blocker in 53 percent, a diuretic in 79 percent, and a cardiac glycoside in 41 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Guidelines for heart failure management in ambulatory settings",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    and European Society of Cardiology, the Veterans Health Administration, Department of Defense published pharmacologic recommendations for the chronic management of patients with heart failure. These guidelines are disseminated particularly for primary care clinicians who may be less inclined to review guidelines put forth by the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    or the European Society of Cardiology [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the availability of guidelines, overall adherence with recommended drug therapies has been suboptimal in both in-patient and outpatient settings [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/12,34,35,37\">",
"     12,34,35,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     STRATEGIES TO IMPROVE GUIDELINE ADHERENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an attempt to improve patient outcomes and reduce cost by increasing guideline adherence, initiatives to improve quality of care have been undertaken by government agencies at the state and federal levels, and by the hospital, regional, and state medical communities, often in association with the ACC or AHA, using quality",
"    <span class=\"nowrap\">",
"     assurance/performance",
"    </span>",
"    improvement projects.",
"   </p>",
"   <p>",
"    The following strategies for hospitals to improve guideline adherence for CHD and HF are supported by evidence:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Establish separate standardized order sheets for CHD and HF, both at the time of admission and at the time of discharge [",
"      <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/15,16\">",
"       15,16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Establish quality of care teams comprised of nurses, pharmacists,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      clinicians, for real-time monitoring who ensure that guideline-based therapies are not omitted in patients unless specific contraindications are documented in the patient chart [",
"      <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Establish a sub-group from the quality of care team in strategy number two who also uptitrate doses of evidence-based medications to achieve target heart rates and blood pressures [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Develop patient information forms and patient discharge forms to improve patient insight into CHD or HF. These forms should be provided to the patient at the time of discharge and gone over by a health care provider (either a trained RN or the MD involved in the patient's care). This allows for a period of time for the patient and family member(s) to ask any questions they may have regarding the patient's disease severity,",
"      <span class=\"nowrap\">",
"       benefits/side-effects",
"      </span>",
"      of the newly prescribed medications, and follow-up plans [",
"      <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Establish a dedicated team comprised of nurses and dieticians to discuss lifestyle modifications, such as healthy eating and smoking cessation, prior to patient discharge. These recommendations should be included with the patient discharge forms [",
"      <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The above strategies are particularly important for post-CABG patients as this population has the lowest prescription rates of evidence-based medical therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evidence to support the use of these strategies comes from quality improvement and governmental initiatives.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Quality improvement initiatives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant efforts have been made in the United States to develop and distribute guidelines for the management of acute MI. However, the Cooperative Cardiovascular Project at the Center for Medicare and Medicaid Services reported in the 1990s that quality of care for Medicare recipients with acute MI remained suboptimal [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/41\">",
"     41",
"    </a>",
"    ]. Other studies also noted disappointing rates of adherence to evidence-based medical therapies recommended in national guidelines, particularly among minorities, females, and older adults, with additional practice variations among geographic regions [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/42-44\">",
"     42-44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In response to these observations, several large quality-improvement programs have been implemented with the goal of increasing the use of evidence-based medical therapies for patients with CHD in the acute phase of the illness, at hospital discharge, and at long-term follow-up. The most notable programs include the Guidelines Applied in Practice (GAP) program from the ACC [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/45\">",
"     45",
"    </a>",
"    ] and the Get With The Guidelines (GWTG) program from the AHA [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Analysis of the impact of these programs offers several important insights [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. First, the dissemination of guidelines alone is not sufficient to achieve significant changes in performance. Rather, active interventions directed at changing systems of care are needed to significantly reduce the gap between guideline-recommended care practices and actual clinical practice [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/24,45,47\">",
"     24,45,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reports from the GAP program [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/24,45,47\">",
"     24,45,47",
"    </a>",
"    ], the Cooperative Cardiovascular Project at the CDC [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/48\">",
"     48",
"    </a>",
"    ], and the Duke Databank [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/2\">",
"     2",
"    </a>",
"    ] have demonstrated a gradual improvement with time in the use of key therapies in patients with acute MI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     GAP program",
"    </span>",
"    &nbsp;&mdash;&nbsp;The GAP pilot project was performed in 10 acute-care hospitals in southeast Michigan that were chosen because of their commitment to quality improvement and excellence in practice [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/45\">",
"     45",
"    </a>",
"    ]. The study involved a random sample of Medicare and non-Medicare patients at baseline and post-intervention who were admitted for treatment of confirmed acute MI in late 2000. A random sample of Medicare patients seen between 1998 and 1999 at 11 voluntary hospitals served as the control group.",
"   </p>",
"   <p>",
"    The project included an initial presentation, creation of customized, guideline-oriented tools designed to facilitate adherence to key quality indicators. These included standard orders, pocket",
"    <span class=\"nowrap\">",
"     guide/pocket",
"    </span>",
"    cards, patient information forms, patient discharge forms, chart stickers, and hospital performance charts. Other components included assignment of supervising clinician and nurse leaders, and both pre- and post-measurement of quality indicators.",
"   </p>",
"   <p>",
"    Significantly higher rates of adherence were observed in the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (81 versus 87 percent) and beta blockers (65 versus 74 percent) on admission, and the use of aspirin (84 versus 92 percent) and smoking cessation counseling (53 versus 65 percent) at discharge. Other indicators including administration of early aspirin, ACE inhibitors at discharge, and smoking cessation counseling showed trends for improvement, but were not statistically higher in the GAP cohort compared to the control group.",
"   </p>",
"   <p>",
"    The GAP pilot project was followed by a similar study in five Flint and Saginaw area hospitals in Michigan where greater emphasis was placed on tool use with a goal of identifying barriers to tool use and ways to overcome these barriers [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/47\">",
"     47",
"    </a>",
"    ]. The findings validated the results of the pilot project. However, patients undergoing coronary artery bypass grafting (CABG) had lower rates of evidence-based therapies compared to recipients of PCI.",
"   </p>",
"   <p>",
"    A later report evaluated the efficacy of real-time monitoring of key quality of care indicators in the GAP program in patients with an acute coronary syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/24\">",
"     24",
"    </a>",
"    ]. Real-time implementation was performed in 1170 patients seen between July 2002 and December 2004; the outcomes were compared to those in 2019 patients seen between January 1999 and June 2002 when real-time monitoring was not used.",
"   </p>",
"   <p>",
"    Real-time monitoring was associated with significant increases in the use of in-hospital ACE inhibitors (73 versus 64 percent), beta blockers (93 versus 90 percent), statins (81 versus 66 percent), and other modalities, and higher discharge rates of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (92 versus 87 percent), beta blockers (87 versus 79 percent), statins (81 versus 65 percent), and ACE inhibitors (67 versus 56 percent). Patient outcomes were also improved. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Efficacy of CHD guideline adherence'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Furthermore, real-time monitoring, compared to lack of use of real-time monitoring, was associated with the following significant benefits during the six months after discharge: fewer rehospitalization for heart disease (20 versus 25 percent), a lower rate of MI (3.5 versus 5.4 percent), and a lower rate of the combined end point of death, MI, or cerebrovascular accident (9.5 versus 13.9 percent).",
"   </p>",
"   <p>",
"    With respect to its effect on mortality, GAP use was associated with significant reductions in mortality in-hospital (10.4 versus 13.6 percent), 30 days (16.7 versus 21.6 percent, adjusted odds ratio 0.74, 95% CI 0.59-0.94), and one year (33.2 versus 38.3 percent, adjusted odds ratio 0.78, 95% CI 0.64-0.95) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/15\">",
"     15",
"    </a>",
"    ]. The improvement in one year mortality was higher when standard discharge tools were used (adjusted odds ratio 0.53, 95% CI 0.36-0.76) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     GWTG program",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Get With The Guidelines (GWTG) program was developed by the AHA to assist clinicians and hospitals in achieving adherence to secondary prevention recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/46\">",
"     46",
"    </a>",
"    ]. The program targets patients presenting with CHD and promotes discharge on recommended key medical therapies and patient counseling for risk factor modification. The different components of secondary prevention are discussed separately [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An integral and unique aspect of the GWTG program was the use of an interactive web-based data collection tool termed the Patient Management Tool (PMT). This interactive quality improvement reporting system, used to prospectively collect data and measure hospital performance, offered additional support in patient management. Reminder screens provided immediate reference to the appropriate guideline and alerted health care providers to specific guideline-recommended interventions that were being overlooked in each patient. The tool also allowed providers to generate patient education sheets and produce written correspondences to the patient's primary care clinician detailing the diagnosis, risk assessment, and interventions performed during the hospitalization.",
"   </p>",
"   <p>",
"    Data from over 1700 patients in 24 participating hospitals, of which 16 were non-teaching hospitals, was collected between July 2000 and June 2001 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/46\">",
"     46",
"    </a>",
"    ]. In comparison to baseline, significant increases in guideline adherence were observed at an average follow up of 10 to 12 months in smoking cessation counseling (87 versus 48 percent), lipid-lowering therapy (79 versus 54 percent), LDL measurement (81 to 59 percent), and cardiac rehabilitation referral (73 to 34 percent). The high baseline use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , beta blockers, and ACE inhibitors was maintained. Thus, significant improvement in the secondary prevention of CHD can occur in less than one year despite variations in hospital settings.",
"   </p>",
"   <p>",
"    While referral by a health care practitioner to a cardiac rehabilitation program is an essential step in a secondary prevention strategy, the benefits of such programs can only be accrued if the patient enrolls. Analysis of patient data from one hospital that used the GWTG program in 2002 and 2003 found that 55 percent of patients in the program were referred for cardiac rehabilitation, but only 34 percent of referred patients (19 percent of all patients) enrolled [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     CRUSADE registry",
"    </span>",
"    &nbsp;&mdash;&nbsp;One database that has been used to evaluate guideline adherence and increase the practice of evidence-based medicine in non-ST elevation ACS (including unstable angina) is the CRUSADE registry, which was developed in 2001; about 200,000 patients were enrolled as of 2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/25\">",
"     25",
"    </a>",
"    ]. In early 2007, the CRUSADE registry and the National Registry for Myocardial Infarction (NRMI) collaborated with the American College of Cardiology Foundation's National Cardiovascular Data Registry to launch a new registry called NCDR-ACTIONTM. This new registry has taken over the CRUSADE database as CRUSADE closed its enrollment as of January 31, 2007 with a final enrollment of 205,048. The goal of this new initiative is to improve the safety and outcomes of ACS patients using this merged database and to provide broader spectrum reporting [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/25\">",
"     25",
"    </a>",
"    ]. Nonetheless, the registry's original data provides invaluable information into guideline adherence and thus is discussed in detail here.",
"   </p>",
"   <p>",
"    The CRUSADE database was used to evaluate the utilization of the early invasive and conservative approaches in a subset of high risk patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/26\">",
"     26",
"    </a>",
"    ]. Patient characteristics such as demographic information (age, gender, race), body mass index, and risk factors for CHD were analyzed. Among 17,296 patients, 62 percent underwent cardiac catheterization at some point during the index hospitalization: 45 percent within the first 48 hours of hospitalization (early invasive approach) and 17 percent after the first 48 hours. Recipients of the early invasive approach were younger, more frequently male and Caucasian, more likely to be under the care of a cardiologist, and less likely to have heart failure or impaired renal function.",
"   </p>",
"   <p>",
"    Recipients of the early invasive approach were also more likely to receive",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines-recommended pharmacologic and nonpharmacologic interventions, both in the acute setting and at time of discharge. These included administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , beta-blockers,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    , statins, ACE inhibitors, and counseling for modifications in diet, smoking cessation, and referral for cardiac rehabilitation. This may have followed from standard post-procedure order sets which emphasize the use of evidence-based treatment for all eligible patients.",
"   </p>",
"   <p>",
"    Patients who were older were often treated conservatively even though clinical trials suggest that they derive greater benefit from an early aggressive approach. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=see_link\">",
"     \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other reports from CRUSADE provided additional observations on guideline adherence:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was a significant increase in the use of each class I recommendation for medical therapy, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      use, beta blockers,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      , and lipid-lowering drugs [",
"      <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Surprisingly, patients at highest risk (eg, those with diabetes or heart failure at presentation, or those &ge;75 years of age) were significantly less likely to receive both medical and interventional therapies, even though interventional therapy in particular is most beneficial in higher risk patients [",
"      <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/52\">",
"       52",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=see_link&amp;anchor=H7#H7\">",
"       \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\", section on 'Early risk assessment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Academic (125) and nonacademic (355) hospitals participating in CRUSADE between January 2001 and March 2004 were evaluated for their level of adherence to guideline recommendations for the use of four acute and five discharge therapies [",
"      <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/53\">",
"       53",
"      </a>",
"      ]. Composite adherence to recommended therapies was significantly but only slightly higher at academic compared with nonacademic hospitals (78 versus 74 percent). However, variance in performance was much greater among the nonacademic hospitals.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Government initiatives",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Center for Medicare and Medicaid Services (CMS) has developed \"Pay for Performance\" initiatives to encourage improvements in quality of care in all health care settings in which Medicare beneficiaries receive services for chronic illnesses such as CHD or HF. These settings include clinicians' offices and other ambulatory care sites, hospitals, nursing homes, home health care agencies, and dialysis facilities. Such initiatives involve monitoring guideline adherence, measuring compliance rates to key quality indicators, and then reimbursing health care providers based upon their performance levels.",
"   </p>",
"   <p>",
"    To implement these initiatives, CMS has collaborated with many public and private organizations that share a common goal of improving quality of health care while avoiding unnecessary health care costs. These organizations include the Joint Commission of the Accreditation of Health Care Organizations (JCAHO), the National Committee for Quality Assurance (NCQA), the American Medical Association (AMA), the National Quality Forum (NQF), and the Agency for Health Care Research and Quality (AHRQ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Premier Hospital Quality Incentive Demonstration is a project through which CMS aims to improve quality of inpatient care for Medicare beneficiaries by providing financial incentives to nearly 300 hospitals for high quality of care for five clinical conditions including acute MI and HF [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/40\">",
"     40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients hospitalized with an acute MI, quality measures include the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      at time of hospital arrival and prescribing aspirin at discharge, use of ACE inhibitors for left ventricular systolic dysfunction, smoking cessation",
"      <span class=\"nowrap\">",
"       advice/counseling,",
"      </span>",
"      administration of a beta blocker at time of hospital arrival and hospital discharge, and timely revascularization procedures including administration of fibrinolytic therapy within 30 minutes of hospital arrival or percutaneous coronary intervention within 120 minutes of hospital arrival.",
"     </li>",
"     <li>",
"      For patients hospitalized for HF, measures for reporting include left ventricular function assessment, detailed discharged instructions,",
"      <span class=\"nowrap\">",
"       administration/prescription",
"      </span>",
"      of ACE inhibitors for left ventricular systolic dysfunction, and smoking cessation",
"      <span class=\"nowrap\">",
"       advice/counseling.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hospitals that score in the top 10 percent for a given set of quality measures receive a 2 percent bonus payment on top of the standard payment for the relevant discharges. Those hospitals scoring in the next highest 10 percent receive a 1 percent bonus payment.",
"   </p>",
"   <p>",
"    Data obtained from in-patient discharges for acute MI from 2003 to 2004 reveal the following [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/40\">",
"     40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Almost all hospitals participating in the PREMIER demonstration for acute MI scored over 90 percent with regard to administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and beta blockers, both at the time of arrival and at the time of discharge.",
"     </li>",
"     <li>",
"      Very few participating hospitals administered fibrinolytic therapy, presumably due to their ability to perform",
"      <span class=\"nowrap\">",
"       urgent/emergent",
"      </span>",
"      PCI or to transfer patients to another institution equipped with such capabilities. Of the reported measures, participating hospitals on average scored the lowest (most less than 70 percent) with regard to performing PCI within 120 minutes [",
"      <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following findings were noted in discharge data for patients hospitalized for HF [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/40\">",
"     40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most participating hospitals evaluated for left ventricular function, counseled for smoking cessation, and administered ACE inhibitors in 80 percent or more of their patients.",
"     </li>",
"     <li>",
"      Most hospitals did poorly in providing patients with detailed discharge instructions (less than 80 percent of patients).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A survey of 256 commercial health maintenance organizations (HMOs) was performed to determine the extent of penetration of pay-for-performance initiatives in the US [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/55\">",
"     55",
"    </a>",
"    ]. More than half of the HMOs used pay-for-performance programs and the majority were clinician-focused (90 percent) as opposed to hospital-focused programs (38 percent). Use of pay-for-performance correlated with geographic region, use of primary care providers as gatekeepers, and whether the health plans received bonuses or penalties based upon performance.",
"   </p>",
"   <p>",
"    The fact that many patients receive care from multiple providers may limit the impact of guidelines. In an evaluation of Medicare practices, beneficiaries visited a median of two primary care clinicians and five specialists in four different practices [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/56\">",
"     56",
"    </a>",
"    ]. In one-third of the studied population, the assigned clinician changed from one year to the next. When many providers are involved in the care of any single Medicare beneficiary, this may impede the ability of any one assigned provider to influence the overall quality of care for a given patient [",
"    <a class=\"abstract\" href=\"UTD.htm?10/44/10953/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of guideline recommendations for the care of patients with coronary heart disease and heart failure by both healthcare practitioners and hospitals can improve short and long term outcomes and potentially reduce healthcare costs. However, evidence suggests that adherence to guidelines is less than optimal. Several quality improvement programs, by both governmental and non-governmental organizations, have been developed in an attempt to foster maximal utilization of evidence-based interventions.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10953/abstract/1\">",
"      Peterson ED, Roe MT, Mulgund J, et al. Association between hospital process performance and outcomes among patients with acute coronary syndromes. JAMA 2006; 295:1912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10953/abstract/2\">",
"      Newby LK, LaPointe NM, Chen AY, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation 2006; 113:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10953/abstract/3\">",
"      Krumholz HM, Radford MJ, Wang Y, et al. National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project. JAMA 1998; 280:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10953/abstract/4\">",
"      Fonarow GC, Gawlinski A, Moughrabi S, Tillisch JH. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol 2001; 87:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10953/abstract/5\">",
"      Fonarow GC, French WJ, Parsons LS, et al. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3. Circulation 2001; 103:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10953/abstract/6\">",
"      Rogers WJ, Canto JG, Lambrew CT, et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3. J Am Coll Cardiol 2000; 36:2056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10953/abstract/7\">",
"      Krumholz HM, Vaccarino V, Ellerbeck EF, et al. Determinants of appropriate use of angiotensin-converting enzyme inhibitors after acute myocardial infarction in persons &gt; or = 65 years of age. Am J Cardiol 1997; 79:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10953/abstract/8\">",
"      Chen J, Radford MJ, Wang Y, et al. Do \"America's Best Hospitals\" perform better for acute myocardial infarction? N Engl J Med 1999; 340:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10953/abstract/9\">",
"      Yan RT, Yan AT, Tan M, et al. Underuse of evidence-based treatment partly explains the worse clinical outcome in diabetic patients with acute coronary syndromes. Am Heart J 2006; 152:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10953/abstract/10\">",
"      Soumerai SB, McLaughlin TJ, Spiegelman D, et al. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA 1997; 277:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10953/abstract/11\">",
"      Smith NL, Psaty BM, Pitt B, et al. Temporal patterns in the medical treatment of congestive heart failure with angiotensin-converting enzyme inhibitors in older adults, 1989 through 1995. Arch Intern Med 1998; 158:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10953/abstract/12\">",
"      Komajda M, Follath F, Swedberg K, et al. The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 2003; 24:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10953/abstract/13\">",
"      Feinglass J, Martin GJ, Lin E, et al. Is heart failure survival improving? Evidence from 2323 elderly patients hospitalized between 1989-2000. Am Heart J 2003; 146:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10953/abstract/14\">",
"      Bahit MC, Granger CB, Alexander KP, et al. Applying the evidence: opportunity in US for 80,000 additional lives saved per year. Circulation 2000; 102(suppl II):II-873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10953/abstract/15\">",
"      Eagle KA, Montoye CK, Riba AL, et al. Guideline-based standardized care is associated with substantially lower mortality in medicare patients with acute myocardial infarction: the American College of Cardiology's Guidelines Applied in Practice (GAP) Projects in Michigan. J Am Coll Cardiol 2005; 46:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10953/abstract/16\">",
"      Jani SM, Montoye C, Mehta R, et al. Sex differences in the application of evidence-based therapies for the treatment of acute myocardial infarction: the American College of Cardiology's Guidelines Applied in Practice projects in Michigan. Arch Intern Med 2006; 166:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10953/abstract/17\">",
"      Calvin JE, Roe MT, Chen AY, et al. Insurance coverage and care of patients with non-ST-segment elevation acute coronary syndromes. Ann Intern Med 2006; 145:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10953/abstract/18\">",
"      Melloni C, Alexander KP, Ou FS, et al. Predictors of early discontinuation of evidence-based medicine after acute coronary syndrome. Am J Cardiol 2009; 104:175.",
"     </a>",
"    </li>",
"    <li>",
"     Anderson J, Adams C, Antman E, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, American College or Physicians, Society for Academic Emergency Medicine, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2007; 50:e1 www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).",
"    </li>",
"    <li>",
"     Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).",
"    </li>",
"    <li>",
"     www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007). www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10953/abstract/22\">",
"      GRACE Investigators. Rationale and design of the GRACE (Global Registry of Acute Coronary Events) Project: a multinational registry of patients hospitalized with acute coronary syndromes. Am Heart J 2001; 141:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10953/abstract/23\">",
"      Butler J, Arbogast PG, BeLue R, et al. Outpatient adherence to beta-blocker therapy after acute myocardial infarction. J Am Coll Cardiol 2002; 40:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10953/abstract/24\">",
"      Vasaiwala S, Nolan E, Ramanath VS, et al. A quality guarantee in acute coronary syndromes: the American College of Cardiology's Guidelines Applied in Practice program taken real-time. Am Heart J 2007; 153:16.",
"     </a>",
"    </li>",
"    <li>",
"     www.crusadeqi.com/Main/HomePage.shtml (Accessed on January 12, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10953/abstract/26\">",
"      Bhatt DL, Roe MT, Peterson ED, et al. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. JAMA 2004; 292:2096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10953/abstract/27\">",
"      Mehta SR, Cannon CP, Fox KA, et al. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA 2005; 293:2908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10953/abstract/28\">",
"      Bavry AA, Kumbhani DJ, Rassi AN, et al. Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials. J Am Coll Cardiol 2006; 48:1319.",
"     </a>",
"    </li>",
"    <li>",
"     Kaiser Permanente Care Management Institute. Secondary prevention of coronary artery disease clinical practice guideline. Oakland (CA): Kaiser Permanente Care Management Institute; 2006:117 www.guideline.gov (Accessed on June 07, 2012).",
"    </li>",
"    <li>",
"     Veterans Health Administration, Department of Defense. VA/DoD clinical practice guideline for the management of ischemic heart disease. Washington (DC): Veterans Health Administration, Department of Defense; 2003 www.guideline.gov (Accessed on June 07, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10953/abstract/31\">",
"      Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10953/abstract/32\">",
"      Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29:2388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10953/abstract/33\">",
"      Fonarow GC, Yancy CW, Heywood JT, ADHERE Scientific Advisory Committee, Study Group, and Investigators. Adherence to heart failure quality-of-care indicators in US hospitals: analysis of the ADHERE Registry. Arch Intern Med 2005; 165:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10953/abstract/34\">",
"      Ansari M, Shlipak MG, Heidenreich PA, et al. Improving guideline adherence: a randomized trial evaluating strategies to increase beta-blocker use in heart failure. Circulation 2003; 107:2799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10953/abstract/35\">",
"      Komajda M, Lapuerta P, Hermans N, et al. Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. Eur Heart J 2005; 26:1653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10953/abstract/36\">",
"      Shibata MC, Nilsson C, Hervas-Malo M, et al. Economic implications of treatment guidelines for congestive heart failure. Can J Cardiol 2005; 21:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10953/abstract/37\">",
"      Cleland JG, Cohen-Solal A, Aguilar JC, et al. Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet 2002; 360:1631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10953/abstract/38\">",
"      Komajda M, Bouhour JB, Amouyel P, et al. Ambulatory heart failure management in private practice in France. Eur J Heart Fail 2001; 3:503.",
"     </a>",
"    </li>",
"    <li>",
"     Veterans Health Administration, Department of Veterans Affairs. The pharmacologic management of chronic heart failure. Washington (DC): Veterans Health Administration, Department of Veterans Affairs; 2003:45 www.guideline.gov (Accessed on June 07, 2012).",
"    </li>",
"    <li>",
"     Center for Medicare and Medicaid Services. Premier Hospital Quality Incentive Demonstration www.cms.hhs.gov/HospitalQualityInits/35_HospitalPremier.asp (Accessed on May 09, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10953/abstract/41\">",
"      Ellerbeck EF, Jencks SF, Radford MJ, et al. Quality of care for Medicare patients with acute myocardial infarction. A four-state pilot study from the Cooperative Cardiovascular Project. JAMA 1995; 273:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10953/abstract/42\">",
"      O'Connor GT, Quinton HB, Traven ND, et al. Geographic variation in the treatment of acute myocardial infarction: the Cooperative Cardiovascular Project. JAMA 1999; 281:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10953/abstract/43\">",
"      Vaccarino V, Horwitz RI, Meehan TP, et al. Sex differences in mortality after myocardial infarction: evidence for a sex-age interaction. Arch Intern Med 1998; 158:2054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10953/abstract/44\">",
"      Allison JJ, Kiefe CI, Centor RM, et al. Racial differences in the medical treatment of elderly Medicare patients with acute myocardial infarction. J Gen Intern Med 1996; 11:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10953/abstract/45\">",
"      Mehta RH, Montoye CK, Gallogly M, et al. Improving quality of care for acute myocardial infarction: The Guidelines Applied in Practice (GAP) Initiative. JAMA 2002; 287:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10953/abstract/46\">",
"      LaBresh KA, Ellrodt AG, Gliklich R, et al. Get with the guidelines for cardiovascular secondary prevention: pilot results. Arch Intern Med 2004; 164:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10953/abstract/47\">",
"      Mehta RH, Montoye CK, Faul J, et al. Enhancing quality of care for acute myocardial infarction: shifting the focus of improvement from key indicators to process of care and tool use: the American College of Cardiology Acute Myocardial Infarction Guidelines Applied in Practice Project in Michigan: Flint and Saginaw Expansion. J Am Coll Cardiol 2004; 43:2166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10953/abstract/48\">",
"      Marciniak TA, Ellerbeck EF, Radford MJ, et al. Improving the quality of care for Medicare patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project. JAMA 1998; 279:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10953/abstract/49\">",
"      AHA, ACC, National Heart, Lung, and Blood Institute, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol 2006; 47:2130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10953/abstract/50\">",
"      Mazzini MJ, Stevens GR, Whalen D, et al. Effect of an American Heart Association Get With the Guidelines program-based clinical pathway on referral and enrollment into cardiac rehabilitation after acute myocardial infarction. Am J Cardiol 2008; 101:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10953/abstract/51\">",
"      Mehta RH, Roe MT, Chen AY, et al. Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative. Arch Intern Med 2006; 166:2027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10953/abstract/52\">",
"      Roe MT, Peterson ED, Newby LK, et al. The influence of risk status on guideline adherence for patients with non-ST-segment elevation acute coronary syndromes. Am Heart J 2006; 151:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10953/abstract/53\">",
"      Patel MR, Chen AY, Roe MT, et al. A comparison of acute coronary syndrome care at academic and nonacademic hospitals. Am J Med 2007; 120:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10953/abstract/54\">",
"      Rogers WJ, Bowlby LJ, Chandra NC, et al. Treatment of myocardial infarction in the United States (1990 to 1993). Observations from the National Registry of Myocardial Infarction. Circulation 1994; 90:2103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10953/abstract/55\">",
"      Rosenthal MB, Landon BE, Normand SL, et al. Pay for performance in commercial HMOs. N Engl J Med 2006; 355:1895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/44/10953/abstract/56\">",
"      Pham HH, Schrag D, O'Malley AS, et al. Care patterns in Medicare and their implications for pay for performance. N Engl J Med 2007; 356:1130.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1550 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.69.132.100-7288C09AE7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_44_10953=[""].join("\n");
var outline_f10_44_10953=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CORONARY HEART DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Efficacy of CHD guideline adherence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Predictors of guideline non-adherence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Assessment of CHD guideline adherence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Guidelines for CHD management in ambulatory settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      HEART FAILURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Beta blockers in HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Efficacy of HF guideline adherence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Assessment of HF guideline adherence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Guidelines for heart failure management in ambulatory settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      STRATEGIES TO IMPROVE GUIDELINE ADHERENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Quality improvement initiatives",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - GAP program",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - GWTG program",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - CRUSADE registry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Government initiatives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=related_link\">",
"      Antiplatelet therapy after coronary artery stenting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/35/20024?source=related_link\">",
"      Clinical practice guidelines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=related_link\">",
"      Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36282?source=related_link\">",
"      Rationale for and clinical trials of beta blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=related_link\">",
"      Use of beta blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_44_10954="ECG pace mapping RVOT tachycardia";
var content_f10_44_10954=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68142%7ECARD%2F59988&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68142%7ECARD%2F59988&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 548px\">",
"   <div class=\"ttl\">",
"    12-lead electrocardiogram (ECG) during electrophysiologic study showing pace mapping of an idiopathic RVOT tachycardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 528px; height: 408px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left panel: 12 lead ECG of spontaneous ventricular tachycardia (VT) in a patient with a structurally normal heart. The VT has a left bundle branch block (LBBB) and an inferior axis morphology, suggesting that the origin is in the right ventricular outflow tract (RVOT). Right panel: A mapping catheter has been positioned in the RVOT and pacing is performed from its tip during sinus rhythm. The \"pace map\" closely approximates the QRS morphology of the spontaneous VT in all 12 leads, suggesting that the mapping catheter is at or near the VT focus.",
"    <div class=\"footnotes\">",
"     S: pacing stimulus artifact.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 558px\">",
"   <div class=\"ttl\">",
"    Intracardiac and surface ECG recordings during electrophysiologic study and radiofrequency catheter ablation of RVOT tachycardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 538px; height: 372px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF0AhoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiue1q+8TW90w0nRtHurMDiS61SW3fOcEbFt3H47qAOhorkm1HxuBn/hG/Dp+muz+v8A150p1Hxxg/8AFOeHO/8AzHZ+3/bnQB1lFcmdR8cYP/FOeHO//Mdn7f8AbnTRqfjc7seHPDh25H/Idn7f9udAHXUVyX9o+N/m/wCKb8O8Z/5js/OP+3Og6j44BP8AxTfh049Ndn9P+vOgDraK5I6j43Gc+HPDnXA/4ns/PGf+fOj+0vHGcf8ACN+HeoH/ACHZ+/8A250AdbRXJf2l444/4pvw7zj/AJjs/f8A7c6Uaj44wP8AinPDnb/mOz9/+3OgDrKK5Iaj43IBHhzw5ggH/kOz9/8AtzoXUfG5Gf8AhG/Do+uuz+v/AF50AdbRXIjUvHG/afDXh4cA5/t2fHXH/PnR/aXjjB/4pvw7kY4/t6bPXH/PnQB11FcoL/xwf+Zd8Of+D6f/AOQ6X7d44/6F7w3/AOD6f/5DoA6qiuTbUPG6qSfDvhzABP8AyHp//kOj7f445/4pzw4cf9R6f/5DoA6yiuTOoeOM/wDIueHDzj/kPT+n/XnR/aHjj/oW/Dmf+w9P6Z/586AOsorkxqPjcnH/AAjnhzOcH/ifT8cZ/wCfOj7f444/4pzw4M/9R6f/AOQ6AOsorkxqHjg4/wCKc8ODPrr0/wD8h0g1HxvkZ8OeHBnpnXp/TP8Az50AdbRXJjUPHBAP/COeHOcf8x6f/wCQ6P7Q8cYB/wCEc8Oc4/5j0/8A8h0AdZRXJf2j44yQPDfh3/wez+v/AF500an43Klh4c8OkAkca7P2OP8AnzoA6+iuT/tDxx/0Lnhzv/zHp+3/AG50HUPHA/5lzw50J416f/5DoA6yiuSOo+NwSD4c8OZwT/yHp+cf9udL/aHjjOP+Ec8Od/8AmPTf/IdAHWUVyn27xxz/AMU74b/8H0//AMh0fb/HHH/FOeG//B9P/wDIdAHV0VyQ1HxuwBHhzw5ggH/kPT9/+3OlGoeODj/inPDnY/8AIen4/wDJOgDrKK5Mah44P/MueHOgPOvT/wDyHSHUvG4cL/wjnhzdjP8AyHp/XH/PnQB1tFcmNQ8cE4/4Rvw4P+49N/8AIdB1DxwP+Zc8OdCeNen/APkOgDrKK5I6j43UEnw54cwAT/yHp+3/AG50p1DxwM/8U54cOPTXp/8A5DoA6yiuTOoeOBn/AIpzw4cemvT/APyHQdQ8cDP/ABTnhw49Nen/APkOgDrKK5Mah43O7Hh3w3xx/wAh6f8A+Q6X7d445/4p3w3/AOD6f/5DoA6uiuU+3+OP+hd8N/8Ag+n/APkOhr/xuoyfDvhvqB/yHp//AJDoA6uiuT/tDxxjJ8OeHPp/b0//AMh0HUPHH/QueHP/AAfT/wDyHQB1lFcn/aHjj/oW/DmP+w9P64/586Q6l44xkeG/Dp5xxr03rj/nzoA62iuTGoeOM4/4Rzw5/wCD6f1/686T+0vHGCf+Eb8O9+P7dn7HH/PnQB1tFcmdQ8bhsf8ACO+HM4JH/E+n5/8AJOl+3+OOf+Kd8Ocf9R6fn/yToA6uiuTGoeOM/wDIueHBzj/kPT+n/XnR9v8AHHH/ABTnhwZ/6j0//wAh0AdZRXJLqPjdgCPDnhzB6H+3p/T/AK866a1kneGE3MKRSsql1Ry6q2MkAkAkA8ZIGfQdKAJ6KKKACiiigAooooAKR1DqVYZBpaKACiiigApkSFN+ccsTT6KACiiigBCASM9qWiigAooooAQAKAB0FLRRQAUY5z3oooAKKKKAEYBgQehpaKKACiiigBAACcd6WiigApCASM9qWigAooooAKRVCjCjAyT+dLRQAUUUUAJgZz3HFLRRQAUUUUAIAFAA6CloooAKZs/el/8AZxT6KACiiigBGAYEHoaWiigAooooAQAAnHeloooAKKKKACiiigDlPif4sk8FeDbzW4dPkv3gKL5akhUDMBvcgEhFzk4BP865Pw18TZNUXRy134fnjv8AVFskl06WWdXDRs5UqwVonG3+IEEV6J4i0g61p32VdR1DTXDrItzYSiOVSPcggj1BBBrkNM+E2hWF9a34utSn1GLUl1SS6lkj33EqxsihwqBdoDHhQvPegBukfF/w3ql5aQQxatFHeR3MltcTWTJDObcMZVRzwxUIx444xnPFWL34reF7LTbS/uri5jtrrSzq8beQxzAGVeQP4iXUY96TTfhZoVha+HLZJ9Qlh0Jr026ySJ+9+1BxIJMKMgCRsbduOM5rM034L6Pp6oItd8RyeVYvpsHm3Ub+RAzq2xQY8YG0DByCCQQaAOr8N+LLbxJoV1qlhaXkCQBgou4wu8hQ2VKsQw6cg+1cd4K+Mulal4ds7vxNFPpN3Jpj6m7vbssEsaHD+SSSW25HHU54zXUeB/AOkeDdK1Kx0t7lxqErTXEsuxSzFdvCxqqLwOyj3zWDpHwY8O2Nl9jvrvVtXtU099Mgiv50K20DnLiMRomGJA+Y5PA5oAs6Z8WvD+paXqt5a2+pl9N8lp7UwAShJfuOPm27eDklhjHOKzW+NOlXD+HG0fStS1CDVr2eykMcZ8y2kiXJG0AhzyOAcYyc8Yqw3wb0WTRpNNn1bWpo/NgmikZoA8LQsSmMRBX6nPmB81Na/CPR7S0tY7bVdbiurbVZtXjvFli80TSrtkH+r27SO23PvQB6MAFAA6CloooAKKKKACiiigDzH9oXVtT0HwH/AGnomsXOmXkN1DGPJ8siVXkVGDB1boCSMY565rstXW8tfB8y6dqypeQ2o8vUbuJZtxUD53VSiktjtgZPTHFWtc0DR9fiii13SdP1OKJi0aXlskwQnjIDA4NST6Pplxo40mfTrKXShGsQsngVoQi42rsI24GBgYwMCgDkfgZrt74j+Feg6nq139s1GeNzPKQoJYSMBkDAHAFd5WdomhaToNvJBoel2GmwSNveOzt0hVmxjJCgAnAHNaNAGZpk2rSXl2upWlpDahv9HeGcuzD/AGgVAB+hrA8X/EbQ/CuqR6dfLf3N60YmeKytWmMUZON746Diux3Lt3bht9c8UgRFdnCKHbAZgOTjpmgDhvD/AMWPCGuahHY2+pm3u5TiOK7iaAyH0UsACfau7rM8QaBpXiKwey1zT7a+tm6pMgOPcHqD7iuIfwJ4o0uRo/Cvje8t9Px8lrqUK3fleyucNt9jnFAHpVFeYDw18TsLu8c6Z1+bGljp7fN1pw8HfEGTmX4jmNvSLSosfqaAPTaK8zHgfxxJxN8TL0Dt5WmQKaP+FeeJ5P8Aj5+JmvN/1yt4Y/5CgD0yivN0+F87oFvPHfjKcH723UPLDfkOKcfhXEmTbeMPGkLeo1Zj/MUAejUV5sfhfd7sf8J/4zMR+8hvxz687cinf8Kh0QnzH1XxI96MFLxtUkM0Z9VPQflQB6PXnWsfF7w9p2pXNrDbavqMFoxS7vLCyaa3t2HUM49O+M1XPgbxjIf7OuvHtzPoT/61jaot4y90Eo4AI4JxmvQdI0yy0fToLDS7aO1s4F2xxRjAUf570AMg1jTZ9Ij1WK+tjpsiCRboyARlfXceBUOj+I9F1pmXSNWsL1l6rbzq5H4A+9czN8J/Bs+pyXk+kLKsj+Z9keRjbBz1cRZ25PfiptV+GHhO+KS2ulQ6VfR48m90xRbTREd1ZcfrmgDtaK8yPhj4lWbGKw8c2NzbngPfaaDKo7cqQCfwpp8N/FB3O7xxpSK3/PPS+V+mWoA9PorzP/hDfHp5PxGlDDoBpkQHvmh/BHjhht/4WXehT82RpsAYH0HtQB6ZRXmX/CDeN5D+++Jl+P8Arnp0C0f8K58Rzf8AH78S/Eb56+RHFDx+AoA9Norzb/hV11zn4geNfb/iYDj/AMdpU+FjO2L3xv4yuoP4on1LaG/FQDQB6OWAIBIBPQZ60ted/wDCm/Bnl/NY3TXOMLdm8l85T6ht3Wo5Pha5dUj8beMUs+jW51DcGTuu4jI+vWgDX1L4meD9N14aPe67ax324Iw5KIx6KzgbQfYmurubq3tbZri5niht1GTLI4VQPUk8Vlaf4T0HT9Dk0a10mzTTJQRLAYgVlz1L5+8fc5NctbfCfRzc7NWvL/V9GhObLSr2Xfb2v0HVvbdnAoA7fStW07V4DNpV/a3sQ4L28qyD8wau1wmp/Czw1LKbrRbZvD+qAYjvdKPkOp7ZUfKw9QRzWbJB8V9M/cWt14b1qIcLcXMT28mPVgpIJ+mKAPTaK8uE/wAX5hs+yeE7U/8APQvLIPyzTzoHxSuh/pPjLRbTrxa6YW6/7zUAenUV5o3gnxxKu2X4lXiA9TFpsAI+nFR/8K98YGTcfijrOO4FjAB/KgD0+ivMT8OfFBP/ACU/xEPpBB/8TSn4a64wOfiT4pBPcNGP/ZaAPTaK8xX4Xapn5viP4xI9rpB/7LTh8MNSMYRviL4xPzZJF0oJ9vu0AemUV5yvwqgZMT+L/GkxPJLasw59elVz8O/FMJMdj8TdeS2P8NxbwzyD6ORmgDutb8QaPoSxtrWqWVgJDhPtEyx7vpk81oxyxyxLLE6vGw3K6nII9Qa4rR/hf4YsvMn1OyXXdSmGJ77VwLmWT/voYUewArOl+FNsJWs7LXtWtPC0pzNocUg8lvVVc/OiHuoNAHW2Hi/w7qGoTWNlrmmzXkLbHhS4UuD6Yzz+Fblcdc/DDwTc2cNtL4Y0sRQqFjKQBGUf7y4b9axj8NtV01yvhXxxrel2f8NpOqXcaf7u/kD2zQB6VRXmo8HePWwr/EeUIfvFdLh3D6Zpj/DrxNN/x8fEzxCRjBEMMMf8loA9NorzWP4WTSEjUfHXjG7iJ/1f2/ywfY7VFP8A+FM+Dyp8y31CSQ9ZGv5ixPqTu60Ad9cahZ2zhLi7t4nJwFklVST+JqSO5gkcLHNEzEZAVwSRXBx/Bn4foBv8NWkzf35neRvzLU1vgx4D2EW+hLbSfwzQTyrIn+627igD0OivMj8ONf09yPDvxC121tx9y3vUjvFUegLjIFNPhP4kKcR/EOAr236TGT/OgD0+qesala6PpdzqGoSiK0tkMkjnsBXnx8HeP3Hz/EZ0z1MemRcfTNWNL+HN82p2134p8X6tr8UDCVbKZI4rcyDozIo+bHYHjNAFW20k6TcJ8QNRku7fUblgdQgaYmOO1fCrGV6DyxsbI5yGr0yCWOeJJYJEkicbldGyGHqCKbdW8N3bS291Ek0EqlHjcZVlPUEV53cfDq+0GQz/AA41t9EjAydKnUz2Ln1Ck5Qn1U0Aek0V5aLz4voNraZ4UkI43rNIAffFBuvjA/C6d4SjzxlpZWx78GgD1KivLTJ8Yc8Q+ESBxyZuffrx9KsaRN8V11ayGr2vhZ9OaZBcm3klEix5G4rngnGcCgD0qiiigAooooAKK4j4ueL9Q8D+F11nT9PtL+NJ44Zo57hoiN7BVK4Rs8nnOOPXpVJfGXiKP4n6d4Su9J0lRcaeNQluY72RtijCyKqmIZIkyFyRlQCcHgAHolcX4xtbrxTqqeGra7ns9NSMT6pPbvtkZCcJArDld2CSeu0e9M+Ifja68Jap4Xto9Ge7tdZ1S301rszqiQNKxH3eWZsAnpjjkg4rptG0mPTGvpFlkmnvLl7mWSQ88n5VHsqhVHsKAORX4P8Aghbu4uBo2TPH5TRm4lKAYxlV3YDcdRzU3hr+1vCurxaFq1wL3Q58x6VetxLFtGRbzE/eO0Ha3U7Tnmu5rL8TaQmtaRLakhJ1Imt5T/yymU5R/wAGAoA1KK5/wXrsutaY66hALXWLN/IvrbOfLkHceqsMMD6GugoAKKKKACiiigAooooAKKKyPE3iXR/C+nm916/hsrfOAXOWY+iqOWPsBQAzxb4itfDOlC8uo5Z5ZZFt7a2gXdJcTNwsaD1P6AE9q4s678ULcm7m8JaPc202PLs4NQKzwf77Fdre+Ola/hNr7xRrLeI9UspbLToVMWk2two8wqcFrlh1VmHAXsvua7egDkfCPjGTVtRk0nW9JudE1tIzMLadgyzRg4LxuOGAJGR1Ga66sHxf4dj8QWMQjma01O0fz7G8QfNBKBwcd1PQqeCKPB2ty6zp0i6hCttq9m/2e+txyI5QM5U91YEMD6GgDeooooAKKKKACiiigAooooAKw/F+uf2JpitboJ9SunFtY2//AD1mb7oPoo6sewBNWPEniDSvDWmPqGu3sNlaIQDJIepPQAdST6CsDwktz4j1RvE+pW0ttbBTFpNtMm144j96ZlPIZ+OD0UD1NAGGnwqkRm1S08U63ZeJ5/mur9J/MSQn7y+S3yhB2HYAVs+FZNX8O6sugeJdVOqx3Kl9Nv5IwkkhUZeKTHBYfeB7jPpXbVjeK9Ml1PSXFkwj1G3YT2kuASsq8gc9jyp9mNAGzRWb4c1VNa0W1vkAV5FxLGDkxSDh0PurAj8K0qACiiigAooooAKKKKACiiigApssiQxPJKypGgLMzHAAHUmnVw/iHVofE2sp4U0a8EgGJdXlgbPkW/aLd03SEbcdQu4+lAGPJrHxC8Ryf2r4Qg0Wz0Ec20epBzNfp/z0yv8Aq1PVepIIJqzp/iHxlo2oQ3Xjy00a30S7dYFOnu8jWcrHCmVmABQ9Nw6Er616LGixoqRqFRQAqqMAAdhUGp2Ntqen3FjfwrPa3CGOSNhwynqKALNFcv4Kv5U+16BqMjNqOlEIryH5ri3P+qm9yQMH/aU+orqKACiiigAooooAKKKKACiiigAoorP1/WLPQdIudS1KURW0C7mPcnoFA7knAA96ANCivMbeHxppqxeKtV1lmhkZZL3QWhTyraFuCEkHzb0GCSSQSDXpkbrJGroQyMAQR0IoAdRRRQAUUUUAFFFFABRRRQByvxE8FWnjvRU0vUdR1KztBKsriyaNTIVIK7i6NwCAeMVSj+HkK+N7HxTL4g12bUbS1WyCSPB5ckQA3BgIgfmYbzgjknGBgDt6KAOP8feA7fxpNpUl5rGr2I0y5S9t0sXhVROhOyQ742JIyeM456V1sCGKGONpHlKKFLvjc2B1OABk+wp9cd408Ra3Z38GkeENIh1TWHj+0Sm5m8mCCLJALMMksSMBR6E9qAOxorzBYvifrzjT9RbS/DMMQ3vqmnuLpp27Ikbj5R6lvTjrXTeDtdvbi4utD8RRLDr1ioZ2QYju4SSFnj9jjlf4W49KAIPGNtc6PqEfivSo3le2i8rULWNCzXVtnOVA/jQ5Yeo3DuK6fTb+11SwgvdPuI7m0nQPHLG2VYHuDVmvO9Q8F67ouo3N78PNWtdPguD5kukXkJe0MmeXTbzGT3A470AeiUV5c2tfFqyb/SPCnhzUUHez1JoifwdaVfiw+lAf8Jr4S13QlztNwsX2q3H/AANOf/HaAPUKK5zw7438M+I41bRNcsLskZ2JMA49ip5B9iK09X1rTNGsZLzVtQtbO1jGWlnlCKPzoA0K4TxJ8RIbTV30Xwxpdz4k1tDia3s2Cx2x7edKflQ+3X2rJ/tnWfiYWtvDLXWjeEzxLrLKUuLwZwUt1Iyqn/np+QrvfDmgaX4b01LDRLKK0tl52oOWPdmPVifU80AcPJo3xL1/J1HxFpfhy1kGfs+mWpnnT2MrnGfUgVqeE/hpo+haodXvJ73W9cYY+36pL50ieojHRAfYV3FFABRWV4m8QaX4Y0iXU9cu0tbOMhS7ZJZj0VQOST2Ark9J+MXgjUvPzrKWJiXeRqEbWxZfVd4G7HtQB6DXHeMrW60jUY/FmkwyXE1tF5N/aR9bm2znI/20JLD1GR3q/wCEPGvh/wAYJct4e1GO7Ns22VQCrDPQ4IBwex6GuioAraZf2mqafb32nXEVzZ3CCSKaJtyup7g1ZrzjVfheRfzXXhLxNq/hlZmMj2tkwa2Lk5LCJuFz3AwKYvhL4hWqFbT4ixzjt9q0eIn8w1AHpVFeYm4+LOlMFaw8Ma/EOrxzvaSN+BBUGmr8S/EFmX/t34ceIbdE+9JZMl2v6beKAPUKCcDJ6V5l/wALXe8jK6F4J8W3tyTtRZrIW8ef9p2Py/lSHwz4v8a7H8aagND0sNzo2kTEtMvpNPwcH+6vHvQBc1v4oWMeoNpnhPTrzxVqiNslj03BhgPpJMfkU+3J9qrhPiprBy03hzw3D12qj3s30ySE/Su70XR9N0OxSy0extrK1TpFBGEH146n3q/QBwfhv4cWtjrK674i1G78Ra+oIW5vcCODPXyYh8qccdzXeUVk+Kddt/DujS39yjykERwwRDMlxKxwkaDuzHigDWorzBrz4s2YF3/ZXhzUo7nn7Ctw0ElpnoDIQQ4HfH4Vv+DdW8RjUJtJ8a2+nR6gY/tFtNYMximjzhl+bkMhK59QQaAEumPhTxSLo7E0LWZgk5Jx9nvDwr/7smAp/wBrB712NU9Z0y01jS7nT9QiWW1uIzHIp9COo9COoPY152uv+JfAA+w6/pOo+ItEiBFvq2np5twEH8M8eQcjIG4HnHrQB6hRXnFh8avAty3l3Osf2ZN3i1GF7dh/30MfrXb6Rrel6zEZdJ1GzvYx/FbzLIP0NAGhRRRQAVgeL/F+ieEbNLjXb5IPMO2KFQXlmb0SMfMx+grn/EXjyefV5vD3gWyTWdfj4nlZitpY57zSDqf9heT7Vf8ACPge30i7fVdYuX1rxHNzJqF0ATHnnZCvSNB2A/GgDBj8aeOtYTzPD/gF7a2Y/JNrF6sDFexMQBYfQmp/tfxVuYwsem+FbF2JG+WeaUKMdcLjPNej0UAeZTeEfHfiFHtfFfiyztdLk4lt9EtWikkXuvmuxZQec4Fdt4Y8OaR4W0tNO0CwhsrRTu2Rj7zd2Y9Sfc1r0jMFUsxAUDJJ4AFAC0V5lcfFqJrmeXSfDHiDVdDt3KS6paW4aMkHBMYJzIM9xVvw/wCONZvtatZNW8OSaT4b1FvJ0+5uZcXDSn7oli/g3YbHPp60AbHjbTrlGtfEGjwGXVtL3ERLwbiBseZEfU4GV/2gPWtvQdYsde0m31LSp1ntJ13I69vUEdiOhB5Bq/XAa14L1bT9UudW8A6tFplxcfNcadcx77Kd+77RzG57svXvQB39FeY/278U9PctfeEND1KFOSbDUjG7D2V16+1Nf4tPpsQk8TeCvFOlR9DKtqLiMfUoc/pQB6hRXA6b8YPAV/CHXxNYW7E4MV0/kSKfdXwRTdW+L/g6yZYbHUjrd85wlnpCfapWP0XgfiRQB30siQxPJK6pGgLM7HAUDqSewrzSTVfFnjuaVvB17baF4bjcxLqk9v58172LwKSAEHZj16jiktvDGpeP7hdT8dRXWn6Urf6L4fSchWXs9yVxuY8/J90D1r0q2gitbeKC2iSKCJQiRooVVUDAAA6CgDzWPwl8QdGIbQ/HMWpqSN8Ot2W8Y9njIYVI158WYPlbS/CV0R/FHPNHu/A5xXpVFAHmSX/xbueF0fwnZZ4zNcyy49/lxV/RvDnirUtctb3x5faPcWtg3nWlnpkUiJ52MCSQuTu2gkKPfNd9RQAyaJJoXilUNG6lWU9weCK85S88e+HS2k6f4YtdcsbY7bW+OpJblof4EZGBO5RwT0OM16TRQB5lJ8QPF1q5ivPhnq5lHU2t5FMh+jcfyph+IvivcMfDHXdvqbmLNeoUUAeWn4ieMGz5fwu1kgHHz3sK1a0rx54qutVs7a9+HGrWVtPMkUlybuJ1hViAXYDnA6mvSKKACiiigAooooAyvEfiHTPDdlHd6zcm3gkkEKERvIWcqWwFUEnhWPTsawLX4kaHd+JNJ0u2kMttqtjLfWeoqR5EoiYiSPPUOoBJBHAHrxUvxH8IXHjCy0+C21Y6eLW58+SN4TNDcrtI2SIHTcOcjnGRyDXE6j8EFuvhroPhiHxDJa3+kT3EkWqQ2uGKTtIZI9m/gFZAPvfwj6UAaGhfGbT9f8RaBpGlaXcebq0T3Ia5lWLy4RIUDgYO4sAWC8fLjnmtPUPElp4J8S2VhqkOoXuo+JtT8tLmK3IgiViViQyHC/Kij5QS3U45rS0vwPb6V4007W7G58u0sdDGhw2XldEEiuH357BAMbffPaqXxI8Ear4t1TQLqw1620yPR7pL6KOTTzcF5lyASfNT5cH7uPxoA72uc8Z2d0IbXWNKiEmo6a/mhAMtNCf9bEPdl5H+0q10MYYIodgzgDJAwCfpTqAIbO4S7tIbiIOElQOA67WAIzgg9DU1cz4n8RTeHNUsp7+Ff+EenHkz3Y62sxPys/pGehbscZ610qsGUMpBUjII5BFAC0EZGD0oooA5XxD8O/CPiKTzNY8P6fcS4x5nl7H65+8uDWZo/wAIPAuk3yXltoEElzGd0b3Mjz7D7B2IFd7RQAiqFUKoAUDAA4AFLRXK+MPHei+Fp4LS8ee71S4/1On2MRnuJPfYvQe5wKAOqqvf3ttp1lNeX9xFbWsKl5JZWCqgHck15m+r/FXXZC2kaBo3h6xYgpLqkxnnK+8aHAPsTkVesvh1earNHP8AEHX5vEIQhhp6xCCx3DoWiH38dfmJHtQBb8NTDxtrKeI5IT/YNqCmlJMmPOc/eusHoCPlXPOMnuK67UtK0/VPK/tKxtrvym3x+fEr7T6jI4q3GixoqRqFRQAqqMAAdhTqAOU8XaFMDba14diSPWtPHyxoAou4f4rdj6HAIPZgPetnw7rNp4g0e21LT3LQTrnDDDIw4ZGHZgQQR6itKuB1+STwJrUuuwRSv4bvW3apDChc20vQXKqP4TwHx6BvWgDvqKitbiG7tori1ljmglUPHJGwZWU9CCOoqWgAooooAKKKKACiuO8U/Efw74dv49PnuJr7VZPu2GnQtcz/AIqmdv8AwIiudm8VfEzVH3aD4Gs7C3P3ZNYvwGI9Sicj6UAen3M8VtBJPcyJFDGpZ3dgFUDqST0ri/Dk0fjTXY/EifvNCsw0elFlI89zxJcYPbjavtk9xWXY+CvEHicxzfE3U7e4tlIYaLpqlLQkdPNY/NLjrg4HtXpMEMVvBHDbxpFDGoVERQqqB0AA6CgB9c940tJW0+HU7GLzNQ0uT7VCucF1xiRP+BIWH1xXQ0UAV9OvIdQsLa8tW3QXEayofUEZFWK4rSpW8J+JjotyWGianI0umzu/EUxJZ7b2B+8n4r2FdrQBWvLCzvV23trBcLjGJYw/8xXF618I/BeqSGYaOlhdk5+06dI1rJ+aEZ/Gu9ooA8rk+G3ijT8R+GPiPrNparwsF7BHdhB7Mwz+dCfDLxBqimLxf8QNa1C0ON1vZIlmrj0YoN35EV6pRQBneH9E03w7pUOm6LZxWdlCPlijGB7knqSfU81o0Vm+INd0vw7pz3+uX9vY2i8GSZ9oJ9B3J9hzQBpUV5g3xUutRjWTwl4J8RazA/3LiSH7JE49VaTqPwpr+L/iRcwH7D8OEhlzgfa9ViCj345NAHqNcX4zv21nUY/CGkzgXVyol1J0OTbWmcNn0aTBRe/JPauehf4teIJRbXltoXhewk+WW4hlN1dKvfZ/AD1wT04rt/CHhPSvCdlLBpUUhkmfzLi6uJDLPcP/AHpHPJP6DtQBs2ltDZ2sNtaxJDbwoI440GFRQMAAemKqeINKh1zRrvTrlnRJ02iRDho26qyn1BAI+laFFAGJ4R1V9S0xo7tl/tOyc2t6oGMSrjJHswww9mrbrivFyTeGtXTxXZCVrPasOr20Yzvh52zgf3kJ59Vz6V2NvNFcwRz28iSwyKHR0OVYHoQe4oAkooooAz73RNKvpDJe6ZY3EhGC8sCMfzIp2maRpulKy6Zp9pZhvveRCqZ+uBV6igAoorzrxD421vUNTuNH+HOkwapd2zmK71C7kMdnaP8A3cjmRx3C9O/WgD0WivK7iz+MGnqs9rq3hXWGP37aa0ktwP8AdYMc/jUQ1z4xx53+EPDc2P8AnnqLLu+maAPWaQkKCWIAHJJ7V5O3iD4wSYWLwVoEJ/vS6nuH5DmpbbQvHHjVjafEL7Fo+iR4drXRrl/MvG/uyPniPGcqOpx6UAdRF8R/Bs19DZQ+JtJkupZ/syRJcKzGTONvFdZXJn4deEVtJIbXw9plqzReSs0FsiyIB0KtjIIODn1Fc63i/wAZ2kY0i08EX2p6vbExyXkk6QWkqjhZVkY/MWHJUcgmgD06ivME8b+PbdBHqHwzuZLjON1pqcLxn8T0px8e+NFI3fDDU8H01KA0Aem0V5h/wnfjlx+5+F9/kdfM1SBasaX408aTarZW+o/Dm8tLSeZIpLldRhkEKk4Lso5wBzQB6PRRRQAUUUUAFFUb7VtPsL2xs728ggur5mS2ikcK0zKMkKO5Aqrc+J9DtYtRludWsoY9OcR3jvMqiBiMhWJ6HHOKANiio4poprdJ4pFeF1Dq4PBUjIOfTFVdJ1jTtYS5fSb62vEtpmtpmgkDhJVAJQkdxkce9AF6iiigCG8tYL21mtbyGOe2mUpJFIoZXU9QQeorzZfCXjLwk3k+A9XsrvRQcx6XrO9vIGeVjmGW2+gOcV6fRQB5h/wlnxG092OqeAbe8iX+LS9SVifcK4H5U6D4w6RaTJB4u0nWvC8rEgPqVsfJ9sSLkV6bUF8ts9pKL5YWtdp8wTAFMd854xQBU0TXdK120W50XUrS/gbo9vMrj9DV+eaK3heaeRIokG53dgqqPUk9K8M8dWnwYtb0G5ktrXVWG5P7BaQTfgIMgH61y0Ol6TNcpJ/whvxN8QWUR3yR6pdt5e318tmBf6UAeq3njW/8X3MulfDbZLGpKXOvyputbfHVYx/y1k9h8o7muk8E+C9L8JW8ptPNutRuTvu9Rum8y4uX9WY9vQDgVi+DPiL4TvGi0a3jl8P3UShYtO1G2+xttzj5AflPPoa9AoAKKKKACiiigApHVXRkdQyMMEEZBFLRQB5lc/DLUNNu5ZPA/i/UvD1q7F/7P8pLm2Vj12K/3B7DimjQfira8QeM9DvF/wCnrS9h/NG/pXp9IzKoJZgAOSSelAHmTa/8TdGx/afhTS9bhH/LTSb3y5P++JAB+RoX4tfZVJ13wV4v0wDq7WHmx/8AfSsa7y917R7A4vtVsLY4zia4ROPxNcbf/GXwVbP5drqcupz5IMWnW0lww9/lGMUAU0+NGiXe6PRdG8Sapc/wxW2mvkn0JOAPxoNt4+8bYW+ZfBmiscSQQus99OvoX+7Hx6ZPNIPixdTYaz8A+L5kf5o2NoqbkHViC3H0PNaeifFfw3qF99ivzfaFeEZWPWbZrTzP91m+U/nQB0HhHwlofhGw+yaBp8Vqp5kk+9JKe7O5+Zj35Nb1NjdZEV42DIwBVlOQQe4p1ABRRRQAUUUUAZfiXQ7HxHo1xpmpxs1vMBhkYq8bA5V0YcqwOCCK4T+3vGfgoLZa1od54ssE4h1TTAv2goO00Jxl/dTg9eDXp9YuveKtA8Pg/wBtazYWLAZ2TzqrY9lzk/lQByNn8afBbzGDVL640W5Bx5OqW727fqMfrXc6NrWma5a/adG1C0v4OPntplkA+uDxXHar8R/hvdIIdT17RLlCM7JcSDH4g1534iufgrNKl1puqPpt+/8Ay18OtNFKR6FY1Ix9RQB9CUV802Gq/E6SeGL4ey+IdS085xP4otIol2diG4dvxrY1Lwx8c9ftPKvPE+jaSkgw6WYKsOP7wUn8jQB6R4q8ew2GptoXhyzfXfExA/0KBgEt89Hnk6Rr+Z9BVfw74AEmqL4g8b3C654hIPlh1/0ayU/wQxngY/vn5jXHeEb3W/hdZG18QeCol0nrNquhu11JI/eSZG/eHPXPOK9a8OeIdK8SadHfaJfQ3du46oeVPoy9VPsaANWiiigAooooAKKKKAEZQylWAKkYIPIIrzOXwb4m8KXMknw51OyXSnYudD1NWaFGJ5MUoyyA5zt5HpivTar3t7a2MXmXtzBbx9N00gQfmaAPOG8YfELTAW1fwAt5EvVtJ1BZW/BXAJp6fGXQbWRE8S6Zr/hwt/HqmntHH/30uRXRSfETwbHMYm8UaOJAdpH2tOv50aj478GxW0323xHojQqMupuo3yP90E5oAv6F4t8Pa/As2i61p96jHA8mdWOfQjOQad4n8UaH4WsvtfiHVLXT4DwpncAsfRR1P4CvHPEep/A/VLpydKtdVvXx8ulWErMxPTmMAbvxqjoGj+VdC68BfCR47lM7rrxJPsCjsI1ZmOe/GMZoA7k33ib4j5Ph+5k8O+EW+Q3kkH+mX6nqYg3+qTBwHPzHqMV6FoOkWWg6RbabpcIhtLdAiL1Jx3J6knqSeSa4nQPiHJZ30ej/ABC0+Hw1qsn/AB7MZt9pcr0+SXoG/wBk4PTrXoisGUMpBUjII5BFAC0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcF8Z/DOoeI/CkE3h+NJPEOkXkOpacGYLuljblSxIABUsOTjOM1w2t+ANZl+Bl/plz4fj1fxdrV1LqF0gkgxa3UpY+YHkYAbFxHlSTzxxmvdqKAOf8MLdnwRYxappMtvdR2nky2EzxSMxVdu0lWKEMBnr0bnHNcV8B9D1jw3H4qstU8NSaLZ3us3Gp2Sia3aNIZNgSILE7bSoTpjbjGDXqtUNQvxZXlhHIFEV1KYdxzkPtJUfjgigC/RWdrOuaVokAm1fUbSyiLBA1xKqAse3JrnfFfjyw0ua0sNJVtX12+TdZ2dplwwPSSRl4WPuWPbpQBd8aeL7bw0ttbRW0upa1ekrZabbkebOR1OTwqDux4FcqfBnjXxG4uvE/jS60kEZTT9BXyVhJ7NKcs5HToBXX+HPDUOnahd6xen7Trl9tM9wx3CMAD91Fn7sY9B16nmuhoA8uHwbsGUC48V+MZi3+t3asw8w+p44qSH4KeFJLgT6y2q63MDktqV9JKG9iAQCK9NooAyPD3hnRPDkBh0HSrLT4zyRbxBCfqRyela9FFAGT4k8OaP4lsDZ69p1tfW56LMgYqfVT1B9xXCw+D/GvhXcPB3idNT0/oun6+GlMQHQJMvzY9iDXqFFAHmP/AAmnj+0Oy9+G0twUO1pLLVImVj/eUNg49jR/wmfjvUs2mmfD240+6bj7TqV9H5EY9TsyWPsK9OooA4vwreeKdO1ZdK8Zy6fem6RpbS+sYmiXcvLQshJ5A+YNnkA9xXaVj+KoGfS/tUIYz2Mi3cYU4J2HLL+K7l/GtWGRJokliYPG6hlYdCDyDQA+ue8ZeI20G0t47KzbUNYvX8mxskbaZX6kk/woo+Zj2ArX1S/ttK065v7+VYbW3jMsjt0VQMmuY8Fafd6hezeKtdjaO/vE2Wdq45srbOVT/fb7zH3A7UAc5/wqV9bf7X448T61ql5Jlngtrpra0Qn+FI17Dpk8nqakX4F+B+POtL+ck/OZb+VvMHo3zcivUKKAOB0/4O/D+xKmLwtp8jKchp1Mx/8AHya7aysbSxj8uytYLaPj5YYwg/IVYooAKo6zo+m63ZNZ6xYWt9at1iuYlkX64I6+9XqKAPMf+Faaj4dmM/w88TXelR5P/Esv83djj0VCQ0eO2007+1fitZkxSeGvDupeVx9oh1FoBN7hGU7fxNemUUAeYTaX8SvE6eTqmqab4VsW5ddL3T3X+6JGwq+5ArR8NQ6n4M1iDSNb1271nTNRyLK6vQPOhmHJid/4gw5UnnII9K76svxLpv8AaujzwIF+0riW3dgDsmU7kYZ6YIH60AalFczF438PRWFtLqWs6fZTSQiR4bi4SN1x94FScjByKi0j4ieE9Y0zUNQ0zXbK4tbBd9yyvgxjsSDg89vXNAEnjTXLqyW10nQhFJ4g1ElLZX5WBB9+dx/cTI47kgd6z/DPwz8PaQoub+yt9Z1uRjJc6pfwrLNM56tls7R2AHAFXPBOmmRrnxLqMONW1UBhvHzQW3WKEemByw7sTnpXV0AZMfhrQo1ZY9F0xFY7mC2sYBPqeKu2dhZ2TSNZ2lvbtJy5ijCFvrgc1ZooAKKKKACuE8U/C/Qdc1F9WszdaLrxO7+0tMlMMpPbeBw/4j8a7uigDzCDw98T9JUQaf4v0fVbZOVfVdPYTH2LRsAfripWu/iuqgDTPCrsxxu+0SgIPXpzmvSqKAPM1T4tXo5m8J6Xj5TlJrgn/aHIH4Gm21r4y8DMNQ1bX38U6K7L9tjktlhmtATzLGV+8i9Sp5xkjpXp1MniSeGSKVQ0cilWUjIIIwRQA5WDKGUgqRkEcgilrjNF8T6Zoenyab4i1K10+406U2qm7mWMzRj/AFbjOM5XH4g1Xh+LngWW/mtE8SWG+JGdpC+Izt6gP0Yj0BoA3/F/iKHw5pizNE91ezuILOzi/wBZczHoi+3cnoACTXJWPwwtdauG1X4jtH4g1aXlYJM/ZLNf+ecUecfVjycVp+D4G8R6mfF+pWbw7kMOkxTrh4bc9ZCp+68nX1C4HrXbUAc/F4K8LRRrHH4b0VUVdoH2GLp6fdptr4G8KWjxPbeGtFieI5RksowV+hxXRUUAQ2trb2cXlWkEUEeSdkSBRk98CpqKKAKWsaVYa1p8tjq1nb3tnKMPDPGHU/ge/vXnJ+F1/wCHZC/w18S3GgwOcyafdRm8tT6bFY5T8DzXqdFAHmRf4uW4AMPhG9wNmVaaLcf7/Ofyo/tj4rxHa3hTw5Ps6umqMgk+gKHH416bRQB5kdc+KwAH/CG+Hy3Ut/a5wfbGzrSN4i+IWkY1nxFoOnNoy/JcWGmStPdQL3mDHAcDugGe+a9OooAraZf2uqafb32nTpcWdwgkilQ5V1PQiue8aeONM8KvBazJc32r3QJtdNsojLcTds7R0XPG44FYV/8ADzWI9QuT4Y8a6hoWk3DmRtOhtYpUjLct5TNygJ5wOBk4610HgzwXp/hcTTJPealqlwcz6jqEvnXEn+zuP3VHZRgCgDmv7c+KGoqPsXhHRtKR/mWS+1Iyso9GRFHzfiRSi7+LEakNpnhSZn5DLcSoI/bBB3Z/CvS6KAPNTq/xVTk+F/DUuRjC6m64PrynT2qfStb+JEmpWkWqeD9HhsmlRLieHVtzKhI3OqlOcDJ2k5Neh0UAFFFFABRRRQAx5Y0kRHkRXfO1SQC2OuPWmvcwRrK0k0SrEMyFnACD39K88+OWi3934e03XtAtZrrXfDt9FqFtDApZ50BAliAHJ3Keg5O3FeY674Q1+88DaNqupWGpiXWdfbWNctLe0+0zwxsGEKmBlO9Y1CZQqeeqnFAH0jbXEN1Ak1tLHNC/KyRsGVvoRXnPxHXVPGk1x4W8L3YtBabZ7/UkOWhccpBHyMSNwS38I+orQ+FCaqvwr09fFVh9ivfJl823trcW77CzFT5UeNjspBKrg5PQHiuY/Z0gfTIPGGnvpOtafFNr11fWZ1Gzni8y1cIsZ3yjLN8pyCS3c9aAOT0bQfBWtyvpHhHRL5vE08ZhvbnVYpZxpS4xIxMvybzyF25ySD0rtNH8A2Hwl8nVvC5vJdOCLDq0EsgcyR54uMnoY8klV4Kk8V6wkaIzsiKrOcsQMFj70k8Uc8MkMyLJFIpR0YZDA8EEelACxSJNEkkTK8bgMrKcgg9CKdXGeHLj/hG9efwvdny7KUGbR5GPDIOXgyf4kPIH90+1dnQAUUUUAFFFFABRRRQAUVieIPFeg+HY9+tavZWQ3BcSzKrZJ9M5rlLz4taPcv8AZvB9pfeKb89I9OiJiX3eYjYo6+v0oA6rxh4i07w1pButULP5zi3gt413SXMrfdiRe5P5eteFXnjzxt4ajGjaxeaN4W+QfYIbm1mvrt4STtCeXlHdeFx7V634V0DV73U18QeNzbtqaArZ6fAd8Fgh7gn70p6F+OOBxXYS2tvNNFNNBFJLESY3ZAWT6HtQB896N4X+JDW9pr/ivULrXdItrkXZ0C52JPIq9HO0bdw+8IicdB1r37RtTtNZ0u21HTZlns7lBJFIO4P8j7VcribUf8Ij4uNoFCaDrTtJExOFt7v+KMdgrgZA/vZ9aAO2ooooAKKKKACiiigAopGYKpZiAoGSTwAK4/Wfid4L0iVobzxHpxuF6wwSiaT/AL5TJoA7GuZ8aeIpdJS20/SYRda/qJMdlb9lx96V/SNMgnueg5NcpP8AErVfEANv8OvC9/qEjf8AMQ1OJrOzT3yw3P8AQAV0vgrwvc6XNPq3iG9XU/Et4gS4ulXbHGg6RQqfuIM/VjyeegB5veeDrLwdfSHU/A83jaTUJBdnUkgilnF0QN6vvI2qT8ykcDJFTar4D8SeKNQtvFWtafpFld6coksdDiQP5oBB2XEowGPHygcK2DXt1FAGfoGrW+t6RbahZn91MuSp6ow4ZD7ggg+4rQriju8JeLBjy08O6zLz2Frek/kFl/8AQx/tV2tABRRRQAUUUUAFFFMmljhiaSZ1jjUZZnOAB6k0APorgNU+L3g2yuHt7bUn1W5Q4aLSoHuyD3GYwR+tUT8YLB4w9r4U8Z3O44UR6QwJ9/mI4oA9NrF8W+IrXw1pRu7rMk0jiC1t05e4mbhI1HqT+XU9K4f/AIWF4u1cND4c+HerQzOMJPrMi2sSn1Yckj6Vs+FPCOq/2nFrnjnVIdW1qJSttFBF5drZg9TGhyS/UbzzjigDi9X+E+uapdReI57vRrzxRcqy3kOr2v2m0ijPKxRAcrs5Gf4s81qaT8FtKu7QSeOZRrmohGSPyl+z21op6LDEuAMf3jk55r1migDl/BN/dRi40DWZvN1XTQAJWPzXVueI5j7nBDf7Sn1FdRXLeNdNuAbbxBo8Jk1jTMlY14+0wEjzIT68ZK56MB61taDrFjr2k2+o6VcLPaTrlWXse6kdmB4IPIIxQBfooooAKKKKACiiuX8YeOtD8KyRW+oTyz6hMMxWFnEZ7mQeojXnHucCgDqKK8sPxR15T5j/AAy8V/ZieCiI0mOxKZ4/Ol/4W844f4fePAw6gaWDj/x+gD1KivLV+MA+YP4D8dq/8K/2Vkt/49xTT4i1r4iOui6XoviHw1pzDOo3+oQC3l8v/nlBgn5m7t/CM9yKAOo0f4jeEdZ16bRdM1+yuNUicxm3ViCzDqFJGGx7ZrrK5TVPAWgXWixWNnptpYyWqj7FcQQqstq6/dZGxkEH8+c9a5qH4n3Wjx/YPFHhXxI2qWx8u5n0/TzPbOR0kRgeVYc4AyOlAHqFFedw/GbwM3FxrJspB96O7tpYnX6hl4qw3xf8AKu5vFWnAepY/wCFAHeUV583xl8Agnb4jtXA7orsD+lWNM+LPgnU9RtbGz163kurqRYYU2MNzsQFXkdSSKAO5ooooAKKKKACiiigAooooAKKKKAMbxXoFv4i0lrSaSS3nRhLbXcX+stpl+7Ih9QfzGQetcUvxA1bwsWs/H+g3w8rhNW0uAz2s6/3mUfNGx7rg+1enUUAecQfG74eyMFfxHFA/pcW8sWP++lFdZoPizw/4hXOh61p9/7W9wrkfgDmtO6sbS7Urd20E6nqJYw38647XfhN4I1ol7rQLSGfqJ7UGCRT6hlxQB3NFeXR/DHV9EA/4Q7xzrdiinKWuobb2Afg2G/8ep40P4qzHypvF/h+GE8GaDS2MmPYM+AaAO18VeJ9I8Kab9u169jtYC2xAclpHPRUUcsT6CuIaHxp4/BM0lx4M8OsTiNNrajdL/tHlYR7DLVseFvhtpejax/beo3N5rviArj7fqLh2j9fLUDbGPoPxruKAPOoPhL4N0pI57bQ4rq+EsZN1eO1xKfmGSWcn8vevQLa2gtY/LtoYoY/7sahR+QqPUIxJb7SpOGDcHpg5/pVmgAooooAKzfEei2niDRrjTb9SYZQCGBwyODlXU9iGAI+laVFAHlreLPHPhk/2frPg688RCHCpqmkyIBcL/eaJsFX9QOM9OKsH4sLBxqPgvxlac4ydODj81Y16VRQB5qvxs8FRyCPUr290uT+7fWM0WPx2kfrXQaT8Q/B+r4/s7xLpM5P8IuVB/InNdPPDFPGUnjSRD1V1BH5GuY1n4eeENZJOpeG9LnJ7m3VT+YxQBtz61pcELSz6lZRxKMl2nUAD65rh9Q+K+mXUr2Xge1uPFmqDgx6f/qYs8AyTH5VGcdMmpIfgt8O4ZxKnhWxLDoG3MB+BOK7rTtPs9Ntlt9OtYLWBekcMYRfyFAHnI+H2seLXFz8SNZknt2IZdD012htIvZ3GHlP1IHtW7Ppngv4b+G7zVBpen6XptooeaWK3BbkgDoCxJJA/Guyrhvin4U1XxhFodhYahb6fp1vfLe3srLvkPlAtEqoVKsN+CwYjhR16UAdR4d1mw8Q6HZatpEwnsLuMSwvtK5U+x5B7YrRrg/g/wCENV8DaHf6JqF5bXmnx3sk2nSRZV1hc7irrtAU7ix+UkfNXeUAFFFFAFHXNKtNb0m507UIy9tcIUcA4I9CD2IPIPYivPo/FmveCC2neLtG1TV7GAYttb02DzvNTsJowQUcdCRkHrXp9FAHm0Pxu8BFtl3rTWE3eO9tZoWH5rj9a6nRfGnhnXMDSNe0y8J6CK5Un8s1tXNpb3S7bqCKZfSRAw/WuT1z4X+CtbZn1Hw3pzyn/lokQjYc54K4oA7IHIyOlFeXR/Bux05i3hvxR4p0b0SC/wDMjX2CuDx7VI/wy1m8TydV+I3ii4tehjhMUBYehZVz+WKAOh8YePNJ8Nzx2B83UNcnH+j6XZDzJ5T9Oij/AGmwK55PBeseN3W7+JEyx6eRmLw9ZTMIUPZppBgyNjIwPlHvXUeDPBGg+DreRNDshHNLzNcysZJpj6u55NdLQBR0fR9O0a0jtdJsbazt0G1UgjCAD8KvUUUAFFFFABRRRQAV5/rfhbX9H1a51j4f3lnE1yfMu9IvlItriTvIrL80bnuRkE9a9AooA8qPi74oWpP2v4bWtyo/itNai5+gYZqxF8VLq148Q+BPFem46yJbLcxj/gSN/SvTay/E+vad4Y0G81nWp/s+n2ih5ZNpbAJAGAOSSSB+NAHK6f8AGHwFeuI/+EjtLWfoYb0Nbup9CHA5rRvfiT4LsYRLdeKdHjQjI/0pCT9ADk1NFL4Y8W+GoNbNpZ6jpl3EJUkmtwxZT6hhkHtijT/h/wCEdOuftFl4b0qGbOdy2y9fyoA5eXxx4g8XSeT8NdLifTXyra/qJMduOxMUf3pCPUgDNdP4L8Gaf4XjlnDPf61dHfe6pcAGe5fuSf4V9FHAFdNGixoEjUKijAVRgAU6gAooooAKKKKAKmq3g0+wluWQuEx8oOM5IH9at1T1dPM06ZMkZAGQM9xVqMlkVj1IBoAins7W4JM9tDKT1Lxhv51B/ZGmnrp9n/35X/Cr1FAFMaXp6jAsbUD0EK/4U5dNsVdXWytgykMpES5BHQjirVFABRRRQAUUUUAea/HLxHrHhqw8IzeHzK9xd+I7Szlt4yim6jYSEw7n4XcVAzkY9RXl2ufEPxi2neInkm1HTbqLxTaaelnB5Es8EMiMWiRsFGYnGCSRnHNfSOoabY6j9m/tCytrv7NMtzB58SyeVKudsi5HysMnDDkZqpL4c0OWSV5dG013luFu5Ga1Ql51+7KTjlx2bqKAPDLD4lazF8E9Q1KXWHm1i91mTS9LkmhQ3VshcAefGi481EEjkBf7vrWn4W8X3niv4UNHfeJbmy8Q6bfS2k8sE0FlNfMgYoAZl2oGRkY8Z+Q9Oa9ei8M6DDqBv4tE0tL4zG5NwtpGJDKQQZN2M7iCRu681Hf+EvDmoNcm/wDD+kXRupFlnM9lG/nOoIVnyvzEAkAnoDQBwvwk8b6pqXw88L3F9Yat4gvLtXS61C1jgWOJllZPn3SKTtAGWQNnaT3xXO+EfiRrOtfHj+zb172z0S5s5xa6bLYSIyskm1ZHYp1YBmyDtAKrndXtumQ21tYxW9jBBb20I2JDAoVEA7KAAAPwpG02xbU01JrO2OopEYFujEplWMnJQPjIXPOM4oA87+OGva14eTwvc6Pq8Vlb3GsW1pdQGFWeZHfnDk/KoAIPy85HIxz6crBlDKQVIyCDkEVla54Z0LX3hbXtE0zU2hBERvbSOYoDjO3cDjOB09K0reCK2t4oLaJIYIlCRxxqFVFAwAAOAAO1AGff+ItE0+6a2v8AWNNtbhQC0U90iOAemQTmq3/CYeGc4/4SLRs9cfbov/iqg13wL4X1+/N9rWhWN7dkAGWWPLEDpzWavwp8CKoUeFtLwDkfue9AG1/wl/hr/oYdH/8AA2L/AOKo/wCEv8Nf9DDo/wD4Gxf/ABVY5+FngYjB8LaXj08kUv8Awq7wP/0LGmf9+aANT/hM/C+M/wDCSaLj/r+i/wDiqQ+NfCoPPiXRB/2/xf8AxVZY+FngYLtHhbSgPTyBT1+GPghc48LaTycn/RxQBbuvG/hUIEPiLRHL5AX7bGc8H0apx408LEZ/4SXRf/A6L/4qsm4+GnglUA/4RbSSGz/y7j+6afD8M/BIjQjwtpH3Rx9nU0AacnjTwtFGZJPEmiqgGcm+i/8Aiqgh8feEJnVIvFGhszdB9uiyf/Hqgh+G3guGUSR+GNJDjoTbKf0NSz/D3wfOGEvhnRyG64tEH8hQBZfxn4XRtr+JNFVvQ38QP/oVA8aeFj08S6J/4Hxf/FVnL8MvBKjA8L6Tj3t1NKfhn4JOP+KX0njj/j2WgC8fHHhQHB8T6ED6HUIv/iqafHXhIDP/AAlGhEe2oRH/ANmqmPhp4JGP+KW0jj/p2WnD4a+CgMf8Ito//gKv+FAFo+O/CSnnxRoXYf8AH/F/8VQfHXhIdfFOgj66hD/8VVb/AIVx4M27f+EX0fb1x9lT/Ck/4Vt4K/6FbR//AAFT/CgCdvH/AIOUZPivQPw1CE/+zUN4/wDBy9fFeg/hqER/9mqAfDbwWP8AmVtG/wDARP8AClHw38FjP/FLaNz/ANOif4UAS/8ACwPB23P/AAleg+n/ACEIv/iqx9T8eabrF1Lo3h5H1qCWJoru/sJVeGz3KQu5weWOeAOa1P8AhXPgzcSfC2iknrmzT/CrN3o2maJ4dnt9H0+1sLfzEkaO2jWIEh1JJwKAMXRPHJh1A2fiuO00qG5XzdLu3uBsuogOQxbG2QdSvcHitpfHPhNpHjXxPoZdM7h9vi4/8eofQNG8S+FtOtdZ063vbMwxyLFcJu2naMH2NUm+GfglkVT4X0jC9MWyg/iep/GgBP8AhZ3gbzTH/wAJdoW4ED/j+jx+ecVPP8Q/BkDbZfFehKf+v+I/+zVN/wAIL4S8jyf+EZ0Ty8Yx9hi/+JqKD4e+D4MeV4Y0ZT6/Y0J/lQA2L4jeCpSNni3QTnp/p8Q/9mp4+IHg4/8AM16D/wCDCL/4qkk+H3g6Rsv4X0UnGP8Ajyj/AMKb/wAK68Gf9Cron/gFH/hQAP8AEXwWrKG8WaEC3A/0+L/4qn/8LB8Hf9DXoX/gfF/8VQnw/wDB6IyL4X0UK3UfY4+f0pB8PvB42/8AFL6L8vT/AEOPj9KABviH4NUZPivQsf8AX/F/8VS/8LB8G/8AQ16F/wCB8X/xVKfAHhAsG/4RjRcj/pyj/wAKjPw68GE5PhbRc/8AXlH/AIUAP/4WD4N/6GvQv/A+L/4qmP8AEbwWhAbxZoQzx/x/xf40H4d+DTjPhbRTjgf6HH/hTl+Hvg5QwXwtogDcH/Qo/wDCgBq/EXwWz7R4s0IkDP8Ax/xf/FU//hYHg7AP/CVaFg8Z+3xf/FUw/DvwaxJPhbRMnn/jyj/wob4eeDQhH/CLaMVHO0Wcf+FABH8RPBkiB08V6FtPTN9GP609viD4NERlPivQvLHcX8R9/wC9WXpfw+8Ew6aGm8MaPGqswYz2seQdx4JI98Vd/wCFfeCFuUJ8NaJ5zcqptk+bHcDHNAEa/FHwIzKq+LtDJbp/pqf41dXx94OYAjxZ4fwef+QjD/8AFU9fA/hRYyg8NaKFPUfYYv8A4mqw+HHgsNn/AIRXRc/9eaf4UATHx94PAz/wlegf+DGH/wCKqEfEbwUWKjxboOQcYN/EP/ZqX/hXXgz/AKFXRP8AwCj/AMKc/wAPvBzqqt4X0UhRgf6FHx+lADx4+8HkZ/4SvQP/AAYw/wDxVcH8VdX0LxdHodhY+O/DWn6db3y3t7K19E8jeUC0SohyrjfgkMRwo69K7Vvhx4Lbr4W0X8LNB/SnJ8OvBiEFfC2i5HrZxn+lAHnHwsRdG0qTwfpfiHRdftHv3vLd7GcSPBYkh3EiKMIxc4ABP3z6V32teIr/AELxOLjWHs7fwnIyWaztkNHOV3CR26KhPyc9Dj1ra0jw1ougi4k0PSbDT5ZV+d7eBYy3pkgdKsyWVrqmm3NnqNvDdWsxZJYpV3o4z3BoAyW+IHg9bz7K3inQxcYzsN9Fn/0Ko5viL4LgkKS+K9CVh1H2+I/+zU0fDfwWLL7J/wAIvo/kZzj7Kmc/XGf1qaDwB4Qt02w+GdGUf9eaH+lAEJ+JHgkKD/wluhYP/T9H/jTl+IvgtgpHivQsN0/0+L/4qn/8K+8HeZv/AOEX0Td6/Yo/8Kjf4c+DHYs3hbRiT/06IP6UAOf4h+DEUs3ivQgB/wBP8X/xVOj+IPg2Tdt8V6D8pwc6hEP5tUI+G/gsHI8LaN+Noh/pQ/w28Fv18LaN+Fog/kKAG3XxF8GrDMT4o0TCELn7bGRuPI/i5p8PxE8GBYoz4s0HzCo4+3xDt/vcVlW3w28HDVNRJ8MaSV3xqo+zrhRtGcD8a04Ph34NNpGh8L6KVwCf9EQnP1xmgC4fHPhIDJ8UaFj/ALCEP/xVNTx34Rdcp4p0Ij/sIRf/ABVVv+FbeCv+hW0f/wABU/wpT8N/BZx/xS2jcf8ATon+FAFoeOfCR6eKNC/8GEP/AMVT7Lxp4Xvp4oLPxJos88rhI4476JmdicBQA2ST6VR/4Vt4K/6FbR//AAFT/CpbL4feEbG9hvLPw5pcFzC6yRyJbqGRgcgj0IIoA6iiiigAooooAKK5Lx34tfwxf+F7aOzW5Gs6pHpzM0m3ygwJ3jg56dOK4XxD8aJ9Kt9Zb+yIo0sdebRTeTSObeFQobzpdiFhnOAoH40Aez0V4n4i+M91oug+G70w+Hbs6tcXEP2uLUn+yKIwpDb/ACywJ3YKlcgio/GPxsvPDt5YQLp2iz+foEWuFn1No1n3yFBDbnyyZGIwy5AyM+lAHrvhuY3GjQSkOC5YneuD949RWnXlnxJ+IuueE9O0jVbfRbB7C8S33W13dPFdtNI2DEihCgKgqSWYDk+ld/a+IdFutYm0m11jTptVgBMtlHco00YGM7kB3DGR1HegDUoryHxZ8W7zRfEeuRW+kW82h6DdWVpqE7zlZma4/iiULghcjIJGe1dN8XPGl54H0LTr7T9MTUZbq/js2V3dViVkdjIxRWOBs5wOhoA7iiuf8Ba+3ifwnYau7WJa5DE/YZzNFw5AwxVSTgDIIGDkdq6CgAooooAKKKKAIbo4jBPTnJ9PlNPgIMMZHTaP5VCJ4bpc28qTKJGjYxuG2sAQQfcHjFS2zbreMj+6PT+lAElFYEXjPw1Lrx0WLXtNfVR1tVuFL59MZ6+3WtyeaK3iaWeRIol5Z3YKB9SaAH0VHBNFcRiS3lSWM9GRgwP4ipKACiiigAooooAKKKKACsfxhZ3eoeG76005lS7mQLGzHAB3DrWxUEkkUqsqyKxSRQwVgdpyDg+nagDzrxV4xuvA3iTwrDqT20fhS9intLi4dcPBcRqWQls4wwUjHsea6H4Xaxq3iLwTp+ta7FFBcahuuYoY1I8uBmJiB55OzaSferXifwponjHQ30rxJZJfWPnmXy/MZMOGOCGUgg8noe5qbUvEPh/w3JYafqWp6fprzL5drBNMse4KMYUE9B0oA26KZNNFDC000iRxKNzO7AKB6k1FaXtreqWs7mC4UdTFIHA/KgCxRRTJpVhheSQ4RRkmgB9FFFABRTUdXGUZWHqDmnUAFFFFABTJziCQ4Jwp4H0p9Z1xq+nDUW0r7faDU2iMgtTKvm7cfe2ZzigDM8R6HbeKvCet6Fd8RX0LREnkoWQFW+obB+orzX4G6b4k1XW/7b8baZd2F1oemx6FZrcoymZgczXA3AZ3YjG4ZB55r2DTyBPcLzvwjE9uVA4/I0zXNd0rQbeOfWtRtbCGRxEj3EoQMx6AZ6mgDRopAQwBUgg8gjvUNveW1ySLa4hmIzny3DYx9KAJ6KQkKCWIAHJJ7UtABRRRQA2QgRsWBKgHIHpVbSJVn023lQEK65APap7pDLbSxqcMyFR+IqLTLYWen29uCT5SBck5JOKALNFFFABRRRQAUUUyaWOGNpJnWONRlmY4AHqTQBShB+13T7flkdACPYkf0rz340z32k+GNG8WaPNdL/YF7HdXVvFIcXFqxCTIy5weCDk9ME132i30d/aR3MTBoZ1EsT54ZWdiMHvxirGlhlhlVzkrPIB7DccD8sUAcV8FnvtT8OXvibU5bkya/eSX1vBMxIt7XO2FFHQDYobjrur0GiigAooooAKKKKACiiigDnvGnhKw8W2dnDfTXVtPY3SXlpdWjhJYJkzhlJBB4JGCCD6ViWXwzstP02W303XfEFpdXF5JfXV/FcRma6lkADeYGjMbDAGF2ADHFd5RQB5nJ8GtBWx0aDTtS1rTZ9LuZ7yK7tJ4xNJNMAHdy0ZGSABwAKm8QfCHQPEd011rt3qd/cto66MZppI921ZfNE4IQYmDfxDjHG3rXo1FAHn/AIj+F9p4isbew1fxJ4nn09IIre4tftiCO7EZyGlAjzuPGSpXOB3ruYLS2gYNDBEjgbdyqAcemanooA4HXvhVoOt+I7nVrqfUY1vJree9sYplFvdyQf6tpFKluP8AZYA45zWhqPgpry1u4Y/FHie0e4v3vhNBeqHi3KF8lNyECIYyFwcEk5rrqKAOPtfAGmWHgAeEdKu9SsLID/j5t7jbc7i+9n8zHVmznjvgYFc3/wAKYsTGQ3i/xqZc8Sf2qcj2xtxXqlFAHlkXwX0yQk6p4n8Xaj6LPqjAAemFAqU/BXw0M+RfeIYD6x6rKP5k16dRQB5afgvpvBTxV4zVh0I1Ynn/AL5pU+DGlbcTeJfGEx9X1Zv6CvUaKAMXw3oVh4csE07SIPKtUkLHncSxUZZieSxPJPcmq2szTS+GBbWM/kXd8wtYZByULEgsMeihj+Fb65EzA7cEZGDz2rFtkjudfjSKWMw6csheIdVlkbCk/RA//fVAGdJ8N/CbaANHTRLOK1X5kdExKj9pA/3t+ec5rAtPhS15cJ/wmvinV/FFlF/qbK62xQ59ZAmPMPpmvTqKAPNLv4PaPFKG8MatrvhiNhiaHSb0xxyj3Vt2D7jFR/8ACltBdQLjWfFFx/eMurSHd9cYr0+igDzE/Bbw6GzDqXiSFe6x6rLgj057Uf8AClvD+f8AkK+Jv/BrJXp1FAHmH/CldA24OseKC3TcdVkyB6UD4J+GipE1/wCIps4yX1WXn8iK9PooA8xPwS8KA7o59djfGN66rNnHpy1C/BfQE4TVvE6r2VdWkAB9a9OooA8y/wCFLeGyP3l94hkPXLarLn+db/hbwVovg66kOiwyxRXSKsyvM8pkkDZEjFifm56111VrksLm12nGWIII6jFAHJeI/FkeiXFzpNkYp/El7NjT7DdlpNyjMjAdEXDkn/ZPes6Dwb4Y0DS5Z/HVxaavqWqyrBdajqqqfPkbOyJAeEUdFVcdPWu8Gm2Q1Q6l9kt/7QMXkG58seZ5ec7d3XGTnFc/8U/Cw8ZeAdZ0QAC4nhLWzE42TKd0Zz2+YDJ9CaAOPtvBlxfa83hfWvFqan4csUW6XR9oW5MZJEcc7jlohg47tjnpWpd/BfwVIQ9jp1xpUv8Az0067lgJ+uGwfyo+DPh/XrG11fXvG8EcHijWZ0NxGjq4jiiQRxrlSR2ZuD/H616PQB5kPgr4YAwbrX29SdUm5Hp1pG+CXhQnIm1xT041SY5HpgnFenUUAeXt8EvDLjEt94ikx03arLx7DBpV+C2g5/e6z4omA4AfVpMAenGOK9PooA8z/wCFIeC8gi21JWGfmXUpwfpw34/WkX4K+Fo12wXGvQjOfk1afj82Nem0UAeZH4L+HCP+Qh4j9v8Aiay8H169aQfBXw3jm/8AETHOSTqsuT+tenUUAeZH4KeGD/y9a+PX/iaS/N9ea29D8BeHfCsKzaVpym5UuXvJ2MtwQy7TmRvmx049uldlUN7/AMez8E9OB9aAOT8X+I38IS2ep3Fjd3elTQ/Z5RZwmWWOUcxfKOdpy657ErVDw/4Qm165m174g2lrdahcRmK208rvhsICPugHrIc/M34DgV6DWH44ttVu/CGrw+Hrt7TWDbu1pMgBIlAyo5BGCRg+xoA4c/CJt5sIvGHiCDwqD8mjQzbQqnrH533yme2eBxmrt18FfAsqg22kS2E68pPZ3c0TofUENj8waw/hF471P4i+IbW7guHh0nTNIiTUYRGFEuoyE7hkjOECE8f3hmvY6APLl+CmgMcXWr+J7uL/AJ5T6o5X36Y608fBTw0AMX3iHeOr/wBqS5Pp37V6dRQB5g/wV0A/PHq/ieK5H3blNWk8xR6DOR6du1NPwW0cjd/wkPi77Rni4/tZvMHtnGP0r1GigDzEfBPwu5Vr261+9l/jkuNVmJk/3sED8sUH4JeFgWMFxr0GTk+Xqs35ck16dRQB5cvwT8PYPmar4mlbsz6pJkD04pV+CmgAY/tjxQVP3gdVkw31r1CigDy8fBLwwqqBe+Icj+L+1Zcn170h+Cfh9mG7V/E5QfdjOqybRXqNFAHl/wDwpTw5n5dR8SL641WTmnW/wR8I+dv1M6vq4U/u47/UZXSIf3VAI4+ua9OooAr2tvDaolvbRJFDDGqRogwEUZAAHbisfxKZptLvLKzkaCe7mS1EsRw8YcLuce4G4j6VwXj/AOJd54F8b6naauLX+yZNFe/01tpV3njypgJzySSCPY11nhnSNcubjRda8Q3yJdCwU3dhDDtQXTDlwSSflVimPxoAxY/gl4MjQBYNU8zvL/adxvb6nf8A5zTD8FfDeMLf+IlA+6Bqsvy/TJr06igDy9fgtoWD5mteKZT2L6q+R9MVa0n4Q6FpeqWd/b6l4haW1lSZUl1J3RirAgMp6jjGPSvRqKACiiigAooooA53xb4rtfDN5oFvdwTytrGoJp8JixhHYEhmyenHauR1j4y6Nppvomsrprq31htERJJI4kkmVQxYyOwVEwepOfauk+IXg8+LbbSWt9QOnajpV/HqFpceSJkEiZGHQkblIJ6EH3rl0+FVzHomoWp1uxu7zU9Sk1PUGv8AR47i2ndwAFEJfKBccEPnOck0AWNd+K8eh2Ohyah4d1FbzVppoYbZLi3YZjAbcJfMCFSDwc+orM8X/FVNH13Sy+j6q62+jHXb2GF4D5ds7eXyTIAxVscLnO4Y9qNz8B4v7B8PafZa1bA6Vd3N4wvdLW6t5WmABUQlwqoMcLlueal8UfBOw8Y3kN1f6zbGWz0NNFh+x2SxpbXEUu9ZkUPhQBlPK9CfmFAHZ618RtL0u+8LWzWepTf8JFJClrMluREnmDK73OAG/wBkZbHOK7WvNvF3gPX/ABMvhWX/AISqyin0OWK883+yS4uLhARvIEwCqQfujPPftXX2HhbRLHW5tat9KsY9anUrPexwhZJM4zk9ecD8qAOQ8R/FrTtE8R6hp0mmX09jpk9rbajqEZQR20lx/qxtJ3MOm4gcVt/Ezx1Z+AdIsL++tLi7W8vo7COOFkUh3V2BLOyqB8h5J4zXM+J/hEmueJNWvF1t7bSdYubS61Gw+zB2le3+7sl3DYGwMja3TjFbviDwnr+r6fc27eJbNnbUXurc3eiw3EcEBTasGwsNxUlj5mQTuweKAOi8Laude0G01NrOWy+0AsIJZEkZQGIB3IzKQQARgng1q1w3hz4eQ6D8NYfCNlrGowBMk6hbFYptzSb2KjBCjJIxzgfnWY3wruCSw8e+MQ+Mbvtif/EUAemUV5ofhbcnAPj3xgV/iBu0+b8dnH4Ug+EsJ4k8X+LnA+6P7Rxt/IUAemUV5mfhLCpzD4v8XRsep/tDP81pB8KG7+N/F5HYfbhx/wCO0AejE4vefu+XyfTmsbwrqPhzVbjVbvw1e2V5K84F7JbShyJFUKA2OnC1xQ8EeIdC1NRoPibUdUt7uPyLy11aYOEiY4aWNguQ69h0PNbWvfDm0meC78K30/hjVYo/J+1aei4lj/uSIRtfkA5PI9aANrxj4qtPC9rbPPBc3d1dSeVb2lqm+SRsZJx2UAEkngVu200dzbxTwsGilQOjDuCMg1w/gvQ007xDcv4l1tNc8ZSWgLymIRCK0LkKqRjhVLKST1J9sVSuLZfFtxJ4Siurq103S3ZdTFs7RNICcwxK45AK/McHoAKAPSaK8z/4U5o0HzaVrPifT5R914dVlbH4OSKX/hU6Z58Y+LsEYYfb/vcf7vFAHpdFeaH4Sw7Qo8X+LgnUj+0Ov/jtIPhHb9W8W+Lie/8AxMf/ALGgD0yivMv+FTtznxv4v5/6fh/8TR/wqbICHxp4vMX/ADz+38f+g5oA9NorzT/hUOntjzvEniuQ+p1Rxx6cAUz/AIU9p/OPEvisZ/6ibUAenVWuFzdWhx0Zv/QTXng+EVoOnirxaOw/4mR+UenT+dUb34bavpN1ZN4S8ba1Z3Lsyv8A2g63kZTad2FYfe5yDQB6wsiM7IrqWXG5QeRnpms7xJqEOnaRNJNOsDy4ghO7BaV/lRV9ySOlcKPgz4et1W40m81nTNZ5MmqW18/nzMeS0m4lWJPqOO2Ks+H/AAVbWXiOzvPF2tz+IfEcYc2ElyPLWKJcDKxL8m8ZGXxnJ4xQB2ugJPDo9pDdztcXEKeTJM/3pGX5Sx9zjNXwcjI6VxfiYLrEx8KQXjxvdStJeeRJtkS14Zueq7iyrkf3jWOPgt4Ytzu0m513S5P71rqkwGPTDMRQB6ZRXmR+EFkxJbxR4tOeoOptz+lJ/wAKb0ncrf2/4q3jq39qycmgD06ivM/+FP6dkP8A8JL4s87/AJ6f2o+SPTGMUv8AwqS2iG2z8V+LLaNuHVdRLbh3+8D1oA9LorzT/hUlrn/kavFuMYx/aR/wzR/wp7R25m13xVI5GCx1eXn8KAPS6K81/wCFQ6amPs/iLxZF641V2z+dN/4VDZ/9DV4u/wDBo3+FAHplVtRz9lO3H3lzn/eFeef8Khs/+hq8Xf8Ag0b/AArO134aPo+mm70bxr4istQWRBFNd3fnxkswAV0YYYUAetGaITCEyIJSNwTcNxHriq2s6hFpWl3N9OGZIELbE+857KvqScAD1Irz5fg3oN/GLzxLNe6p4kch5dYFw8EwYdPLCnaijsoGPXNNtvAkGlaxptx4t8W6rrVlDdRrpVnfuoVLjkqWKAeYwwdu7gfXFAHWeAkt/wCxGni0G20G6uJnlu7SBEXEx6lioAZiMZaujrgvFV/ro1qbw74ftLmC41JVlTVRGGgs4+kjHP8Ay04+VcckgngVnj4M6Eo3Rav4mS46+cNXmzu7tjOMnntjmgD02ivMv+FQ2WcnxT4tLdm/tJsj9P50f8KitWQLN4r8WyDpzqTD+Q9eaAPTaK81PwktMgp4p8Wo3cjUjyfy/wA4pv8AwqjZlLfxp4uhtn5lhF8CH/EqSPwNAHplFeZD4RwDlfF3i4N2P9odP/HaP+FQWEvN54m8V3B7k6my5/LFAHptFeZH4O6U7BpfEHip3UYRv7VkG38B1/GkPwht8ADxd4ux3zqJ5H5UAenUV5l/wqG17eLPF4H/AGEif5ig/CK1K4/4SzxcPUjUj/hQB6bSEhQSxAA5JPavMv8AhT9ock+LPF+fX+0zx+lH/CmtGuiF1zWfEesWy8C3u9Rfy8ehC7c/jQBofE628F3Fhp2ueM7eG7s9OnjmtpgzNtcnggIfmXIBIORgcjiu4sbu3v7OG7spo57aZBJHLGwZXUjIII6ivPtE0ZtP8WW/h210ry/DmlK11byyjKfvAwWKPnnaTJnPbbTLr4dz3N1JoaTR2HgTeboWljLJFPJMxy0ZYfdiDZbCkElsdBQB6VRXmS/CCxgPl2PibxVaWmci3TUmZR9CwJ/Wl/4VLFux/wAJf4t8onJT+0Ov44zQB6ZRXmTfCK3IGPFvi4HPX+0T09OlWdJ+F0en6paXj+K/FF0lrMs8cE99mPIbOGAA3A4wQaAPRKKKKACiiigAoqlqeq2GlfZP7SvILX7XcJaW/muF82Z87Y1z1Y4OB7Vm6h4z8N6bFeS3+uafbx2c4trhpJ1URSkZCN6MQCcUAb9YsdtGul6vHbqsXmSTMfLTYd55LZ7nPOarTeOPC0GhQ61L4g0tdJml8iO7+0r5TSYJ2Bs43YU8e1Zl38QvCOn6PBeXniLTI7TUmm+ySmdSswVirEEZ4B4J6A0AdD4ThS38M6XFEGCJboBuOT07n1rVqrpaqun24jdJI9g2OhyrL2IPoRiqula7p+oX13p0F9aS6nZBftdtFIGaAtyNwHTNAGpRWBqHjHw7p2vQaLf6zY2+qzFQls8oDkt90exPYHr2q34k8QaT4Z006hr+oW9hZhxH5s7YBY9APU8H8qANSiuYvPH/AISstM0/UbvxFpcFjqCs1pPJcKqzBSA2098EgH0NdBY3dvf2VveWUyT2txGssUsZyrowyrA9wQQaAJ6KKKACiiigCpz/AGr2x5H4/eq3WWJIv+EnaPnzhZhj6Bd5/r/StSgCnHFH/assvlKJfLCeZgZK9cZ64yTVpY0V3ZVUM/LEDk9uahUD7YzYG7BHXt8tFnfW16ZxaTxymCUwyhDnY46qffmgCxRRRQAUUUUAFFFFABRRRQAVDLbxyzwTOMyQklD6ZGD+lTUUAFV3iQ38U3lgyCNl39wMg4/SrFRMc3SKGxhCSMdeRQBDFpllDqdxqMVrCt/cIscs4Ub3Vc7QT6DNW6Y8saOiu6qznCgnBY9ePWn0AFFFFABRRRQAUU3zE83y9w343be+PWnUAFFFFABUF5aw3kQjuYxIgdZAD/eUgg/mKnooAKoavEkq2nmRLIEuY2GRnaQeD+FX6rX4kKRmNQ22RSR3PzCgCzRVKTVLWPV49Ndyt08JuFUjgoGCnn6kcVdoAKKKKACiiigArnfiL4li8H+CNZ16bafsVuzxq3R5D8qKfqxUfjXRVjeKtF0fW9NjTxFDHNY2kyXuJZGSNXj+ZWfBAZR1IbKnuKAOR+CHjm98Z6JqcWuPYNrel3jWtz9hbdC6nlJEOT8pGRnP8Jr0euT0jTfC+k+LTc6RaR22qazaBzJb7hFNFHjb8oOwHDZBxkjPNdZQAUUUUAFFFFAFdx/pqHj7v+NYWq+L7PS/G+j+G7yCeOXVYJZba6OPKZohl485zuC8+laWnSCUW7qSVIbGfq1c18WvAI8f6JaWsOpyaRqFncC4t76KLzGj+Uqy43LwQ3qOgoA2fA3ie38YeH49ZsLeeGymlkSAzAAyqjlfMAH8JIJHtW/VDw/pNtoOhafpNgu20soEt4geu1VABPvxzV+gAooooAKKKKACiiigDzj43eFtV8WWHhO10YTq1p4htLy5nglSOS2gUSB5UL8Fl3AgYJz2NeY618L/ABbFp/iCC1ttR1J5fE9pqUFy95bi5ngjQhpNxKqHBIAyB24r6VooA+adR+G/jJvh3Z2EOlXLTxeLxrEcCXlsL1LXa+XeUnyml3Hj73UZyBgdT4y0XxVqnwut/D1n4Z1ia6ubaWOSabVbNZ4m3ttWcgBXjOVYhOcADg817bVSeQok+WbClcevJoA5fTvDviKHTdN2eI3sZrfTo4H0+3tYGtFnEW3cCyeZtDcgbxwAK4j4N/D7xN4M+IXiO51RrKfTLu1gU3saEPeTDJZ8GRmVssxYsMMT8uAMV7FbMxnulZidsgxnsNq/1zUNnaTQ6lf3Ek++Gcp5Uf8AzzwuD+Z5oA8P8dfDvxRqXinxZb6fp6T2HiK/027TVPtEa/Y1txhw6k7yRj5doPB7V6D4w1fxr/wjept4f8IxTazHftbWKy3sLK0Gzi7O4qB1K+WTu9eM13tFAHzlf/DzV4vAvhiz0rwfrMesaTFeLbTprVrFJBPMV3SvglWVjk4UnABGOQa7Ww8J/E9rCzS68dWVrJDDGpSDTkcFgg3bicZ+bPQDjHFesUUAeWN4N+I6AGL4jhn64k0uIjP4dv8ACgeFficgO34gWTE8/PpSdfzr1OigDyw+EviZJu8z4hWqenl6WnT8T1pB4L+I2Np+JDbc5J/syLPvXqlFAHk58CfEBb43EfxFYkR+UrPp0ZYrnPPb8am/4Q34iyfu5fiNsiHzb4tNiDk46HPGK9SooA8nXwp8Q9IvGmsPHI1WKHMxt7+yUPORgmMMuAqnGPUZqrpfgG58Xz32teIXv/D2pzyCSyTTrspPbQtnIlx8pdv4uD0GDXrq/wDHw34/yWqtphbteAN8O4Y9NxP9RQB59/wr/wAY2KmPR/iTqggH3EvrSKdlHoWwCe1MPhf4oj5B4804oB8rnSxvJ9+cY+lep0UAeVDwj8TpRmb4h20THr5OlpgfTJpf+EM+I4JcfEcF+m06ZFtA9fXNeqUUAeVr4N+JPJPxHTPYf2XHj8aP+EM+I7fK3xI2pjGU0uLd+vH6V6pRQB5Z/wAIb8R/+ijjg8f8SuLke9KfB3xHI/5KKg+mmR16lRQB5cfBPxAdtr/EqdUx1j0yENn8sYpD4H+IAJK/E25JGSM6ZBgn0Ix0r1KigDy7/hX3i3Um+z+I/iBfz6Yf9ZDZW0ds8o/ulxyB9KiGjeIDerdaVqEzatoGLKJbriPUYR8zI/8AtFTHh+zZr1aoWH+lLuPG35RjvznmgDyyx8Of8LJudS1TxZZ6jphAVNKtmlEdxYADDyqV6MzrnnPAH0qZPhbqmi8eDfHOuabCx+a3uyt5HnuRvGQT9a9ChjI1SOUZ2tHKnHQnzAf8a0aAPLh4b+KMwFlc+NdKjsSQHvLfTsXe32ySgPvik/4V34qvx9l1z4hanNp8XzQG0hS3nMg5VpHA+YA846HHNepUUAeWp4P+I198mrfEJLWNfutpunIrt/vF8/pRJ4N+ItsPL0/4i+dEerXumxtIPoVwK9SooA8sbwB40crct8RbxdRA2ealjFsKf3duMdec0v8Awh/xITaE+IquG+/5mlxZHH8OPf1r1KigDy1fBvxGx83xHGcdBpcXX/CkbwP8QXJJ+Jlwp6ALpsIGPfjrXqdFAHlg8C+P2ID/ABOuwo/u6bBn+VPPgnx95YI+Jdz5q5xnTYNpz6jFeoUUAeV/8IX8R24f4lMF7ldMhz/Kq9z4F+IEawyxfEy7e6UhtkthF5LEEYBAGcHPNeuVBcBGYLJkjYWwPYigDymTR9X8e6ta6V4+0CBNL0wNHcSrKyLfXGDtki2tkRYBOGOQWA7VZPwu1bQ93/CDeNNW01Jf9dDfkXqMezLv5U+uK9FlcJdM2H+WWMZ7cjb/AFq/QB5avhL4lFfKf4hwCL/noulx+Z+vH6Uf8I18UmQW7+OdLWBek6aWPOb2PzbfyFepUUAeWDwV8ROGPxKk3jPy/wBmQ7T9eM0n/CGfEfO4fEj5m+8v9mRbR/u//Xr1SigDyv8A4Qj4hzfJcfEqWOPrug02IPn6njFPtPh54mvrmO38YeNbnWNERg72aWyQG5IwQsrL1TPUDGa9RooA4zVfDEPiLRFszdT2l3aiN7W5gbY0EqMxQ+4HAK9COKwD4R+IusESa347i0t4xiOPRLMBG93MmST7dK7/AEaC5hl1H7TFHGj3TNBtOSY8Dk+nOeK06APKj4K+JDYU/EoqqY2sumRbm/3uP5UHwX8SFwsfxJJXoWk0yIsB6jHevVaKAPKj4L+JGQv/AAsj5D1b+zIt3vjtQ3gn4iWmF074jPKs/Nw97YRu0Z9YQOAPY5r1WigDxXSvB/xC1W3tdM1/xjAuiNuD3Gnw+TeuAW+Qv90A55IGfStZfC1z8PNup6drfifW4yRZw6fczfaEi8zhWIABwr7SSc4XNdL4MuJJ7i6Ek7SKlxLsVv4FJ4A9uD+ddfQB5b/wr7xdpqk+HvH9/D5x8yeG/hS6QSH7xRiAyqSThe3FInhD4kyDFx8RIo8cKYNLjyfc7s816nRQB5X/AMIf8So+I/iJE46Zk0yPOPw71b0nwh48tdXtLm/+IMl5aRzI81r/AGdEglQEbk3AZGQMZr0migAooooAKKKKAI554oEDTypGpOMuwUZ/GgXEJMYEsZMgygDD5h7eteV/tFaJqWv6J4RtdI05NQlXxJaSSRzWzXECR7ZQWnVf+WQyN3QYPXmvO9H8M61pXw00vV7LQdVi8V+FdflvJNPW2dVmikk2zRWoAw0LIVI25+63ryAfS5uIVWQtNGBGcOSw+X6+lUNSvILKOea8nghhkKCNncLu/EnFeA6p4U8R6l4E0PQpNDvbm/8AFGpS694gBZoEjUEOtu8pUiNv9UAOuYzwKLuG/vfgpZaB4r8JaxceItOS60qC5TQzfiPy9oV0BxgOm0LKMjKMc+oB9D2qsL26brHJsZW7HjB/kKsCWMymISIZAMlM8geuK4HwDY+LbLwt4Wg26Xp9lbadDFcafcwyy3KuqYIEwkCjovBQ45HNcH8LfD/jHSvjlquo+JtL3Pf6WTd6hHO7wFzLlVjJjAyAETy88KN2Sc0Ae9vIiFQ7qpY4UE4yfQU6vF/jLB5fxL8Capb6Rr97Jp9x513LZWdzcwxwYcDhAU37s5wN2MZ4xXtFABRXD+Ita8dWusTw6H4Usb7Tlx5dxLqSxs/HPy445rJ/4Sj4mRtiX4f2UinoYtYj/XIoA9OorzIeIfihNgxeCNJtwRnE+rBj9PlFAX4s6onzSeF9C2HPyrJdM/tyQAP1oA9NorzFvEXxN0s+ReeCtP1grwLrT9SWFX99kgyKB4u+I8+BB8OYomzybjWIgP0FAHp1FeZf298VDgDwZoik9zqucf8AjtH9t/FVvlXwhoEbHkO+pkhfYgDJoA9FXBunO07kyBx7L0quCEudOULgNG4HHI4U4/nUGgammrWNvdKVjlmRt0YOfLcbQ6++GzT9Su00+zsbm5I8tJo0kc8Bd/yBvplhQBqUV55qmsav4x1W50zwTqL6Xbaa/wDpGrtbrLHLMOPIRW4YA/eYemBVY6z8U7J/s0nhXRNUKcfbYNR8hJPfy2BIP40AemUV5kfEHxRI+XwRpCn31cH/ANloXxD8Ufm3eBtJPpjV1/8AiaAPTaK8xbxN8T04Pw/0+QnoU1pAB9crQNf+Kb7XXwXosan/AJZvquWH4hcUAenUV5mB8V9WUMW8NeHlQ52bXvHk9icgAfTmo5PFnxKsCYrv4e29+y8efY6rGqP7hXG4D2NAHqFFeYJ4v+I84Hk/DeOLP/PbWYhj64FOPiT4oHp4B00fXWk/+JoA9NquyOb1WHKBefbrXnR8RfFGQbI/AmlQuekkmsKyr9QFyfwrqfB+u3Gr27jU7T7FqkD/AGe7tg25I5QCfkb+JSCD+NAGrIzRy2rEggzOhK9Od2P6VfrF8R3C2GivfYYRWcn2hwgySit83H0ya5W78Tt47kOmfDrxHBAYAJbzU4YBcLCP4I1DfKWY8n0APcigD0SivMxqfxT07day+HtC1ooAFvYb42wk92jYHB+nFJ/bnxUKkjwdoQz0B1U5H1+XmgD02ivMj4i+KKDJ8CaVJjsmsKM/mtI3ij4nRYMnw+sJQf8AnlrKZH5rQB6dRXmCeIvilcRjy/A2k2rHvPqwfH1CinCH4r6umZLvw34dCHpFE948n13EAD9aAPTaK8yk8QfE7SlMV54N0zWthx9p07URCJB6iOQZB9s1GPGXxGmH7n4Z7D/021iEfyFAHqNFeZf8JJ8UCMjwDpi8dDrSE/8AoNL/AMJB8UFjDHwRpDtkgqurgemDkr9aAPTKgnH72M9wMf8Ajy15z/wk3xPAGfh/pxPHTWk/+Jre8JazrN/Lc2finTLbTtYtlSQRW0xljkiduGDY45Qgj2oA6C9P7u6YMB5ZRyT22kN/Sr9VrmJrq0u4CuzzFaMNnrlcZritQ8axa1a2mkeE9Rt38QX6fM0eJDYIMiSaRT/dI2hTjLEds0Ad9RXmJuvinoX+irpujeKIY+EvPtH2KaQf7aHKg/Tik/4Sf4odf+Fe2Ax2/tuPn9KAPT6K8x/4Sb4oYJ/4V9p59v7bj/8AiaYfGPxIiO2X4aLI3XdFrURX+VAHqNFeYL4p+JtwN0Pw9srdfS41mMn9Fpy3fxX1TdB/ZnhzQVYf8fTzvdOn0QYBP14oA9NorzB774oeG8JcaXpfjC36+faSixnX2KNlT+FRnx/46dlSL4W6kGPUyalAF/PtQB6nRXmI8UfE6Vd0fw+sI89PN1lMj6gLSN4h+KijI8DaO59Bq4H9KAPT6K8uPif4pJuLfD3TZAOgj1pMn81rR8N614uvdWttR8RafDoOlSsbMaZI6zTNKeVm8xeAMgqF9OaANzRbVYNcbcvzm2Ev3s8tI/P4jFdJWIJLa01yAMNh/s93L/wqiOv/AMXXHtq3xHu9+saNpuhzaVKT9m0y4keO4aPPyyGX7oLDB2kcAjvQB6XRXmI8R/FEkf8AFB6WAex1lPl+vH8qT/hIvimwyvgTSU9m1hSf0FAHp9FeYf8ACSfFIcHwFpbE8AjWEGPc8dKs6Zr/AMSZtVs4tQ8FaZbWDzolxMuqq7Rxk4ZwuOSBk470AejUUUUAFFFFABRRRQAVSuboxT7F6mSNSAM8N3P5fpV2qtzjzk6glk5H1NAElxC0xiKzyxeW4ciPHzgfwnIPH0xU1FFABRRRQAUUUUAFFFFABRRRQAUUUUAZlnpltp88gtVZPtM0k785+dgMkenSpbvTrbU9Gk0/UIxcWs8PlSo38YIwatOwEyKc/MGHH4UsHEMf+6P5UAQaVp9rpWnW1hp8CQWlugjijQcKB/nrVqiigAooooAKKKKACiiigAooooAKaUXIOxTznOOhx1p1MlVmMZQgbWyfcYNADbdP9HAkw27JPHByc/1pllY2lhEYrG2gtoyc7IYwg/IVLAMQRjJOFHJ+lPoAKKKKACiiigAooooAKKKKACiiigAqK4TMbMm1ZMD5iM8A5qWmT58mTHXaf5UAJC27zOAMORxVTTtF0zTLm7uNO0+0tbi7fzLiSGFUaVvViBz+NWoMfvME/fOaloAKKKKACiiigAooooAKKKKACiiigAqlrMUctg/nYAVlcMRnaQQQRV2qWtDOkXmCRiJjx14GaAOY8XzN/aekWQ+VdQie0LgEldxQ49gQrc12UUaRRJHGoWNAFVR0AHQVQtrd2vLa42r5C2wUbvvBsgj9K0aACiiigAooooAKKKKACiiigDzn41XviO10rSo/CtzHHLLd/wCk26XcVtc3EIBLLA8oKhuhPGcdO9eZav4n1u6+Glh4i8P+LPEdqy6qmlSwXsds7gtLtbLhMORnAYdccjINfQetaLpWuWy2+t6ZY6jbq24RXdukyg+uGBGabJoOkSaZBp0mlWD6fAyvFatboYo2U5UqmMAg8jA4oA8t1aTWtH+Lfgbw+fGOrT2d5DPLdrKLcGVosMgOI+A2dpxyR0wea8r1z4m/Ee18Ba5PBPOFhvnu4tY8lSsdstwbY22du3f5mxh32k19QXvhfQL7V4tVvdD0u41SJlaO8mtI3mQqcqQ5G4EHkc8Uk+haM2my6TLo+nSaTM4Z7JrZDCzFy5YpjaTuAbp1560AZ/xKvLKw8J3N1qniG68PWcTK0l5aFBMR/cTcrck46An0rx241zx23wu8MXn/AAkcEF/51xNds97awXMlqoyiMXDJ5oBXOBxkbua991nR9M1y0FprWnWWo2oYOIbuBZk3DodrAjPJ596zW8E+FG0+OwbwzoZsY5DKlubCLy1cgAsF24BIA568UAeC6z4/1jUrGxex8R6ppdnD4PuNdgnmWFJry8SVkWOT5drDC/dUDIOareIfiR4se31vWP7Wm0+/0ew0O4s9KjRBHevdKjTh1ILNgsVGDxj1r6O1Lw5oeqRWkWp6Npt5FaY+zpcWqSCHGB8gYHb0HT0p174f0a+1K21C+0nT7nULXHkXM1sjyxYORtcjK8+hoAx/FviDxBpN9DDonhK41uF49zzR3kUIQ5+7huSe9Yn/AAmnjb/oml5/4NbevRqKAPOf+E08bf8ARNLz/wAGtvR/wmnjb/oml5/4NbevRqKAPOf+E08bf9E0vP8Awa29H/CaeNv+iaXn/g1t69GooA85/wCE08bf9E0vP/Brb0f8Jp42/wCiaXn/AINbevRqKAPM5/G3jVcf8W1vQ2DtxqUDc49qkTxn41VEA+Gt6eAP+QpAO1ehzsVUY684HQHg9T2qWgDzgeNPGpGf+FaXv/g1t6X/AITTxt/0TS8/8GtvXo1FAHnP/CaeNv8Aoml5/wCDW3o/4TTxt/0TS8/8GtvXo1FAHnP/AAmnjb/oml5/4Nbej/hNPG3/AETS8/8ABrb16NRQB5z/AMJp42/6Jpef+DW3o/4TTxt/0TS8/wDBrb16NRQB5z/wmnjb/oml5/4Nbej/AITTxt/0TS8/8GtvXo1FAHnP/CaeNv8Aoml5/wCDW3qKfxt40BiB+G98uXGcapAa9LqK4/5Zf74oA86g8aeNBDGE+Gl7tCgDOqwCpP8AhNPG3/RNLz/wa29ehwf6mPv8o/lT6APOf+E08bf9E0vP/Brb0f8ACaeNv+iaXn/g1t69GooA85/4TTxt/wBE0vP/AAa29H/CaeNe/wANLz/wa29ejUUAecjxp41zz8NLzH/YVt6d/wAJn4y/6Jtf/wDgzt/8a9EooA84PjfxiCR/wrXUTj01GCm/8J14y/6Jlqf/AIMbf/GvSaKAPNv+E68Zf9Ey1P8A8GNv/jSnxz4xCKR8NNTLEnK/2jb8frXpFFAHm3/CdeMv+iZan/4Mbf8AxqO58deMlhkx8M9TPB5/tGA/1zXptMnz5MmOu0/yoA80g8ceNF83d8MtTwXJH/Ext+n51L/wnXjL/omWp/8Agxt/8a9Dts/vc4/1h71NQB5qfHfjIDJ+GOqfhqNuf60J478Yvn/i2eqDHrqEAr0qigDzP/hPvGP/AETHVv8AwPgo/wCE+8Y/9Ex1b/wPgr0yigDzP/hPvGP/AETHVv8AwPgo/wCE+8Y/9Ex1b/wPgr0yigDzP/hPvGP/AETHVv8AwPgo/wCE+8Y/9Ex1b/wPgr0yigDzP/hPvGP/AETHVv8AwPgo/wCE+8Y/9Ex1b/wPgr0yigDzP/hPvGP/AETHVv8AwPgqOfx34vlgkjb4YauVdSpA1CDOD+NeoUUAeYp488YIiqvwx1bAGB/p8FB+IPjAdfhhrH4X0Jr06igDzL/hYPi3OB8Mda/G8hH9aU+P/FxXK/DLWTj1vYB/WvTKKAPMf+Fg+MMZ/wCFYax6f8fsNXNK8beKrvU7S2u/h3qdnbzSrHJcvewssKkgFyByQBzgV6FRQAUUUUAFFFFABRRRQAVXmBadAuPvKTn0+arFZs+nTya9a6gmo3McEMLxvZKF8qUk8O3GcjnGD3oA0qKKKACiiigAooooAKKKKACiiigAooooAiufuD8f/QTUtZHifSLnWbGG3tNWvdKeOdJTNaFdzqM5Q5B+U55+la9ABRRRQAUUUUAFFFFABRRRQAUUUUAFRTgny8AnDg1LWb4i02bVtHuLK11K70yaUALdWpAkj5zxkEUAXrc7reI+qg/pUlMgQxQxxl2kKqFLt1bHc+9PoAKKKKACiiigAooooAKKKKACiiigApk5xBIePunr9KfTZULxOgdkLAgMvUe4oASNWXduOcsSPpT6zvD+nS6VpFvZ3F/c6jNGMPdXOPMlOerYAFaNABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABUc0oi28ZywX6ZqSsHWfCem6xem6vJtYSUgDFrrF3bJx0+SKVVz74zQBuCRCxAZSQAevrwP5Gl3LnG4Z+tcoPAGjDpdeIx/3MWof/H6E8AaKiBEufEaoOijxFqAA/8AI9AHWZHXIx0qOOTO/JxhiOT2Fcx/wgWjj/l78Sf+FHqP/wAfo/4QHR8Efa/EmD1/4qPUOf8AyPQB1QIOcEHHFBYDPI4965T/AIQHRuf9K8R89f8Aio9Q/wDj9L/wgOjnP+leJOev/FR6h/8AH6AOoeQK6qcc5yc9MU4soOCwH41yh8A6MTk3XiM/9zHqH/x+g+AdGJybrxGf+5j1D/4/QB1ZYDqR+dLkdMjPSuUPgHRz1u/En/hR6h/8fo/4QLR+v2vxJnr/AMjHqP8A8foA6lWyiseMgGnZ5x3rlP8AhAdH/wCfrxJ/4Ueof/H6P+EC0c/8vfiT/wAKPUf/AI/QB1QZSOGBH1o3LkjI4rlB4B0YDAuvEYH/AGMeof8Ax+l/4QHR/wDn68Sf+FHqH/x+gDqty5xuGfrQWAOCRn0rlP8AhAdGzn7V4jz/ANjHqH/x+j/hAdGzn7V4jz/2Meof/H6AOqZsDI55A/XFKCDnBBxxXK/8IFo/T7X4kx1/5GPUf/j9L/wgekf8/niT/wAKPUf/AI/QB1JYDqR+dG5cZ3DH1rlT4B0c9bvxJ/4Ueof/AB+k/wCEB0bGPtXiPH/Yx6h/8foA6pXBLcjGcD34zShgehH51yo8A6OOl34k/wDCj1D/AOP0DwDo46XfiT/wo9Q/+P0AdUGUnAYH8aaXG5QpByefyJrlh4B0YHIuvEY/7mPUP/j9A8A6MDkXXiMf9zHqH/x+gDqwwOORz70bl4+Yc9Oa5X/hAdHGP9K8ScdP+Kj1D/4/Sf8ACA6Nx/pXiPjp/wAVHqH/AMfoA6zPOO9BIHXiuU/4QLSM5+1+JM/9jHqP/wAfo/4QLR+n2vxJjr/yMeo//H6AOq3DcFzyRnH+frSB1OfmHGc/hXLf8IDo+c/avEmfX/hI9R/+P0f8IDo//P14k/8ACj1D/wCP0AdTvG7GRjByc9MUu5efmHHXmuU/4QHRuf8ASvEfPX/io9Q/+P0f8IDo3P8ApXiPnr/xUeof/H6AOryOeRx19qCRkAkZPQVyv/CBaPz/AKX4k56/8VHqPP8A5HoPgLRyQTd+JMjof+Ej1H/4/QB1dIWAOCQDXLf8IHpH/P54k/8ACj1H/wCP03/hAdG4/wBK8R8dP+Kj1D/4/QB1hIHXimBv3h54wMc/WuX/AOEB0f8A5+vEn/hR6h/8fo/4QHR/+frxJ/4Ueof/AB+gDqgykcMCPrSb1xncMcDr6nArlR4B0YDAuvEYH/Yx6h/8fo/4QDRsY+1eI8f9jFqH1/570AdUzgdCM5HH44oWRGGVZSOe/pXLf8IDo/8Az9eJP/Cj1D/4/SDwDowORdeIwfbxHqH/AMfoA6vcPUUpOBk9K5Q+AtHPW78SHt/yMeo//H6P+EC0fn/S/EnPX/io9R5/8j0AdVnkjI64oLAdSPzrlf8AhAtH6/a/Emev/Ix6j/8AH6D4B0c9bvxJ/wCFHqH/AMfoA6rcuM7hj60hcZXaQQTj9M1yv/CA6NjH2rxHj/sY9Q/+P0o8A6OOl34k/wDCj1D/AOP0AdVkccjnp70BlJwGB/GuV/4QLR+P9L8ScdP+Kj1Hj/yPSDwDowORdeIx/wBzHqH/AMfoA6sMpOAwP40iPuVSSNxAOK5UeAdGByLrxGP+5j1D/wCP0v8AwgOjjH+leJOOn/FR6h/8foA6sEHoQe9AORkdK5QeAtHHS78SDt/yMeo//H6P+EC0fGPtfiTA/wCpj1H/AOP0AdTu+cg9gP1o3rtLZGASM/pXLf8ACBaRnP2vxJn/ALGPUf8A4/QfAOjkYN14kx6f8JHqH/x+gDqS6g43DOCfy60kkgWN2BHygn8q5Y+AdG/5+vEfcf8AIx6h36/8t6P+EA0Ygg3XiPBzn/iotQ5/8j0AdXuXn5hx15oDAnAIJrlP+EA0bJP2rxHk5/5mLUO/X/lvXT20CW8EcUe8rGoQGRy7EAY5ZiSx46kknvQBLRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAYHivxj4f8JLbnxHqkFh9oV2hEmSZAmN20AEnG4fnXO6v8W/C1roWq6npV6utDTI457mCwIZ1idgvmDOAwGecHjBzzWj4y8F/8JJ4i0XVPt/2b+zbW+tvK8nf5n2mJU3Z3DG3bnGDnPasTw98KbfTZoBfaj9utF8Mp4bmg+z+X5qB2YyZ3HGQxG3Bx1zQB02m+MLDU/F8mg6ektw0Wnx6hJdpjykWRsRoT13MAWHGMVQ0v4i6PP4ZbxBqki6bpct9LZ2UkrF2uwrlFdFAydxViFAJwM1y/h/4Z6r4J+G/iHS9B1Q6t4i1NVgS/uV8ny4wiwoPvNxGm4jnk8V0WtfD2GfRvC1poV+dMuvDbo1hM8AnT5YzGRJHld2VPUEHPOaAJ774o+CrCO1e98Q2cC3MQmiD7gWQuybsYyBuVgc4wQc4rZ8M+KtD8UJdv4f1K3v1tJfJmMRPyNjI69QR0I4PY1w3iH4V3viF9Tn1TxGkl7qGhf2NLKmnhFB+0NN5oUP0+bbtznjJYmup8KeEf7A8TeJNX+3faP7Y+yfuvK2eT5EAi67ju3Yz0GOnPWgDqqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPHP2n9WOkeB7WaDxBdaVeG6i8qCCcRfal8xN+eNxCjn5SOvORXHfHTWoJPFlhrGleIPt8EumW6W2hWt5dwyXxedz5sLQ4VjtOO/TkdK+lKKAPmD4i6pqqfELxHm71KDxMl/pQ8PWiTSBWhYfvgiA7XUndvJyMjHFexfFTW9Z0u58K2GgXkFlNq+piyknltxNsQxO2QpI5yo7/nXe0UAfO3hb4k+MZbHTr3U9RsrpNQ0TVbhIkshH5U1m7IshO47ixXJHAGcAd6zb/4kePrHQrzUm1zT5fI0LTtf8v8AswLnz2CtBnf93nJbrnptHFfTdFAHnuqu/iL4vaZpkbsdO8OWx1K7Cn5WupQY4Eb/AHU81/xWvL7D4seMHm8T+Q0WrXtnZ3Fzb21hbpLbJtkCqWIImQhSTskGWwelfQtjpVjY3l9dWltHFc30gluZFHzSsFCgk+wAFXaAPnXTfid4ofw3fTf2xpl3bLqNjA+rRQrK2n28wfzZJY0wo2lFAB6b/m6V7T4C1Eap4bhuk1uLXUMkirfxQCFZQHI6Dg4xjcODjIroaKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Five surface ECG leads (I, II, aVF, V1, V6) and intracardiac recordings from the high right atrium (HRA3-4), distal (USER1) and proximal (USER3) electrode pairs from a catheter in the right ventricular outflow tract (RVOT), His bundle region (HBE3-4), the right ventricular apex (RVA3-4), and stimulus artifact channel (STIM) in a patient with ventricular tachycardia (VT). The catheter is in the RVOT; during spontaneous VT, the tip of the mapping catheter (USER1) is activated about 30 ms prior to the onset of the QRS in the surface ECG. Radiofrequency (RF) application at this site initially caused a salvo of nonsustained VT which terminated spontaneously, suggesting heating of an automatic focus; a sinus beat is seen at the end of the panel. Following RF application, there was no further spontaneous or inducible VT and the patient has remained symptom-free during follow-up.",
"    <div class=\"footnotes\">",
"     A: atrial electrogram; V: ventricular electrogram.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_44_10954=[""].join("\n");
var outline_f10_44_10954=null;
var title_f10_44_10955="Diagnostic criteria NF1";
var content_f10_44_10955=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63696&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63696&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    NIH diagnostic criteria for neurofibromatosis type 1",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Two or more of the following clinical features must be present:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Six or more caf&eacute; au lait macules of more than 5 mm in greatest diameter in prepubertal individuals, and more than 15 mm in greatest diameter in postpubertal individuals.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Two or more neurofibromas of any type or one plexiform neurofibroma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Freckling in the axillary or inguinal regions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Optic glioma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Two or more iris hamartoma (Lisch nodules)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Distinctive bony lesion such as sphenoid dysplasia, or thinning of the long bone cortex with or without pseudoarthrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A first-degree relative (parent, sibling, or offspring) with NF 1 based on the above criteria.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_44_10955=[""].join("\n");
var outline_f10_44_10955=null;
var title_f10_44_10956="ACC AHA CABG asx CAD mild AP";
var content_f10_44_10956=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F69950&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F69950&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA Guideline Summary: Coronary artery bypass graft surgery (CABG) in patients with asymptomatic ischemia or mild angina",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence",
"and/or general agreement that CABG should be performed in patients with",
"asymptomatic ischemia or mild angina in the following settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Significant left main coronary artery disease.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Significant left main equivalent disease, which is defined as &ge;70 percent stenosis of the proximal left anterior descending (LAD) and proximal left circumflex arteries.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Three-vessel disease; the survival benefit is greater with a reduced left ventricular ejection fraction (less than 50 percent) and/or a large area of myocardium at risk on noninvasive testing.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Significant proximal",
"LAD disease with one- or two-vessel disease with a reduced left",
"ventricular ejection fraction (less than 50 percent) and/or a large",
"area of myocardium at risk on noninvasive testing.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; One or two-vessel disease not involving the proximal LAD with a large area of myocardium at risk and high-risk criteria on noninvasive testing.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa - The weight of",
"evidence or opinion is in favor of benefit from CABG in patients with",
"asymptomatic ischemia or mild angina in the following setting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Significant proximal LAD disease with one- or two-vessel disease in the absence of the above high-risk features.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIb - The evidence or",
"opinion is less well established for the use of CABG in patients with",
"asymptomatic ischemia or mild angina in the following setting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; One or two-vessel disease not involving the proximal LAD in the absence of the above high-risk features.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation 2004; 110:e340.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_44_10956=[""].join("\n");
var outline_f10_44_10956=null;
var title_f10_44_10957="Rifabutin and HAART";
var content_f10_44_10957=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F82486&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F82486&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for coadministering antiretroviral drugs with RIFABUTIN",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Antiretroviral dose change",
"       </td>",
"       <td class=\"subtitle1\">",
"        Rifabutin dose change",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Non-nucleoside reverse-transcriptase inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Efavirenz",
"       </td>",
"       <td>",
"        No change",
"       </td>",
"       <td>",
"        &uarr; to 450 to 600 mg (daily or intermittent)",
"       </td>",
"       <td>",
"        Rifabutin AUC &darr; by 38 percent. Effect of efavirenz + protease inhibitor(s) on rifabutin concentration has not been studied. Efavrirenz should not be used during the&nbsp;first trimester of pregnancy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nevirapine",
"       </td>",
"       <td>",
"        No change",
"       </td>",
"       <td>",
"        No change (300 mg daily or&nbsp;three times/week)",
"       </td>",
"       <td>",
"        Rifabutin and nevirapine AUC not significantly changed.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rilpivirine",
"       </td>",
"       <td colspan=\"2\">",
"        Rifabutin and rilpivirine should not be used together",
"       </td>",
"       <td>",
"        Rilpivirine AUC &darr; by 46 percent.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Etravirine",
"       </td>",
"       <td>",
"        No change",
"       </td>",
"       <td>",
"        No change (300 mg daily or&nbsp;three times/week)",
"       </td>",
"       <td>",
"        Etravirine Cmin &darr; by 45 percent, but this was not thought to warrant a change in dose. If etravirine is used with a ritonavir-boosted protease inhibitor, rifabutin should not be co-administered.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Single protease inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fosamprenavir",
"       </td>",
"       <td>",
"        No change",
"       </td>",
"       <td>",
"        &darr; to 150 mg/day or 300 mg&nbsp;three times/week",
"       </td>",
"       <td>",
"        No published clinical experience.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Atazanavir",
"       </td>",
"       <td>",
"        No change",
"       </td>",
"       <td>",
"        &darr; to 150 mg/day or 300 mg&nbsp;three times/week",
"       </td>",
"       <td>",
"        No published clinical experience. Rifabutin AUC &uarr; by 250 percent.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Dual protease inhibitor combinations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lopinavir/ritonavir (Kaletra)",
"       </td>",
"       <td>",
"        No change",
"       </td>",
"       <td>",
"        &darr; to 150 mg/day or 300 mg&nbsp;three times/week",
"       </td>",
"       <td>",
"        Rifabutin AUC &uarr; by 303 percent; 25-O-des-acetyl rifabutin (active metabolite) AUC &uarr; by 47.5 fold.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ritonavir (any dose) with saquinavir, indinavir, amprenavir, fos-amprenavir, atazanavir, tipranavir, or darunavir",
"       </td>",
"       <td>",
"        No change",
"       </td>",
"       <td>",
"        &darr; to 150 mg/day or 300 mg&nbsp;three times/week",
"       </td>",
"       <td>",
"        Rifabutin AUC &uarr; and 25-O-des-acetyl rifabutin (active metabolite) AUC &uarr;, by varying degrees.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        CCR-5 receptor antagonists",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Maraviroc",
"       </td>",
"       <td>",
"        No change",
"       </td>",
"       <td>",
"        No change",
"       </td>",
"       <td>",
"        If used without a strong CYP3A inducer or inhibitor, use maraviroc 300 mg twice daily. If used with a strong CYP3A inhibitor, use miraviroc 150 mg twice daily.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Integrase inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Raltegravir",
"       </td>",
"       <td>",
"        No change",
"       </td>",
"       <td>",
"        No change",
"       </td>",
"       <td>",
"        No clinical experience; a significant interaction is unlikely, but this has not yet been studied.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     &nbsp;",
"    </p>",
"    <div class=\"footnotes\">",
"     AUC: Area under curve; Cmin: Minimum concentration.",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      Department of Health and Human Services:",
"      <a href=\"file://www.aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf\">",
"       file://www.aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf",
"      </a>",
"      (November 21, 2012)",
"     </p>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_44_10957=[""].join("\n");
var outline_f10_44_10957=null;
var title_f10_44_10958="Glottic view without ELM";
var content_f10_44_10958=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F64433&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F64433&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    View of glottis without external laryngeal manipulation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 236px; height: 236px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    External laryngeal manipulation (ELM)&nbsp;improves the glottic view in more than 50 percent of patients with inadequate initial views, such as that above.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Orebaugh SL. Direct laryngoscopy. In: Atlas of Airway Management: Techniques and Tools, Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_44_10958=[""].join("\n");
var outline_f10_44_10958=null;
var title_f10_44_10959="Mitral stenosis pulsed wave Doppler";
var content_f10_44_10959=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/68524/mspudop2_conv.mp4?title=Mitral+stenosis+pulsed+wave+Doppler\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mitral stenosis pulsed wave Doppler",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 311px; height: 230px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_44_10959=[""].join("\n");
var outline_f10_44_10959=null;
